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Fanconi anemia (FA) is a rare disorder that is characterized by bone-
marrow failure in the first decade of life, developmental abnormalities, and 
predisposition to malignancies. The majority of patients have mutations in one of 
the 22 known FA genes, while a small number of patients have not been assigned 
to a complementation group. FA proteins are required for the proper repair of DNA 
interstrand crosslinks (ICL), a deleterious type of DNA damage that covalently 
binds DNA strands. We have used Whole Exome Sequencing (WES) in 
conjunction with cell-based assays to determine disease-causing mutations in a 
subset of patients enrolled in the International Fanconi Anemia Registry (IFAR) 
who are not assigned to a known complementation group. In this thesis, we 
present three cases that were the focus of study. 
We describe a new FA complementation group identified in a patient 
presenting with typical FA features and deficiency of the ubiquitin-conjugating 
enzyme (E2), UBE2T. No pathogenic gene variants were identified by WES, but 
RNA sequencing (RNA-seq) uncovered a significant decrease in UBE2T 
transcript, and western blot confirmed deficiency of UBE2T protein. Sanger 
sequencing of genomic DNA revealed a large paternal deletion and maternal 
duplication resulting from Alu-mediated recombination. In the absence of UBE2T, 
the patient cells are defective for FA pathway activation and are hypersensitive to 
crosslinking agents. These cellular defects are complemented by expression of 
wild type UBE2T demonstrating that deficiency of the protein UBE2T causes this 
individual’s FA. 
WES of a sibling pair with FA revealed biallelic mutations 
in FANCD1/BRCA2. Both siblings presented with multiple developmental 
abnormalities at birth, but did not develop any early childhood malignancies or 
hematological abnormalities typically associated with the FANCD1 
complementation group. FANCD1/BRCA2 is best known for its role in homologous 
recombination directed repair of DNA double strand breaks, a function also 
required during the repair of ICLs. Each sibling inherited a LOF BRCA2 mutation 
in trans to a missense mutation of the BRCA2 DNA binding domain. Evaluation of 
BRCA2 DNA binding domain mutations revealed that this domain is important for 
replication fork protection, and to a lesser extent canonical homologous 
recombination. 
FA is a very heterogeneous disorder and as a consequence of overlapping 
clinical features, patients may be misdiagnosed with FA in lieu of another DNA 
repair or replication deficiency. Besides identifying FA mutations, we have 
identified non-FA patient enrolled in the IFAR. This individual has a defect in 
resolving DNA replication stress that presented in childhood as tri-lineage bone 
marrow failure, facial dysmorphia, and small stature. Our analysis demonstrated 
that the patient cells lack the hallmarks of FA, but are defective for cellular 
resistance to DNA replication stress. 
iii 
ACKNOWLEDGEMENTS
I would first like to thank my advisor Dr. Agata Smogorzewska for the 
wonderful opportunity to pursue my thesis research in her laboratory. I appreciate 
the tremendous amount of time and energy she has spent mentoring me over the 
years, from which I have greatly benefited. 
I am grateful for my Faculty Advisory Committee, Dr. Hironori Funabiki, Dr. 
Jean-Laurent Casanova, and Dr. Christopher Park, who have been generous with 
their time, given advice, and shared their expertise year after year. I would like to 
thank Dr. Alberto Ciccia for accepting the invitation to be the external examiner on 
my committee. 
I am thankful to the Rockefeller Dean’s office and Tri-Institutional MD-PhD 
program office for their support. A special thank you to Olaf Anderson and Ruthie 
Gotian who have offered encouragement and advice through the years. 
I would also like to acknowledge past and present Smogorzewska 
laboratory members. A special thank you to Frank Lach for all that he does to keep 
the laboratory running and for sharing his expertise in gene mutation analysis and 
chromosomal breakage. I would like to thank Anderson Wang, Sunandini Sridhar, 
and Liz Garner for their assistance in learning molecular biology techniques when 
iv 
I joined the laboratory. I would like to acknowledge Ray Noonan for working with 
me to optimize efficient CRISPR/Cas9 gene editing to generate many cell lines for 
these studies and for his assistance with experiments. I thank Ryan White for 
sharing his expertise in flow cytometry and lively discussions. 
I thank my fellow grad student and labmate, Brooke for being an amazing 
colleague and friend through the years. I am appreciative of all our scientific as 
well as non-scientific talks. I am grateful for the support of my family and friends. I 
would like to express my gratitude to my husband David for his unwavering support 
and encouragement throughout the years. 
v 
TABLE OF CONTENTS 
Chapter 1: Introduction ....................................................................................... 1
1.1 DNA replication and genome maintenance ............................................ 2
1.1.1 Cell division and replication ............................................................... 2
1.1.2 DNA damage response ..................................................................... 3
1.2 Fanconi anemia/BRCA DNA repair pathway ............................................... 8
1.3 Disorders of interstrand crosslink repair .................................................... 12
1.3.1 Fanconi anemia ............................................................................... 12
1.3.2 Homologous recombination deficient FA subtypes ......................... 15
1.4 BRCA2 in homologous recombination and cancer susceptibility ............... 17
1.4.1 BRCA2 structure and function ......................................................... 17
1.4.2 Canonical homologous recombination pathway .............................. 18
1.4.3 BRCA1 and BRCA2 in cancer susceptibility .................................... 20
1.5 The role of BRCA2 in replication fork protection ........................................ 25
1.5.1 Homologous recombination independent function of BRCA2 in 
replication fork protection ......................................................................... 25
1.5.2 BRCA2 independent role of RAD51 in replication fork reversal ...... 27
1.5.3 Nuclease processing at stalled replication forks in BRCA2 deficient 
cells ........................................................................................................... 31
1.5.4 DNA translocases in replication fork protection and processing ..... 36
1.5.5 Deficiency of RADX, a RAD51 effector protein, rescues nascent 
strand degradation in BRCA2 deficient cells ............................................ 39
 vi 
1.5.6. MUS81 cleavage of stalled replication forks in BRCA2 deficient cells
 .................................................................................................................. 44	
1.6 Objectives .................................................................................................. 46	
Chapter 2: Deficiency of UBE2T causes a new subtype of Fanconi anemia 
and is the primary E2 ubiquitin-conjugating enzyme necessary for FANCD2 
and FANCI ubiquitination ................................................................................. 49	
2.1 Introduction ................................................................................................ 50	
2.2 Results ....................................................................................................... 50	
2.2.1 Presentation of Fanconi anemia patient of unknown complementation 
group ........................................................................................................ 50	
2.2.2 Cellular phenotype of Fanconi anemia cell line of unknown 
complementation group ............................................................................ 53	
2.2.3 Whole exome sequencing and high-resolution array comparative 
genomic hybridization ............................................................................... 54	
2.2.4 Identification of biallelic UBE2T mutations in the subject ................ 57	
2.2.5 Complementation of RA2627 cellular defects by wild type UBE2T 
expression ................................................................................................ 67	
2.2.6 The primary role of UBE2T is in ICL repair ...................................... 67	
2.2.7 A potential a mechanism of FA pathway regulation through UBE2T
 .................................................................................................................. 70	
2.3 Summary and Conclusion .......................................................................... 76	
vii 
Chapter 3: Differential roles of the BRCA2 DNA binding domain in replication 
fork protection in response to hydroxyurea and DNA interstrand crosslink 
damage ............................................................................................................... 80
3.1 Introduction ................................................................................................ 81
3.2 Results ....................................................................................................... 84
3.2.1 Atypical presentation of Fanconi anemia in individuals with biallelic 
FANCD1/BRCA2 mutations ...................................................................... 84
3.2.2 Phenotype of FANCD1/BRCA2 DNA binding domain patient cell lines
 .................................................................................................................. 89
3.2.3 CRISPR/Cas9 mediated correction of the BRCA2 c.IVS19-1G>A 
mutation rescues cellular defects of patient HSC62 fibroblasts ............... 97
3.2.4 Defective ICL repair in HSC62 cells results in increased RPA 
activation that is dependent on DNA2 and WRN .................................... 100
3.2.5 Generation of isogenic BRCA2 DNA binding domain mutations in 
human fibroblasts ................................................................................... 104
3.2.6 Determination of homologous recombination efficiency in DNA binding 
domain mutants ...................................................................................... 117
3.2.7 The BRCA2 DNA binding domain is required for replication fork 
protection at HU-stalled forks and ICLs to prevent resection by DNA2 .. 118
3.2.8 Depletion of SLX4 or MUS81 does not rescue MMC induced RPA foci 
in BRCA2 DBD mutants ......................................................................... 129
3.2.9 Replication fork remodeling by SNF2 family translocases, 
SMARCAL1, ZRANB3, and HLTF, is not required for ICL repair ........... 130
viii 
3.2.10 Depletion of RADX partially rescues defects of ICL repair in BRCA2 
DNA binding domain mutants ................................................................. 133
3.2.11 ICLs are a substrate of nucleolytic processing in the absence of a 
functioning FA pathway .......................................................................... 143
3.3 Summary and Conclusions ...................................................................... 147
Chapter 4: Novel bone marrow failure and DNA repair deficiency syndrome
........................................................................................................................... 156
4.1 Introduction .............................................................................................. 157
4.2 Results ..................................................................................................... 157
4.2.1 A patient enrolled in the International Fanconi Anemia Registry 
identified as non-FA ................................................................................ 157
4.2.2 Characterization of patient derived cells reveals no defects in ICL 
repair....................................................................................................... 160
4.2.3 Analysis of DNA replication in RA2177 cells reveals abnormalities only 
under conditions of replication stress ..................................................... 163
4.2.4 Genetic analysis and evaluation of candidate disease-causing genes
 ................................................................................................................ 164
4.3 Summary and Conclusions ...................................................................... 173
Chapter 5: Discussion .................................................................................... 176
5.1 Investigating the genetic cause of disease in individuals not assigned to a 
Fanconi anemia complementation group ....................................................... 177
5.2 BRCA2 DNA binding domain mutations and implications for cancer ...... 182
5.3 Defective replication fork protection at ICLs and HU-stalled forks ........... 186
ix 
5.4 Implications of defective replication fork protection ................................. 188
5.5 Concluding Remarks ............................................................................... 191
Chapter 6: Materials and Methods ................................................................. 193
6.1 Experimental Procedures ........................................................................ 194
6.1.1 Study subjects ............................................................................... 194
6.1.2 Cell lines ........................................................................................ 194
6.1.3 Plasmids and mutagenesis ............................................................ 195
6.1.4 Viral transfection/transduction ....................................................... 195
6.1.5 RNAi .............................................................................................. 196
6.1.6 PCR, reverse transcription, and RT qPCR .................................... 196
6.1.7 Gene targeting ............................................................................... 197
6.1.8 Chromosomal breakage ................................................................ 198
6.1.9 Cell survival studies ....................................................................... 198
6.1.10 Cell cycle ..................................................................................... 199
6.1.11 Western blot ................................................................................ 199
6.1.12 Immunofluorescence ................................................................... 200
6.1.13 Sister chromatid exchange .......................................................... 200
6.1.14 mClover homologous recombination assay ................................. 201
6.1.15 DNA molecular combing and DNA fibers .................................... 201
6.1.16 aCGH ........................................................................................... 203
6.1.17 Whole Exome Sequencing .......................................................... 204
6.1.18 RNA sequencing .......................................................................... 205
x 
Chapter 7: References .................................................................................... 213
 xi 
LIST OF TABLES 
 
Table 2.1 Chromosome breakage analysis of subject's peripheral blood samples 
treated with DEB .......................................................................................... 52	
Table 6.1 List of cell lines .................................................................................. 206	
Table 6.2 List of cloning primers ....................................................................... 207	
Table 6.3 List of siRNAs .................................................................................... 208	
Table 6.4 List of shRNAs ................................................................................... 209	
Table 6.5 List of sequencing primers ................................................................ 209	
Table 6.6 List of RT qPCR primers ................................................................... 210	
Table 6.7 List of sgRNAs ................................................................................... 210	
Table 6.8 List of oligonucleotide donor templates for ........................................ 211	
Table 6.9 List of antibodies ............................................................................... 212	
 
 xii 
LIST OF FIGURES 
 
Figure 1.1 Activation of the DDR kinases DNA-PKcs and ATM. ........................... 5	
Figure 1.2 Replication stress and ATR activation. ................................................ 7	
Figure 1.3 Fanconi anemia pathway. .................................................................. 11	
Figure 1.4 Double strand break repair by homologous recombination. ............... 22	
Figure 1.5 BRCA2 and RAD51 mediated replication fork protection ................... 35	
Figure 1.6 Replication fork reversal mediated by the SNF2 family translocases 
SMARCAL1, ZRANB3, and HLTF. ............................................................... 40	
Figure 1.7 RADX modulates RAD51 activity at replication forks ......................... 43	
Figure 2.1 Characterization of cell lines from an individual with FA under study. 56	
Figure 2.2 FANCA cDNA fails to complement RA2627 FANCD2 and FANCI 
monoubiquitination defect. ........................................................................... 58	
Figure 2.3 UBE2T is deficient in RA2627 cells. ................................................... 60	
Figure 2.4 UBE2T deficiency is the result of AluYa5 mediated non-allelic 
homologous recombination. ......................................................................... 62	
Figure 2.5 Identification of paternally-derived deletion resulting from AluYa5 
mediated non-allelic homologous recombination. ........................................ 64	
Figure 2.6 Identification of maternally-derived duplication mutation resulting from 
AluYa5 mediated non-allelic homologous recombination. ........................... 66	
Figure 2.7 UBE2T cDNA complements RA2627 hypersensitivity to crosslinking 
agents and monoubiquitination of FANCD2 and FANCI. ............................. 69	
 xiii 
Figure 2.8 UBE2T does not have a major role in repair of other types of DNA 
damage. ....................................................................................................... 73	
Figure 2.9 UBE2T/FANCT deficient RA2627 cells expressing UBE2T S5D 
phosphomimetic are defective for FANCD2 and FANCI monoubiquitination.
 ..................................................................................................................... 75	
Figure 3.1 BRCA2 mutations identified in a sibling pair with atypical Fanconi 
anemia ......................................................................................................... 83	
Figure 3.2 Schematic of BRCA2 structure showing location of patient DNA binding 
domain mutations. ........................................................................................ 86	
Figure 3.3 Characterization of BRCA2 patient lymphoblast cell lines from a sibling 
pair with atypical Fanconi anemia. ............................................................... 91	
Figure 3.4 Cellular sensitivity of HSC62 BRCA2 c.IVS19-1G>A patient fibroblast 
cell line. ........................................................................................................ 94	
Figure 3.5 Characterization of HSC62 BRCA2 c.IVS19-1G>A fibroblast cell line 
from an adult patient with atypical Fanconi anemia. .................................... 96	
Figure 3.6 Complementation of HSC62 BRCA2 c.IVS19-1G>A DNA binding 
domain patient fibroblast cell line at the endogenous locus by CRISPR/Cas9 
mediated gene targeting. ............................................................................. 99	
Figure 3.7 Defects in RAD51 foci formation in HSC62 BRCA2 patient fibroblasts 
are rescued by gene correction. ................................................................. 102	
Figure 3.8 Rescue of cellular sensitivity of HSC62 BRCA2 patient fibroblasts to 
genotoxic agents by gene correction. ........................................................ 103	
 xiv 
Figure 3.9 Depletion of DNA2 and WRN in HSC62 patient cells suppresses 
increased RPA activation and foci formation induced by MMC. ................ 106	
Figure 3.10 Generation of isogenic BRCA2 DNA binding domain mutants by 
CRISPR/Cas9 mediated gene targeting in human fibroblasts. .................. 110	
Figure 3.11 RAD51 foci formation in BRCA2 DNA binding domain mutants 
following ionizing radiation. ........................................................................ 111	
Figure 3.12 RAD51 foci formation in BRCA2 DNA binding domain mutants 
following mitomycin C. ............................................................................... 112	
Figure 3.13 Cellular sensitivity of isogenic BRCA2 DNA binding domain mutants.
 ................................................................................................................... 113	
Figure 3.14 BRCA2 DNA binding domain mutants have increased RPA foci 
formation following mitomycin C. ............................................................... 114	
Figure 3.15 CRISPR/Cas9 mediated gene targeting to mutagenize key DNA 
interacting residues of the BRCA2 DNA binding domain. .......................... 116	
Figure 3.16 HEK293T BRCA2 DNA binding domain and Exon 27 p.S3291A clones 
generated by CRISPR/Cas9 gene editing. ................................................. 119	
Figure 3.17 Homologous recombination efficiency of BRCA2 DNA binding domain 
mutants. ..................................................................................................... 121	
Figure 3.18 Depletion of DNA2 and WRN suppresses increased RPA activation 
and foci formation induced by MMC in BRCA2 DNA binding domain mutants.
 ................................................................................................................... 124	
 xv 
Figure 3.19 BRCA2 DNA binding domain mutants are defective in replication fork 
protection at hydroxyurea-stalled forks. ..................................................... 126	
Figure 3.20 DNA2 promotes nascent strand degradation at hydroxyurea-stalled 
replication forks. ......................................................................................... 128	
Figure 3.21 Depletion of SLX4 or MUS81 does not rescue increased RPA 
activation and foci formation in BRCA2 DNA binding domain mutants. ..... 132	
Figure 3.22 SMARCAL1 and ZRANB3 translocases do not have a major role in 
cellular resistance to DNA interstrand crosslinks. ...................................... 134	
Figure 3.23 Depletion of SMARCAL1 and ZRANB3 translocases rescues nascent 
strand degradation at HU-stalled replication forks but does not promote 
cellular resistance to MMC or CPT in BRCA2 DBD mutants. .................... 136	
Figure 3.24 Depletion of SMARCAL1 or ZRANB2 translocases does not rescue 
increased RPA activation and foci formation induced by MMC in BRCA2 DNA 
binding domain mutants. ............................................................................ 137	
Figure 3.25 Depletion of HLTF translocases does not rescue increased RPA 
activation and foci formation in BRCA2 DNA binding domain mutants. ..... 138	
Figure 3.26 Deficiency of RADX does not impact homologous recombination 
efficiency in BRCA2 DNA binding domain mutants. ................................... 140	
Figure 3.27 Depletion of RADX partially rescues ICL repair defects in BRCA2 DNA 
binding domain mutants. ............................................................................ 142	
Figure 3.28 Deficiency of Fanconi anemia proteins results in hyper-
phosphorylation and foci formation of RPA after MMC. ............................. 145	
 xvi 
Figure 3.29 The role of BRCA2 in homologous recombination and replication fork 
protection requires the DNA binding domain. ............................................ 146	
Figure 4.1 Bone marrow failure in a non-Fanconi anemia family enrolled in the 
IFAR. .......................................................................................................... 158	
Figure 4.2 RA2177 fibroblasts do not display features of ICL repair defects. ... 161	
Figure 4.3 RA2177 fibroblasts are hypersensitive to replication stress inducing 
agents ........................................................................................................ 162	
Figure 4.4 Parental fibroblasts behave as wild type. ......................................... 165	
Figure 4.5 RA2143 patient LCLs display hypersensitivity to replication stress. 166	
Figure 4.6 Assessment of replication fork progression in RA2177 cells under 
conditions of replication stress. .................................................................. 167	
Figure 4.7 Assessment of replication fork dynamics in RA2177 patient cells. .. 168	
Figure 4.8 PFAS variants do not cause the cellular defects to replication stress in 




LIST OF ABBREVIATIONS 
3HB three-helix bundle 
 
53BP1 Tumor suppressor p53 binding protein 1  
9-1-1 complex Rad9-Hus1-Rad1 complex  
aa Amino acid  
ACTH Adrenocorticotropic hormone  
AML Acute myeloid leukemia  
APIM AlkB homolog 2 PCNA-interaction motif  
ATM Ataxia-telangiectasia mutated  
ATR Ataxia-telangiectasia and Rad3-related  
ATRIP ATR-interacting protein   
BLM Bloom syndrome RecQ like helicase  
BMF Bone marrow failure  
BMT Bone marrow transplant  
BRCA Breast cancer susceptibility protein  
BRCA1 Breast cancer susceptibility protein 1  
BRCA2 Breast cancer susceptibility protein 2  
BRCA2mut BRCA2 patient cell line  
BrdU Bromodeoxyuridine  
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
 
C-terminus Carboxyl-terminus  
 xviii 
CADD Combined annotation dependent depletion  
Cas9 CRISPR associated protein 9  
cDNA Complementary DNA  
CFS Common fragile sites  
CHK1 Checkpoint kinase 1  
CHK2 Checkpoint kinase 2  
CldU 5-Chloro-2’-deoxyuridine  
CMG complex Cdc45/Mcm2-7/Gins complex  
CNS Central nervous system  
CNV Copy number variant  
CPT Camptothecin  
CRISPR Clustered regularly interspaced short palindromic repeats 
 
CtIP Ct-BP-interacting protein  
DBA Diamond-Blackfan anemia  
DBD DNA binding domain  
DKC Dyskeratosis congenita  
DDR DNA damage response  
DEB Diepoxybutane  
DIG-TMP Digoxigenin-trimethylpsoralen  
DNA-PKcs DNA-dependent protein kinase, catalytic subunit 
 
DNA2 DNA replication helicase/nuclease 2  
DR-GFP Direct repeat fluorescent protein  
 xix 
DSB DNA double strand break  
dsDNA Double stranded DNA  
DSS1 Decreased sperm survival 1  
EM Electron microscopy  
ETAA1 Ewing’s tumor-associated antigen 1  
EV Empty vector  
EXO1 Exonuclease 1  
FA-A Fanconi anemia complementation group A 
 
FA-D1 Fanconi anemia complementation group D-1 
 
FA-like Fanconi anemia-like  
FAAP100 FA core complex associated protein 100  
FAAP24 FA core complex associated protein 24  
FAN1 FANCD2/FANCI-associated nuclease 1  
FANCA Fanconi anemia complementation group A  
FANCB Fanconi anemia complementation group B  
FANC Fanconi anemia complementation group C  
FANCD1 Fanconi anemia complementation group D1  
FANCD2 Fanconi anemia complementation group D2  
FANCE Fanconi anemia complementation group E  
FANCF Fanconi anemia complementation group F  
FANCG Fanconi anemia complementation group G  
FANCI Fanconi anemia complementation group I  
 xx 
FANCJ Fanconi anemia complementation group J  
FANCL Fanconi anemia complementation group L  
FANCM Fanconi anemia complementation group M  
FANCN Fanconi anemia complementation group N  
FANCO Fanconi anemia complementation group O  
FANCP Fanconi anemia complementation group P  
FANCQ Fanconi anemia complementation group Q  
FANCR Fanconi anemia complementation group R  
FANCS Fanconi anemia complementation group S  
FANCT Fanconi anemia complementation group T  
FANCU Fanconi anemia complementation group U  
FANCV Fanconi anemia complementation group V  
FANCW Fanconi anemia complementation group W  
G2-phase Gap 2 phase  
GH Growth hormone  
gnomAD Genome Aggregation Database  
GVHD Graft versus host disease  
HBOC Hereditary breast and ovarian cancer  
HDR Homology directed repair  
HJ Holliday junction  
HR Homologous recombination  
HU Hydroxyurea  
 xxi 
ICL Interstrand crosslinks  
ID2 FANCI/FANCD2  
IdU 5-Iodo-2’-deoxyuridine  
IFAR International Fanconi Anemia Registry  
IR Ionizing radiation  
KIN Karyomegalic interstitial nephritis  
LCL Lymphoblastoid cell line  
LIG4 DNA Ligase 4  
LMNA Lamin A  
LOF Loss of function  
LUC Luciferase  
MMC Mitomycin C  
MRN MRE11-RAD50-NBS1  
N-terminus Amine-terminus  
NAHR Non-allelic homologous recombination  
NBS1 Nijmegen breakage syndrome 1  
NEIL3 Nei like DNA glycosylase 3  
NHEJ Non-homologous end joining  
NLS Nuclear localization signal  
OB1 Oligonucleotide/oligosaccharide-binding fold 1 
 
OB2 Oligonucleotide/oligosaccharide-binding fold 2 
 
OB3 Oligonucleotide/oligosaccharide-binding fold 3 
 
 xxii 
PALB2 Partner and localizer of BRCA2  
PARPi PARP inhibitor  
PB Peripheral blood  
PCNA Proliferating cell nuclear antigen  
PCR Polymerase chain reaction  
PDA Patent ductus arteriosus  
PFAS Phosphoribosylformylglycinamidine synthase  
PI3K Phosphoinositide 3-kinase  
PIKK Phosphoinositide 3-kinase (PI3K) related kinases 
 
PIP Box PCNA-interacting protein box  
POLd DNA-polymerase delta  
POL e DNA-polymerase epsilon  
POLx DNA-polymerase zeta  
RAD50mut RAD50 patient cell line  
RFWD3 Ring finger and WD repeat domain 3  
RNAi RNA interference   
RNAseq RNA sequencing  
RPA Replication protein A  
RT q PCR Quantitative reverse transcription PCR  
S-phase Synthesis-phase  
s.d. Standard deviation  
SCC Squamous cell carcinoma  
 xxiii 
SCE Sister chromatid exchange  
SDS Shwachman-Diamond syndrome  
sgRNA Single-guide RNA  
shRNA Short hairpin RNA   
siRNA Small interfering RNAs  
SLX4mut SLX4 patient cell line  
ssDNA single stranded DNA  
TBI Total body irradiation  
TLS POL Translesion synthesis polymerase  
TMP Trimethylpsoralen  
Ub Ubiquitin  
UBE2T Ubiquitin conjugating enzyme E2 T  
UV Ultraviolet light  
VSD Ventricular septal defect  
VUS Variant of unknown significance   
WES Whole exome sequencing  




Chapter 1: Introduction 
  
 2 
1.1 DNA replication and genome maintenance 
1.1.1 Cell division and replication 
For growth and development, cells must undergo cellular reproduction by 
which the parental cell divides resulting in two genetically identical daughter cells. 
This requires that the genetic material is precisely duplicated. High fidelity DNA 
replication is important for cell viability and normal function, and it also prevents 
mutations and tumorigenesis. The DNA replication machinery, a large multiprotein 
complex termed the replisome, initiates replication from many places in the 
eukaryotic genome called replication origins during the S-phase of the cell cycle. 
At the very basic level, the eukaryotic replisome consists of the Cdc45, MCM2-7, 
and Gins (CMG) helicase, DNA polymerases, PCNA sliding clamps, primase, and 
single stranded binding protein RPA (O'Donnell et al., 2013). During replication, 
the CMG helicase unwinds the DNA duplex and the DNA polymerases synthesize 
nucleotides along the template parental strand.  
 
During replication, the replisome may encounter many obstacles that pose 
a risk to precisely copying the genetic material. Cellular responses have evolved 
to manage replication stress imposed by these obstacles and work to ensure that 
the genome is fully and accurately reproduced each cell cycle. Cells can also incur 
damage that is repaired outside of S-phase that can result from normal cellular 
metabolism or insults from exogenous sources. Repair of these DNA lesions 
requires many dedicated pathways.  
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1.1.2 DNA damage response 
Damaged DNA must be repaired to ensure integrity of the genetic material 
to ensure normal function and prevent tumorigenesis. The cellular DNA damage 
response (DDR) primarily depends on the activation of three phosphoinositide 3-
kinase (PI3K) related kinases (PIKK), ATM, ATR, and DNA-PK (Blackford and 
Jackson, 2017). 
 
DNA-PKcs and ATM activation 
 The DNA-PKcs and ATM kinase are both involved in signaling and directing 
repair of DNA double strand breaks (DSB). DNA-PKcs serves as a regulator of 
DNA repair by non-homologous end joining (NHEJ) and is recruited to DSBs by 
Ku proteins where it becomes activated and undergoes auto-phosphorylation 
(Figure 1.1A) (Kienker et al., 2000; Kurimasa et al., 1999). DNA-PKcs binds and 
stabilizes broken DNA ends to prohibit end-resection and promote NHEJ. NHEJ is 
the primary repair pathway of DSBs outside of S/G2 phases (Ciccia and Elledge, 
2010). DSB repair by NHEJ involves the ligation of the broken ends of DNA and is 
generally efficient, but is an error-prone repair pathway when DNA ends are joined 
irrespective of homology (Blackford and Jackson, 2017). 
 
ATM has a more global role in the repair of DSB. ATM is recruited to DSBs 
through interaction with NBS1, a part of the MRE11-RAD50-NBS1 (MRN) complex 
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(Figure 1.1B). Activated ATM initiates a signaling cascade that promotes DNA 
repair activation, chromatin signaling, apoptosis, senescence, and transcription 
(Blackford and Jackson, 2017; Matsuoka et al., 2007). At DSBs, ATM promotes 
end-resection to channel repair to the homologous recombination (HR) pathway. 
Due to crosstalk in DSB repair, ATM activation can contribute to promoting a 
minority of repair events by NHEJ (Blackford and Jackson, 2017; Ciccia and 
Elledge, 2010). However, during S/G2 phase of the cell cycle the homologous 




 The ATR kinase is activated in response to DNA replication stress (Figure 
1.2). Replication stress is defined as the slowing or stalling of the replication fork 
(Zeman and Cimprich, 2014). The replisome may encounter many obstacles such 
as damaged DNA template, difficult to replicate regions (repetitive DNA 
sequences), active transcription machinery, RNA-DNA hybrids, DNA-protein 
structures, and secondary DNA structures that all cause replication stress (Zeman 
and Cimprich, 2014). Activation of oncogenes and rapid cell proliferation also 
generate replication stress (Ahuja et al., 2016; Neelsen et al., 2013; Zeman and 
Cimprich, 2014). These obstacles ultimately cause slowing of the DNA 
polymerases and activation of the ATR kinase.  
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Figure 1.1 Activation of the DDR kinases DNA-PKcs and ATM. 
(A) DNA-PKcs is recruited to DSBs by the Ku heterodimer and becomes activated. 
DNA-PKcs stabilizes the DNA ends and undergoes auto-phosphorylation that 
permits end processing by ARTEMIS. NHEJ repair factors LIG4/XRCC4 and XLF, 
promote the ligation of the DNA ends. (B) ATM is recruited to DSBs by the MRN 
complex. ATM is activated resulting in a signaling cascade that promotes DSB 
repair by HR and activation of p53 and CHK2. Consequences of the ATM signaling 
cascade include DDR activation, chromatin signaling, regulation of transcription, 
senescence, and apoptosis. 
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 The generation of single stranded DNA (ssDNA) at stressed replication 
forks serves to recruit the ATR interacting protein (ATRIP) (Saldivar et al., 2017; 
Zou and Elledge, 2003). ATRIP binding facilitates the association of ATR; 
however, ATR activation requires the binding of an activator protein, either 
TOPBP1 or ETAA1 (Kumagai et al., 2006). The RAD9-RAD1-HUS1 (9-1-1) 
checkpoint complex binds at the ssDNA-dsDNA junction and recruits TOPBP1 
which directly interact with ATRIP-ATR (Mordes et al., 2008; Zou and Elledge, 
2003). ETAA1 binds RPA on ssDNA where it then can activate ATR by association 
with the ATRIP-ATR complex (Bass et al., 2016; Haahr et al., 2016).  
 
 Once activated, ATR phosphorylates downstream targets including the 
CHK1 kinase to promote the DNA damage response (Blackford and Jackson, 
2017; Liu et al., 2006; Sorensen et al., 2004). The ATR kinase modulates the 
response to replication stress by activating and recruiting DNA repair machinery 
to DNA lesions, preventing new origin firing, and promoting replication fork stability 
and processing so that replication may resume (Saldivar et al., 2017). In the 
absence of ATR, replication stress leads to extensive ssDNA formation resulting 
in RPA exhaustion and DNA breakage (Toledo et al., 2013). Improper response to 
replication stress can result in replication fork collapse. In the absence of ATR 
activity, the replisome components are stable; however, the proteome at the stalled 
fork is altered reflecting the requirement of ATR activity for modulating effectors of 
the replication stress response to prevent fork collapse (Dungrawala et al., 2015).  
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Figure 1.2 Replication stress and ATR activation. 
The generation of ssDNA at stressed replication forks serves to recruit ATRIP 
through ssDNA bound RPA. ATRIP binding facilitates ATR association, but ATR 
activation requires the binding of an ATR activating protein, TOPBP1 or ETAA1. 
The 9-1-1 checkpoint complex binds at the ssDNA-dsDNA junction and recruits 
TOPBP1. ETAA1 interacts with RPA where it interacts with the ATRIP-ATR 
complex. Once activated, ATR phosphorylates downstream targets including the 
CHK1 kinase to promote the DNA damage response.  
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1.2 Fanconi anemia/BRCA DNA repair pathway 
The Fanconi anemia (FA) pathway is responsible for resolving interstrand 
crosslinks (ICLs), deleterious DNA lesions that covalently link the two DNA strands 
impeding transcription and replication. During DNA replication, ICLs cause 
replication fork stalling resulting in checkpoint and FA pathway activation (Figure 
1.3) (Garcia-Higuera et al., 2001; Knipscheer et al., 2009). FANCM function is 
important for efficient checkpoint-signaling by ATR; an activity that extends to ICL 
repair where FANCM is reported to promote ATR activation by regulating RPA 
recruitment at ICLs (Collis et al., 2008; Huang et al., 2010; Schwab et al., 2010; 
Singh et al., 2013). ATR activation results in phosphorylation of the FA factors 
FANCA, FANCG, FANCD2, and FANCI (Ho et al., 2006; Ishiai et al., 2008; Wang, 
2008; Wilson et al., 2008). Removal of ICLs is a multistep process requiring 
activation of the FA core complex (composed of FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, FANCL, FANCM, and their interacting factors), 
nucleolytic processing at the lesion, translesion synthesis (TLS) past the DNA 
crosslink adduct, and homologous recombination.  
 
A key step in ICL repair is the core complex-mediated monoubiquitination 
of FANCD2 and FANCI at K561 and K523, respectively (Garcia-Higuera et al., 
2001; Smogorzewska et al., 2007a; Timmers et al., 2001; Walden and Deans, 
2014). Ubiquitin transfer requires the activity of an E1 ubiquitin-activating enzyme, 
an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligating enzyme (Hershko 
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and Ciechanover, 1998). The FANCL subunit of the FA core complex is the E3 
ubiquitin-ligase that monoubiquitinates FANCD2 and FANCI (Meetei et al., 2003a). 
UBE2T is the E2 ubiquitin-conjugating enzyme and its interaction with FANCL is 
required for monoubiquitination of FANCD2 and FANCI (Alpi et al., 2008; Hira et 
al., 2015; Hodson et al., 2014; Longerich et al., 2009; Machida et al., 2006; 
Rajendra et al., 2014; Rickman et al., 2015; Sato et al., 2012).  
 
Monoubiquitinated FANCD2 and FANCI form a heterodimer (ID2 complex) 
that is recruited to chromatin and is required for the downstream processing of the 
ICL. Nucleolytic unhooking of the crosslink is dependent on FANCP/SLX4 and 
FANCO/XPF (Kim et al., 2011; Kim et al., 2013; Klein Douwel et al., 2014; 
Niedernhofer et al., 2004).  Unhooking of the ICL enables translesion bypass on 
one strand and double strand break (DSB) repair by homologous recombination 
(HR) on the second strand (Howlett et al., 2002; Litman et al., 2005; Long et al., 
2011; Xia et al., 2007).   
 
The current working model of interstrand crosslink repair has been 
corroborated by studies in Xenopus egg extracts where replication intermediates 
of plasmids carrying a site-specific ICL (pICL) can be analyzed synchronously 
(Zhang and Walter, 2014). Repair in this system is replication dependent and 
results in ATR activation and monoubiquitination of FANCI and FANCD2 (Raschle 
et al., 2008). In this model of ICL repair, two replication forks converge on the pICL, 
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one of the leading strands is extended to within one nucleotide of the lesion, and 
dual incisions that require XPF are made on either side of the lesion generating a 
double strand break (Klein Douwel et al., 2014; Raschle et al., 2008; Zhang et al., 
2015). In the absence of the I/D2 complex repair of the pICL is defective and no 
incisions are made (Knipscheer et al., 2009). Translesion synthesis restores the 
adduct containing strand while RAD51-mediated HR is required to repair the 
incised DNA ends (Long et al., 2011; Raschle et al., 2015). Synthesis across from 
the lesion and extension requires a replicative polymerase and a complex of Rev1 
and POLx respectively (Budzowska et al., 2015; Raschle et al., 2008).  
 
An alternative repair pathway of ICLs described from Xenopus egg extract 
studies utilizes the NEIL3 DNA glycosylase. In this model, dual forks converge on 
the pICL and NEIL3 cleaves a N-glycosyl bond of the psoralen crosslink to release 
the ICL without incising the DNA (Semlow et al., 2016). 
 
The dual fork model proposed from Xenopus egg extract studies is 
performed on a 6-kb plasmid that guarantees that the replication forks, in this 
limited space, will converge (Raschle et al., 2008; Zhang and Walter, 2014). 
However, in mammalian cells distance between origins is much greater and single 
fork collisions with ICLs may occur. How repair may be similar or different from 
converging forks is unclear. One proposed mechanism of single fork collisions is 
ICL traverse. Using DNA-fiber techniques to examine fluorescently labeled ICLs,  
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Figure 1.3 Fanconi anemia pathway. 
The FA pathway is responsible for resolving DNA interstrand crosslinks (ICLs) 
that impede DNA replication.  Stalling of replication machinery at ICLs results in 
the activation of the FA pathway. The activated FA core complex composed of 8 
FA proteins, FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and 
FANCM, monoubiquitinates FANCI and FANCD2 via the E3 ubiquitin ligase 
activity of FANCL and E2 ubiquitin-conjugating enzyme FANCT/UBE2T. The 
ubiquitinated FANCI and FANCD2 complex orchestrates downstream processing 
of the ICL, which entails unhooking by nucleolytic processing of the lesion, 
translesion bypass, and homologous recombination. 
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it was discovered that in 60% of ICL containing species, lesion bypass occurred 
without ICL unhooking. ICL traverse required the activity of FANCM (Huang et al., 
2013). 
In both the ICL traverse and glycosylase studies, psoralen based ICLs were 
used. NEIL3 mediated repair does not occur on cisplatin based ICLs largely used 
in other Xenopus studies These data suggest that ICLs produced endogenously 
or by exogenous chemicals may be repaired by many different pathways and 
repair mechanisms identified using specific crosslinking agents may not apply to 
all types of ICLs.  
 
1.3 Disorders of interstrand crosslink repair 
1.3.1 Fanconi anemia 
Fanconi anemia (FA) is a rare disorder with an incidence of 1/100,000 that 
results when genes important for resolving DNA interstrand crosslinks are mutated 
(Kottemann and Smogorzewska, 2013). FA is a heterogeneous disorder 
characterized by developmental abnormalities, bone marrow failure (BMF), 
predisposition to solid tumors and leukemia, and cellular hypersensitivity to 
crosslinking agents (Auerbach, 2009; Nalepa and Clapp, 2018). FA patient 
mutations have been identified in 22 FANC genes, -A, -B, -C, -D1 (BRCA2), -D2, 
-E, -F, -G, -I, -J (BRIP), -L, -M, -N (PALB2), -O (RAD51C), -P (SLX4), -Q (XPF), -
R (RAD51), -S (BRCA1), -T (UBE2T), -U (XRCC2), -V (REV7), and -W (RFWD3)  
(Bagby, 2018; Wang and Smogorzewska, 2015). FA is largely inherited in an 
autosomal recessive manner; however, there are exceptions, FANCB is X-linked 
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and FANCR is autosomal dominant (Ameziane et al., 2015; Meetei et al., 2004; 
Wang et al., 2015). A minority of FA patients still have unknown causative gene 
mutations.  
  
Patients with FA may present at birth with a spectrum of developmental 
malformations that range in severity including short stature, renal dysplasia or 
ectopia, craniofacial abnormalities, radial ray malformations, VATER association, 
central nervous system defects (CNS), café-au-lait spots, cardiac defects, or 
gastrointestinal or genitourinary malformations (Alter and Rosenberg, 2013; 
Nalepa and Clapp, 2018; Stivaros et al., 2015). FA patients often present with BMF 
in the first decade of life with a median age of seven years old. Some patients will 
present with acute myeloid leukemia (AML) or myelodysplastic syndrome 
(Auerbach, 2009). Endocrine dysfunction including growth hormone (GH) 
deficiency, abnormal glucose metabolism, dyslipidemia, hypothyroidism, 
hypogonadism, and infertility are frequent in individuals with FA (Petryk et al., 
2015). FA patients also develop solid tumors at an increased incidence. Head and 
neck squamous cell carcinoma (SCC) and anogenital SCC incidence are elevated 
500-700 fold in individuals with FA (Kutler et al., 2003; Nalepa and Clapp, 2018). 
 
Diagnosis of FA is based on chromosomal breakage tests of peripheral 
blood (PB) samples or lymphocytes exposed to either the crosslinking agent 
diepoxybutane (DEB) or mitomycin C (MMC) (Auerbach, 2009; Auerbach and 
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Wolman, 1976).  FA patient cells show increased chromosomal breakage levels 
when treated with these genotoxic agents compared to normal cells. Somatic 
mosaicism of the hematopoietic compartment can occur in FA resulting in partial 
or full rescue of chromosomal breakage (Gregory et al., 2001; Lo Ten Foe et al., 
1997; Soulier et al., 2005; Waisfisz et al., 1999). Patient fibroblasts can be tested 
in individuals with suspected mosaicism or those post hematopoietic stem cell 
transplant to confirm diagnosis. 
 
Exogenous compounds, many common chemotherapeutics, such as 
mitomycin C (MMC), diepoxybutane (DEB), cisplatin, psoralen, and nitrogen 
mustards can generate DNA ICLs. The endogenous source of DNA ICLs has been 
an intense area of study and current models provide evidence that naturally 
occurring biological metabolites such as aldehydes are suspected to generate 
ICLs in vivo (Garaycoechea et al., 2012; Hira et al., 2013; Langevin et al., 2011; 
Oberbeck et al., 2014; Ren et al., 2013; Ridpath et al., 2007).  
 
Karyomegalic Interstitial Nephritis (KIN) is a second disorder of ICL repair. 
Although patient cells are sensitive to ICLs the disease is distinct from FA. KIN is 
an autosomal recessive disorder that results from mutations in Fanconi anemia-
associated nuclease 1 (FAN1). FAN1 was discovered as an interactor of the FA 
pathway, is recruited to ICLs by the ID2 complex, and may have a specific role in 
the nucleolytic processing of the DNA lesion (Kratz et al., 2010; Liu et al., 2010; 
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MacKay et al., 2010; Smogorzewska et al., 2010). KIN is characterized by tubular 
degeneration, fibrosis, and karyomegally in the kidney that results in end stage 
kidney disease (Zhou et al., 2012). The discovery that FAN1 mutations do not 
result in FA was surprising, but recent studies have demonstrated that FAN1 has 
roles outside of the FA pathway and cells deficient for FAN1 have a milder 
sensitivity to ICLs than FANC protein deficiency (Thongthip et al., 2016; Zhou et 
al., 2012). 
 
1.3.2 Homologous recombination deficient FA subtypes 
The Fanconi anemia repair pathway requires HR factors for proper ICL 
repair. A number of proteins mutated in FA, FANCD1/BRCA2, FANCN/PALB2, 
FANCJ/BRIP1, FANCQ/RAD51C, FANCR/RAD51, and FANCS/BRCA1, are 
known for their importance in facilitating HR (Howlett et al., 2002; Litman et al., 
2005; Rahman et al., 2007; Sawyer et al., 2015; Vaz et al., 2010; Xia et al., 2007). 
In contrast to other FA subtypes, carriers of single allele mutations in many of these 
genes (-D1, -N, -J, -Q, and –S) are predisposed to breast and/or ovarian cancers 
(Bryant et al., 2005; Patel et al., 1998; Rahman et al., 2007; Ratajska et al., 2012; 
Wong et al., 2011). 
 
FA patients with biallelic mutations in complementation groups 
FANCD1/BRCA2 or FANCN/PALB2 present with a more severe clinical phenotype 
than those in other complementation groups; developing embryonal malignancies 
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and acute myeloid leukemia (AML) early in childhood (Alter et al., 2007; 
Tischkowitz and Xia, 2010). Medulloblastoma and Wilms tumor are the 
predominant solid tumors of the FANCD1/BRCA2 and FANCN/PALB2 
complementation group (Alter et al., 2007; Tischkowitz and Xia, 2010).  
 
Biallelic FANCS/BRCA1 mutations have only recently been described in a 
limited number of patients. All individuals display a number of congenital 
abnormalities typical of FA, but no bone marrow failure. Two female individuals 
identified with biallelic FANCS/BRCA1 mutations each developed cancer, ovarian 
and breast, in their 20s. Both of these BRCA1/FANCS individuals carried loss of 
function (LOF) mutations in trans to a hypomorphic missense allele (Domchek et 
al., 2013; Sawyer et al., 2015). In two other families, homozygous LOF mutations 
have been identified and the children display congenital abnormalities 
characteristic of FA and one child presented with neuroblastoma at the age of 2 
(Freire et al., 2018; Mehmet Demirel, 2016).  
 
FA patients with biallelic FANCO/RAD51C mutations present with an FA-
like syndrome; characterized by developmental abnormalities and intermediate 
chromosomal breakage, but no bone marrow failure (Vaz et al., 2010). Similarly, 
monoallelic dominant negative FANCR/RAD51 mutations result in an FA-like 
syndrome characterized by mild chromosomal breakage levels, defects in ICL 
repair, but no bone marrow failure or cancer (Ameziane et al., 2015; Wang et al., 
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2015). Examination of FANCR/RAD51 patient cells revealed intact HR activity 
likely accounting for the absence of early childhood malignancies associated with 
FANCD1 and FANCN complementation groups.  
 
1.4 BRCA2 in homologous recombination and cancer susceptibility 
1.4.1 BRCA2 structure and function 
  The identification of the BRCA breast cancer susceptibility genes was 
pursued on the observation that there was familial clustering of highly penetrant 
and autosomal dominant breast cancer (King, 2014). Shortly after the discovery of 
BRCA1 and BRCA2, the generation of mouse models for each, demonstrated that 
homozygous inactivation of either gene is embryonic lethal and that these genes 
are essential (Hakem et al., 1996; Liu et al., 1996; Sharan et al., 1997). BRCA1 
and BRCA2 deficient cells display spontaneous chromosomal aberrations and 
hypersensitivity to genotoxic agents including DSBs induced by ionizing radiation 
(IR) (Chen et al., 1998; Connor et al., 1997; Deng and Scott, 2000; Patel et al., 
1998; Sharan et al., 1997; Shen et al., 1998). Both BRCA1 and BRCA2 were 
identified as interactors of the RAD51 recombinase and found to be important for 
the repair of DSBs by homology directed repair (Chen et al., 1998; Moynahan et 
al., 1999; Moynahan et al., 2001; Scully et al., 1997; Sharan et al., 1997; 
Snouwaert et al., 1999). 
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 BRCA2 is a large protein composed of 3418 amino acid (aa) residues and 
a molecular weight of 390 kDa.  At the N-terminus BRCA2 interacts with PALB2 
through aa 21-39. BRCA2 has eight BRC repeats composed of aa 1009-2083 that 
bind to RAD51 (Roy et al., 2012). The BRCA2 DNA binding domain (DBD) is 
composed of five domains, a helical domain, three oligonucleotide/oligosaccharide 
binding (OB) folds (OB1/OB2/OB3), and a Tower domain (Yang et al., 2002). The 
Tower domain is composed of a 130 aa structure of anti-parallel helices that extend 
out from the OB2 domain and are supporting a three-helix bundle (3HB) (Yang et 
al., 2002). The BRCA2 DBD binds ssDNA and dsDNA, but the binding preference 
is for ssDNA tails in the context of dsDNA. This DNA binding activity is dependent 
on OB2, OB3, and the Tower domain. 3HB domains generally recognize dsDNA 
so the Tower domain in conjunction with the OB folds may provide recognition of 
dsDNA/ssDNA junctions (Jensen, 2013; Yang et al., 2002). The small peptide 
protein DSS1 binds BRCA2 though interaction with the helical domain, OB1, and 
OB2 (Yang et al., 2002). An NLS and additional RAD51 binding domain are located 
at the C-terminus (Roy et al., 2012).   
 
1.4.2 Canonical homologous recombination pathway 
To initiate DSB repair by HR, BRCA1 localizes to breaks to promote end-
resection and the generation of 3’ ssDNA overhangs (Jasin and Rothstein, 2013). 
End resection is modulated by the competing factors 53BP1-Rif1 and BRCA1-
CtIP. 53BP1-Rif1 favors end-protection and the NHEJ pathway of DSB repair while 
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BRCA1-CtIP promotes end-resection and HR (Bunting et al., 2010; Di Virgilio et 
al., 2013; Escribano-Diaz et al., 2013). Pathway choice by these factors is 
modulated by chromatin modifications and cyclin dependent kinases to promote 
HR during S/G2 phases (Nielsen et al., 2016; Tang et al., 2013). The deletion of 
53BP1 in BRCA1 deficient cells rescues HR defects (Bunting et al., 2010). 
Similarly, deletion of 53BP1 rescues the embryonic lethality of homozygous 
BRCA1 mice and suppresses tumor formation (Cao et al., 2009). These data 
suggest that the primary role of BRCA1 is pathway choice and to promote end-
resection for repair by HR.  
 
The MRE11-RAD50-NBS1 (MRN) complex and the CtIP endonuclease 
initiate symmetrical end-resection of the DSB in the 3’ to 5’ direction (Figure 1.4). 
Longer 3’ ssDNA tails are generated by more extensive resection by either the 
EXO1 exonuclease or the BLM-DNA2 helicase nuclease complex in the 5’ to 3’ 
direction (Gravel et al., 2008; Mimitou and Symington, 2008; Sartori et al., 2007; 
Symington, 2014; Zhu et al., 2008). The ssDNA overhangs are coated by RPA, 
which is replaced by RAD51 nucleofilaments prior to HR. 
 
PALB2 is a BRCA1 and BRCA2 interacting partner required for proper 
RAD51 filament formation (Xia et al., 2006). BRCA1 promotes BRCA2 localization 
to DSBs through the mutual interaction of PALB2 (Sy et al., 2009; Zhang et al., 
2009a; Zhang et al., 2009b). While BRCA2-PALB2 interact irrespective of cell 
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cycle, the BRCA1-PALB2 interaction is inhibited by ubiquitination outside of S/G2 
phase. Deubiquitination of PALB2 results in the BRCA1-PALB2-BRCA2 interaction 
and permits BRCA2 recruitment to DSBs (Orthwein et al., 2015). 
BRCA2 is required for displacing the ssDNA binding protein RPA from the 
3’ overhangs and loading RAD51 nucleofilaments (Jensen et al., 2010; Yang et 
al., 2005). RAD51 nucleofilaments invade the sister chromatid to perform 
homology search. The homologous DNA is then used as a template for precise 
DNA repair (Jasin and Rothstein, 2013; Jensen et al., 2010). Following strand 
invasion and DNA synthesis, double Holliday junctions (HJ), are dissolved by 
either the BLM/TOPOIIIa/RMI1-RMI2 (BTR) complex or resolved by nucleolytic 
processing by GEN1 or the SLX4-SLX1/MUS81-EME1 complex (Sarbajna and 
West, 2014). 
1.4.3 BRCA1 and BRCA2 in cancer susceptibility 
Heterozygous germline BRCA1 or BRCA2 mutations predispose individuals 
to hereditary breast and ovarian cancer (HBOC) and to a lesser extent pancreatic, 
prostate, and other cancers (Prakash et al., 2015). Carriers of BRCA1 mutations 
largely experience increased risk of female breast and ovarian cancer. BRCA2 
mutation carriers are predisposed to female and male breast cancer, ovarian, 
pancreas, and prostate cancers (Attard et al., 2016; Rustgi, 2014; Venkitaraman, 
2014). The estimated life-time risk for ovarian cancer by the age of 70 for BRCA1 
Figure 1.4 Double strand break repair by homologous recombination. 
Homologous recombination mediated repair of DSBs requires the formation of 3’ 
ssDNA overhangs. The MRE11-RAD50-NBS1 (MRN) complex senses DSB and 
with the CtIP endonuclease initiates DNA end resection. The EXO1 exonuclease 
or the BLM-DNA2 helicase nuclease complex are responsible for more extensive 
resection. BRCA2 loads and stabilizes RAD51 nucleofilaments on the ssDNA 
overhangs displacing the ssDNA binding protein RPA. RAD51 nucleofilaments 
invade the sister chromatid to perform homology search. DNA synthesis can 




and BRCA2 carriers is 57-65% and 45-55% respectively (Nielsen et al., 2016). 
BRCA1 carries have a higher lifetime risk of ovarian cancer at 39-44% by the age 
of 70 compared to BRCA2 carriers’ lifetime risk of 11-18% (Nielsen et al., 2016). 
PALB2 carriers also have an increased lifetime risk of breast cancer of 35% with 
no significant increase in ovarian cancer (Nielsen et al., 2016; Rahman et al., 
2007). BRCA mutations account for approximately 25% of HBOCs, and the list of 
associated candidate HBOC genes is growing, but for the majority, more 
information is required to determine if they pose a significant risk. 
 
Cells null for BRCA1 or BRCA2 are generally nonviable and deficiency of 
either protein is embryonic lethal (Feng and Jasin, 2017; Gowen et al., 1996; 
Hakem et al., 1996; Ludwig et al., 1997). However, in the context of malignancy, 
BRCA1 and BRCA2 loss of function (LOF) tumors do arise when the wild type 
(WT) allele becomes mutated. These cancer cells have acquired the ability to 
handle high levels of replication stress despite BRCA1 or BRCA2 deficiency. 
Current treatment regimens such as radiation therapy, cisplatin, and PARP 
inhibitor (PARPi) take advantage of loss of HR in these malignancies. 
Understanding the mechanism of how these factors work to suppress 
tumorigenesis will be informative for hereditary tumors, but also sporadic tumors 
that display what has been termed BRCAness. BRCAness describes tumors that 
have characteristics of BRCA1 or BRCA2 LOF but do not result from germline 
mutation. BRCAness can arise via somatic mutation or silencing of either gene, 
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mutations in other genes in the HR network, or other undefined mechanisms (Lord 
and Ashworth, 2016).  
 
PARP inhibition in combination with BRCA1 or BRCA2 deficiency is 
synthetically lethal making PARP inhibitor (PARPi) therapy an attractive treatment 
option for hereditary BRCA cancers. PARPi has shown efficacy in treating BRCA1 
or BRCA2 mutated tumors (Farmer et al., 2005, Bryant et al 2005., Lord et al 2015). 
Like with most therapies, advanced cancers acquire chemo-resistance. A clinically 
confirmed mechanism of chemotherapy resistance in BRCA1/2 tumors is 
acquisition of secondary mutations that restore BRCA1/2 activity providing 
resistance to platinum based and PARPi therapy (Barber et al., 2013; Edwards et 
al., 2008; Norquist et al., 2011; Sakai et al., 2008; Swisher et al., 2008). Other 
mechanisms of resistance have been investigated for BRCA1/2 cancers including 
loss of 53BP1, REV7, or PARP1 activity, drug efflux transporters, and restoration 
of replication fork protection (Jaspers et al., 2013; Patch et al., 2015; Pettitt et al., 
2013; Ray Chaudhuri et al., 2016; Rottenberg et al., 2008; Xu et al., 2015).   
 
PARPi synthetic lethality has been attributed to a few proposed 
mechanisms: (1) the persistence of single strand breaks (SSBs), that once 
encountered during replication results in replication fork collapse and DSB 
generation that would require canonical homology directed repair (HDR) and (2) 
the “trapping” of PARP1 on DNA by inhibiting auto PARylation activity that would 
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release the protein, generating a protein-DNA lesion during replication (Lord and 
Ashworth, 2017). The role of PARP1 in promoting nascent strand degradation by 
MRE11 in BRCA deficient cells adds further complexity to the mechanism of 
PARPi lethality and acquired chemoresistance (Ding et al., 2016).  
 
1.5 The role of BRCA2 in replication fork protection 
1.5.1 Homologous recombination independent function of BRCA2 in 
replication fork protection 
Outside of its role in HR mediated DSB repair, BRCA2 function is required 
to protect stalled replication forks (Figure 1.5). By studying DNA replication at the 
single molecule level (DNA fibers), the Jasin laboratory discovered that BRCA2 
protects stalled replication forks from nucleolytic processing by the MRE11 
nuclease. Importantly, this activity appeared to be independent of the canonical 
HR function of BRCA2. The study identified the BRCA2 S3291A mutant as a 
separation of function mutant, which permitted the uncoupling of the two roles of 
BRCA2 in HR and replication fork protection (Schlacher et al., 2011). BRCA2 
Ser3291 is a cyclin-dependent kinase phosphorylation site that regulates the C-
terminal interaction of BRCA2 and RAD51 (Esashi et al., 2005). The C-terminal 
interacting domain of BRCA2 is hypothesized to stabilize RAD51 nucleofilaments 
on ssDNA and upon phosphorylation of Ser3291 this interaction is lost (Davies and 
Pellegrini, 2007). The S3291A BRCA2 mutant is proficient for HDR activity, but is 
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unable to protect against nascent strand degradation by MRE11 (Feng and Jasin, 
2017; Schlacher et al., 2011).  
 
In the absence of BRCA2, newly synthesized ssDNA at stalled replication 
forks is not protected and undergoes extensive degradation that is reported to 
result in increased chromosomal aberrations (Schlacher et al., 2011). The BRCA2 
C-terminal interaction and stabilization of RAD51 on the nascent ssDNA is required 
for replication fork protection. In support of this conclusion, disruption of RAD51 
nucleofilaments by expression of the BRC4 peptide results in nascent strand 
degradation. Conversely, overexpression of a RAD51 mutant, K133R, that forms 
stable nucleofilaments due to loss of ATPase activity required for dissociation from 
DNA, renders replication forks resistant to degradation (Schlacher et al., 2011).  
 
Furthermore, depletion or inhibition of RAD51 has been shown to also result 
in nascent strand degradation at stalled replication forks and cause replication fork 
restart defects (Hashimoto et al., 2010; Petermann et al., 2010; Taglialatela et al., 
2017). However, the role of RAD51 recombinase in replication fork protection has 
been disputed due to conflicting results among studies. In other studies, RAD51 
depletion does not result in nascent strand degradation at stalled replication forks 
(Feng and Jasin, 2017; Lemacon et al., 2017; Mijic et al., 2017; Thangavel et al., 
2015). Different thresholds of RAD51 activity may account for these discrepancies, 
which may be in part due to a newly described BRCA2 independent role of RAD51 
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in replication fork reversal (discussed below) identified by electron microscopy 
(EM) analysis of replication fork intermediates by (Lemacon et al., 2017; Mijic et 
al., 2017).    
 
Following the discovery that BRCA2 and RAD51 are required for the 
protection of stalled replication forks, other proteins in the DNA damage response 
pathway were also found to have a role including BRCA1, RAD51 paralogs, FA 
proteins including FANCA and FANCD2, BOD1L, Abro1, RECQ1, and WRNIP1 
(Higgs et al., 2015; Leuzzi et al., 2016; Schlacher et al., 2012; Somyajit et al., 2015; 
Xu et al., 2017).  
 
1.5.2 BRCA2 independent role of RAD51 in replication fork reversal 
Replication forks that slow and stall can undergo remodeling into a reversed 
replication fork structure. Reversed forks are formed when the parental DNA 
strands reanneal and nascent DNA strands anneal forming a “regressed arm” and 
a joint molecule resembling a Holliday junction. Replicating cells display a baseline 
level of reversed replication forks that is increased upon exogenous genotoxic 
stress to a wide array of agents including topoisomerase inhibitors, DNA 
interstrand-crosslinking agents, DNA synthesis inhibitors, alkylating agents, and 
UV (Berti et al., 2013; Ray Chaudhuri et al., 2012; Zellweger et al., 2015). 
Additionally, EM analysis suggests that cells undergoing rapid proliferation utilize 
replication fork slowing and fork reversal as a means to protect against genomic 
 28 
instability produced by endogenous replication stress (Ahuja et al., 2016). There is 
evidence to support fork reversal as a mechanism to protect against genomic 
instability as it may guard against extensive ssDNA generation, provide DNA repair 
machinery access to the damaged template, or promote lesion bypass (Betous et 
al., 2012; Cortez, 2015; Couch et al., 2013; Ray Chaudhuri et al., 2012; Zellweger 
et al., 2015). However, reversed replication forks are also a substrate liable to 
nuclease processing and DSB formation (Couch et al., 2013; Neelsen et al., 2013; 
Schlacher et al., 2011; Schlacher et al., 2012; Ying et al., 2012).   
 
EM analysis of replication fork intermediates from BRCA2 depleted cells 
shows a decrease in reversed replication fork intermediates. The levels of reversed 
replication fork species are rescued by MRE11 inhibition (Lemacon et al., 2017; 
Mijic et al., 2017). Interestingly, in BRCA2 deficient cells, reversed replication fork 
intermediates are detected at normal levels at early time points after replication 
stress but then decrease due to MRE11 dependent nucleolytic processing 
(Lemacon et al., 2017). These data along with observations from DNA fiber 
analysis suggest that BRCA2 protects reversed replication fork structures from 
nucleases.  
 
Analysis of replication fork species by EM in RAD51 depleted cells also 
shows a decrease in reversed replication forks (Kolinjivadi et al., 2017; Mijic et al., 
2017; Zellweger et al., 2015). Unlike BRCA2 depleted cells, the reversed 
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replication fork levels in RAD51 depleted cells are not rescued by MRE11 inhibition 
(Mijic et al., 2017). Levels of reversed replication forks in BRCA2 deficient cells are 
not rescued by RAD51 depletion or with concomitant MRE11 inhibition despite 
rescue of nascent strand degradation at stalled replication forks (Mijic et al., 2017). 
Conclusions from this work are that BRCA2 and RAD51 are both important for 
protecting reversed replication forks by stabilization of RAD51 nucleofilaments, 
while RAD51 may perform an additional independent function in promoting 
replication fork reversal. These data suggest a model by which depleting RAD51 
prevents replication fork reversal and averts the formation of a substrate for 
MRE11 degradation in the absence of BRCA2/RAD51 nucleofilament formation. 
A RAD51 dominant negative separation of function mutant, T131P, 
identified in an individual with Fanconi anemia-like syndrome is proficient for HDR 
but deficient for replication fork protection (Mijic et al., 2017; Wang et al., 2015). 
The RAD51-T131P mutant does not form stable nucleofilaments due to 
hyperactive ATPase activity (Wang et al., 2015). The RAD51-T131P mutant cells 
undergo MRE11 dependent nascent strand degradation at stalled replication forks 
(Mijic et al., 2017). Reversed replication fork species are also decreased in 
RAD51-T131P cells but are rescued by MRE11 inhibition (Mijic et al., 2017). The 
RAD51-T131P cells are heterozygous and express RAD51 mutant protein at a 
ratio of 1:5 to WT (Wang et al., 2015). The RAD51 activity presumably is enough 
to support replication fork reversal, but not the formation of stable RAD51 
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nucleofilaments that can protect the reversed replication fork from MRE11 
degradation.  
 
The differences in the reporting of the requirement of RAD51 for protecting 
against nascent strand degradation may be due to the extent that RAD51 is 
depleted or inhibited. The use of the BRC4 peptide or B02 inhibitor, like RAD51-
T131P, may prohibit stable RAD51 nucleofilament formation leaving DNA 
vulnerable to nuclease degradation but still leave enough RAD51 activity for 
replication fork reversal (Schlacher et al., 2012; Taglialatela et al., 2017). The 
formation of stable RAD51 nucleofilaments may not be required for replication fork 
reversal activity, but is required for protection of the regressed fork from nucleolytic 
activity (Kolinjivadi et al., 2017; Mijic et al., 2017).  
 
EM analysis of replication fork structures has largely focused on reversed 
replication forks, but other intermediates have also been identified. RAD51 and 
BRCA2 depletion in Xenopus egg extracts results in replication fork intermediates 
with increased ssDNA at the fork and behind the fork (Hashimoto et al., 2010; 
Kolinjivadi et al., 2017). MRE11 inhibition rescues ssDNA gaps behind the fork but 
not the increased ssDNA at the fork junction (Hashimoto et al., 2010; Kolinjivadi et 
al., 2017). Replication forks with ssDNA at the junction may be intermediates that 
proceed replication fork reversal; however, levels in BRCA2 and RAD51 depleted 
extracts appear to be similar despite the perceived independent role of RAD51 in 
 31 
fork reversal (Kolinjivadi et al., 2017). Cells treated with genotoxic agents also 
show increased regions of ssDNA behind the fork and at the fork (Zellweger et al., 
2015). While unprotected reversed replication forks are targeted by MRE11, 
internal ssDNA gaps behind the fork are also MRE11 substrates, and further 
understanding of the role of BRCA2/RAD51 fork protection in preventing their 
generation is needed. 
 
1.5.3 Nuclease processing at stalled replication forks in BRCA2 deficient 
cells 
Restoring replication fork protection in BRCA2 deficient cells has been an 
intense area of research that has largely focused on prohibiting processing by 
MRE11. MRE11 travels with the replisome and its recruitment to chromatin is 
enhanced by exogenous replication stress (Dungrawala et al., 2015; Mirzoeva and 
Petrini, 2003; Robison et al., 2004). The presence of MRE11 at the replisome 
following replication stress is PARP1 dependent, important for Chk1 signaling, and 
replication fork restart (Bryant et al., 2009; Lee and Dunphy, 2013; Olson et al., 
2007; Trenz et al., 2006). While MRE11 is required for the processing of stalled 
replication forks, aberrant activity at unprotected stalled replication forks in BRCA1 
and BRCA2 deficient cells contributes to increased genomic instability (Ray 
Chaudhuri et al., 2016; Schlacher et al., 2011; Schlacher et al., 2012; Ying et al., 
2012). In BRCA2 deficient cells treated with genotoxic agents, MRE11 inhibition 
reduces genomic instability providing evidence that replication fork protection may 
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be an important mechanism for resistance to DNA damage (Ray Chaudhuri et al., 
2016; Schlacher et al., 2011).    
 
Despite the hypersensitivity of BRCA1 and BRCA2 deficient cells to PARPi, 
deficiency of PARP1 protects against nascent strand degradation of stalled 
replication forks by preventing MRE11 recruitment (Bryant et al., 2009; Ding et al., 
2016; Ray Chaudhuri et al., 2016; Ray Chaudhuri et al., 2012). Recent work has 
demonstrated that MRE11 recruitment to sites of replication stress is also 
dependent on PTIP and the associated methyltransferases MLL3/MLL4, the 
chromatin remodeler CHD4, and RAD52 (Mijic et al., 2017; Ray Chaudhuri et al., 
2016). Depletion of these factors rescues nascent strand degradation in BRCA 
deficient cells similar to MRE11 inhibition. Similarly, the decrease in reversed 
replication fork intermediates in BRCA2 deficient cells treated with genotoxic 
agents are rescued by RAD52 inhibition or depletion of PTIP (Lemacon et al., 
2017; Mijic et al., 2017). These data suggest that deficiency of PARP1, MLL4, 
PTIP, CHD4, or RAD52, in BRCA1 or BRCA2 deficient cells rescues nascent 
strand degradation by prohibiting MRE11 fork processing (Mijic et al., 2017; Ray 
Chaudhuri et al., 2016).  
  
Recent studies extend the resection of unprotected nascent DNA at stalled 
forks to EXO1 and CtIP. Depletion of EXO1 or CtIP rescues nascent strand 
degradation in BRCA2 deficient cells (Lemacon et al., 2017). Similarly, knockdown 
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of EXO1 rescues reversed fork levels that are decreased in BRCA1/2 deficient 
cells treated with replication stress inducing drugs (Lemacon et al., 2017). A clear 
role for DNA2 in the processing of stalled replication forks in BRCA deficient cells 
has not been determined. Lemacon et al found that DNA2 depletion does not 
rescue nascent strand degradation in BRCA2 deficient cells. On the contrary, 
Chaudhuri et al show that in BRCA2 deficient B-cells DNA2 inhibition is epistatic 
with MRE11 in the rescue of nascent strand degradation. It is unclear what 
accounts for the difference in the requirement of DNA2 for nascent strand 
degradation in BRCA2 deficient cells, but the studies use different cell types and 
assess the role of DNA2 using two different methods, by siRNA depletion and 
small molecule inhibitor (Lemacon et al., 2017; Ray Chaudhuri et al., 2016). 
Further investigation will be required to determine the dependency of DNA2 in 
nascent strand degradation of BRCA2 deficient cells. The implication of EXO1 and 
CtIP leaves us to contemplate a model of resection similar to DSB end resection 
at unprotected regressed forks. In the absence of BRCA2, resection may be 
initiated by CtIP and MRE11 followed by more extensive processing by EXO1. 
Although it is also possible that the nucleases have different substrates at stalled 
replication forks. 
  
Figure 1.5 BRCA2 and RAD51 mediated replication fork protection 
Replication fork reversal is proposed to be a global response to replication stress 
that requires RAD51-mediated fork reversal. When a replication fork encounters 
replication stress the generation of ssDNA may serve to promote replication fork 
reversal that entails the annealing of the nascent strand DNA and reannealing of 
the parental DNA strands. This process requires RAD51 in a BRCA2 independent 
process. To prevent nuclease degradation, RAD51 must be loaded and stabilized 




1.5.4 DNA translocases in replication fork protection and processing 
Similar to RAD51 depletion in BRCA2 deficient cells, depletion of any of the 
three ATPase dependent DNA translocases of the SNF2 family of chromatin 
remodelers, SMARCAL1, ZRANB3, or HLTF, rescue resection of nascent strand 
DNA by loss of replication fork reversal. These related proteins have been shown 
to have similar fork remodeling activity in vitro. SMARCAL1 demonstrates affinity 
for DNA fork structures and catalyzes activity promoting strand annealing, fork 
regression, and branch migration (Betous et al., 2012; Ciccia et al., 2012; Yusufzai 
and Kadonaga, 2008). ZRANB3 and HLTF also catalyze replication fork reversal 
in vitro (Ciccia et al., 2012; Yuan et al., 2012; Yusufzai and Kadonaga, 2010). 
These translocases have been found to associate with the replication fork; 
however, how they each associate with the fork is different (Figure 1.6). 
SMARCAL1 travels with the replication fork and becomes further enriched 
following replication stress through interaction with RPA. (Bansbach et al., 2009; 
Betous et al., 2012; Ciccia et al., 2009; Dungrawala et al., 2015; Kolinjivadi et al., 
2017; Postow et al., 2009; Yuan et al., 2009). SMARCAL1 interaction with RPA is 
important for providing substrate specificity to promote replication fork reversal and 
prevent activity during normal DNA replication (Betous et al., 2013). ATR 
phosphorylation of S652 of RPA bound SMARCAL1 has been shown to be 
important for regulating its activity at the replication fork (Couch et al., 2013). 
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HLTF and ZRANB3 have been shown to interact with PCNA. HLTF contains 
a RING finger domain and a N-terminal HIRAN domain (Poole and Cortez, 2017). 
HLTF acts as ubiquitin ligase to polyubiquitinate PCNA in a MMS2-Ubc13 
dependent manner (Motegi et al., 2008; Unk et al., 2008). In vitro studies indicate 
the HIRAN domain of HLTF recognizes the 3’ end of the leading strand to promote 
replication fork reversal (Kile et al., 2015). Upon replication stress, ZRANB3 is 
recruited to DNA through a PCNA-interacting protein (PIP) box and an AlkB 
homolog 2 PCNA-interaction motif (APIM) to PCNA (Ciccia et al., 2012; Weston et 
al., 2012; Yuan et al., 2012). ZRANB3 contains a NPL4 zinc finger (NZF) motif that 
preferentially binds K-63 poly-ubiquitinated PCNA and is required for its 
localization to sites of replication stress (Ciccia et al., 2012; Vujanovic et al., 2017). 
In the absence of any of the three translocases, SMARCAL1, ZRANB3, or 
HLTF, cells become hypersensitive to replication stress inducing agents and have 
increased genomic instability (Bansbach et al., 2009; Ciccia et al., 2009; 
Taglialatela et al., 2017). Likewise, translocase activity must be carefully regulated 
to prevent inappropriate fork reversal and breakage. Overexpression of 
SMARCAL1 increases ssDNA and DNA damage (Bansbach et al., 2009). 
Similarly, in ATR inhibited cells, excessive ssDNA is generated in part due to 
aberrant SMARCAL1 activity (Couch et al., 2013). Inappropriate SMARCAL1 
activity generates intermediates that have been shown to be acted on by SLX4 
coupled nucleases and CtIP (Couch et al., 2013). 
38 
Despite similar biochemical activity, SMARCAL1 and ZRANB3, do not act 
redundantly as increased DNA damage accrues upon depletion of both proteins 
(Ciccia et al., 2012). This may be attributed to synergistic functions at replication 
forks, different roles and replication fork substrates, or roles outside of more global 
replication fork remodeling. SMARCAL1 activity is also important for replication 
through difficult to replicate telomeric sequences, a function not attributed to 
ZRANB3 or HLTF (Poole et al., 2015). 
Recent work has further expanded the role of SMARCAL1, ZRANB3, and 
HLTF to replication fork reversal in vivo.  Depletion of SMARCAL1, ZRANB3, and 
HLTF results in decreased detection of reversed replication fork intermediates by 
EM (Vujanovic et al., 2017). Depletion of any of any of these three translocases 
rescues nascent strand degradation at forks defective for BRCA2 replication fork 
protection. This is thought to occur by preventing replication fork reversal, a 
substrate for MRE11 (Kolinjivadi et al., 2017; Taglialatela et al., 2017; Vujanovic 
et al., 2017). SMARCAL1 depletion in BRCA1, BRCA2, or FANCD2 deficient cells 
rescues degradation of nascent DNA at stalled replication forks (Kolinjivadi et al., 
2017; Taglialatela et al., 2017). Similarly, depletion of ZRNAB3 or HLTF in BRCA1 
or BRCA2 deficient cells rescues nascent strand degradation (Mijic et al., 2017; 
Taglialatela et al., 2017). 
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 The overall impact of rescuing nascent strand degradation in replication fork 
protection deficient cells by depletion of these translocases is unclear, as depletion 
on their own increases DNA damage and current findings are contradictory. In one 
study, DNA damage is reduced by ZRANB3 depletion in BRCA deficient cells, with 
no further rescue observed with co-depletion of SMARCAL1 (Taglialatela et al., 
2017). While another study observes rescue of nascent strand degradation by 
ZRANB3 depletion, but increased genomic instability (Mijic et al., 2017). These two 
studies analyzed different cell types under different conditions of damage, 
hydroxyurea (HU) versus camptothecin (CPT), likely in part contributing to the 
observed differences. Replication fork reversal is a response to many types of DNA 
damage, so moving forward it is of interest to clarify how each of these 
translocases respond to specific types of damage and if they work cooperatively 
or have distinct roles at different replication fork substrates (Zellweger et al., 2015).   
 
1.5.5 Deficiency of RADX, a RAD51 effector protein, rescues nascent strand 
degradation in BRCA2 deficient cells 
RADX is a single stranded DNA binding protein recently identified as being 
enriched at replication forks following replication stress (Figure 1.7) (Dungrawala 
et al., 2017). RADX has sequence similarity to RPA and binds through three RPA-
like OB folds. RADX is recruited to replication forks where it modulates the RAD51 
recombinase (Dungrawala et al., 2017). In the absence of RADX, increased levels 
of RAD51 accumulate at stalled replication forks while BRCA2 levels are 
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Figure 1.6 Replication fork reversal mediated by the SNF2 family 
translocases SMARCAL1, ZRANB3, and HLTF. 
Replication fork reversal is mediated by the SNF2 family chromatin remodelers 
SMARCAL1, ZRANB3, and HLTF. HLTF is important for the polyubiquitination of 
PCNA that serves as a platform for recruitment of ZRANB3. SMARCAL1 is 
recruited to the replication fork through interaction with RPA. How these 
translocases remodel the replication fork and whether they work synergistically to 
reverse replication forks is unclear and needs further investigation. 
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unaffected. Conversely RADX overexpression results in a decrease in RAD51 
recruitment to stalled replication forks (Dungrawala et al., 2017). 
Depletion of RADX results in increased DNA damage and DSB formation 
and slowed replication fork progression (Dungrawala et al., 2017; Schubert et al., 
2017). These defects are rescued by co-depletion of RAD51. Similarly, depletion 
of replication fork remodelers, SMARCAL1 and ZRNAB3, or the MUS81 nuclease 
rescue DSBs in RADX depleted cells. These data suggest that in the absence of 
RADX, hyperactivity of RAD51 interferes with normal replication and promotes 
inappropriate replication fork remodeling that results in DSBs mediated by MUS81 
(Dungrawala et al., 2017). 
RADX levels must be carefully controlled as overexpression also increases 
DNA damage. RADX overexpression increases nascent strand degradation at 
stalled replication forks, which likely is the result of antagonizing the protective 
RAD51 nucleofilament. Conversely, depletion of RADX rescues nascent strand 
degradation but not HDR defects in BRCA2 deficient cells. In BRCA2 depleted 
cells, some RAD51 nucleofilament formation may occur in the absence of RADX 
antagonism, which may be significant enough to protect the nascent DNA from 
degradation (Dungrawala et al., 2017). RADX depletion also increases BRCA2 
deficient cells resistance to PARPi (Dungrawala et al., 2017). This presents the 
tradeoff of RADX inhibition to promote replication fork protection in BRCA2 
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deficient cells versus the possibility of inappropriate fork reversal promoted during 
replication that may result in DSBs. Increased viability of BRCA2 deficient and 
RAD51 depleted U2OS cells to genotoxic agents by RADX inhibition suggest 
restoration of replication fork protection is more important.  
 
Another effector protein of RAD51 is FBH1, a 3’-5’ DNA helicase of the UvrD 
family that contains an F-Box domain, a PIP box, and APIM (Bacquin et al., 2013; 
Kim et al., 2002). FBH1 negatively modulates RAD51 through its E3 ubiquitin 
ligase activity that preferentially targets K58/64 of RAD51 (Chu et al., 2015; Kim et 
al., 2002). Unlike RADX, FBH1 depletion in BRCA2 deficient cells does not rescue 
replication fork protection (Higgs et al., 2015; Leuzzi et al., 2016). However, FBH1 
depletion in cells deficient for either BOD1L or WRNIP1, two other replication fork 
protection factors, does rescue nascent strand degradation at stalled replication 
forks (Higgs et al., 2015; Leuzzi et al., 2016). Further investigation is required to 





Figure 1.7 RADX modulates RAD51 activity at replication forks 
(A) The proposed model of RADX activity is to regulate RAD51 activity at the 
replication fork to prevent unnecessary RAD51 association and fork reversal 
during normal DNA replication progression. Upon RADX depletion there is 
increased genomic instability and DSBs that may be the result of inappropriate fork 
remodeling leading to increased fork cleavage and collapse. (B) The depletion of 
RADX in BRCA2 deficient cells rescues nascent strand degradation at HU stalled 
replication forks. Removal of RADX antagonism of RAD51 may permit rescue of 
RAD51 fork protection and prevent degradation by nucleases.   
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1.5.6. MUS81 cleavage of stalled replication forks in BRCA2 deficient cells 
MUS81 has previously been described as the nuclease responsible for the 
DSBs formed during replication stress that results in replication fork collapse. 
However, MUS81 is also important for replication fork restart and depletion of 
MUS81 increases chromosomal aberrations in cells challenged by replication 
stress (Franchitto et al., 2008; Hanada et al., 2007; Pepe and West, 2014; 
Regairaz et al., 2011). MUS81 activity is responsible for breakage at late 
replicating regions in the genome also known as common fragile sites (CFS). 
However, without MUS81 processing CFSs can cause greater genomic instability 
during mitosis (Naim et al., 2013; Ying et al., 2013). Controlled DNA breakage by 
MUS81 is a necessary compromise to promote genome stability and resume 
replication at stalled forks. However, in the case of oncogene-induced DNA 
replication stress, when the cell cycle is deregulated, there is increased MUS81 
dependent DSB formation that contributes to increased genome instability (Murfuni 
et al., 2013; Neelsen et al., 2013). 
MUS81 depletion prevents DSB formation in BRCA2 deficient cells, but 
does not rescue nascent strand degradation. Prevention of nascent strand 
degradation by MRE11 or EXO1 deficiency also decreases DSB formation in 
BRCA2 deficient cells (Lemacon et al., 2017). This places MUS81 activity and 
breakage downstream of MRE11 and EXO1 processing. (Lemacon et al., 2017). 
Reversed replication fork intermediates, visualized by EM, are rescued by 
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depletion of MUS81 in BRCA2 deficient cells, but these replication fork 
intermediates appear to have a ssDNA flap (Lemacon et al., 2017). The ssDNA 
flap intermediate may be the product of MRE11 or EXO1 processing and the 
substrate for MUS81 cleavage (Lemacon et al., 2017). 
Another study identified EZH2, a histone methyl transferase, as important 
for promoting MUS81 processing of stalled replication forks in BRCA2 deficient but 
not BRCA1 deficient cells (Rondinelli et al., 2017). The same study found that 
MUS81 depletion rescued replication fork degradation in BRCA2 deficient cells 
which is in contrast to Lemacon et al’s findings. EZH2 co-depletion with MRE11 
further augmented fork protection, suggesting a separate mechanism from MRE11 
recruitment by MLL3/MLL4/PTIP (Rondinelli et al., 2017). 
Replication fork restart in BRCA2 deficient cells is defective in the absence 
of MUS81 (Lemacon et al., 2017). Similarly, EZH2 inhibition results in reduced 
replication fork restart in BRCA2 deficient cells (Rondinelli et al., 2017). DSBs 
generated in BRCA2 deficient cells, following replication fork stress, are transient 
and return to control levels (Lemacon et al., 2017). Inhibition of nucleases in 
BRCA2 deficient cells rescues nascent strand degradation and breakage, but also 
result in defects in replication fork restart. It is possible that processing of reversed 
replication forks by nucleases is required for replication fork restart and that DNA 




 The objective of this thesis was to investigate novel genes mutated in FA 
families that have not been assigned to one of the known FA complementation 
groups. To achieve this objective, families that fit this criterion were identified from 
the International Fanconi Anemia Registry (IFAR) and were evaluated by Whole 
Exome Sequencing (WES) and cell-based assays. Examination of patient-derived 
cells for hypersensitivity to drugs that generate ICLs and other DNA damaging 
agents demonstrated that despite the overlap in clinical features they behaved 
differently suggesting the patients do not harbor mutations in the same gene. I will 
present three cases identified from the IFAR that were the focus of study in this 
thesis.  
 
 The first case, the subject of Chapter 2, is the identification of biallelic 
UBE2T mutations as causing a new subtype of FA in an individual with typical FA 
features. Pathogenic mutations were not identified by WES, but a large duplication 
and a large deletion were detected by sequencing of the UBE2T locus upon 
discovery of a significant decrease in UBE2T transcripts by RNA sequencing 
(RNAseq). Analysis of cells deficient for UBE2T demonstrated it is the primary E2 
of the FA pathway and is required for monubiquitination of the ID2 complex. 
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The second case, the subject of Chapter 3, is the unexpected identification 
of compound heterozygous biallelic FANCD1/BRCA2 mutations in a sibling pair 
that does not display the typical clinical findings of this complementation group. 
Their atypical presentation had previously precluded their screening for the 
FANCD1 complementation group. The objective of this study was to determine the 
function of the DBD of BRCA2 that is mutated in this family in order to better 
understand the functions of BRCA2 and the consequences its disruption has on 
human diseases such as FA and HBOC. The work herein determined that the 
BRCA2 DBD is required for replication fork protection and to a lesser extent HR. 
The third and final case, the subject of Chapter 4, describes an individual 
enrolled in the IFAR that cellular characterization revealed to not have defects in 
ICL repair. Due to the heterogeneous nature of FA, defects of other pathways 
important for DNA repair or replication can have overlapping clinical features 
leading to misdiagnosis. Cellular analysis revealed no classic hallmarks of FA, but 
defects in the cellular response to DNA replication stress. The genetic basis of 
disease in this individual is still under investigation. 
The identification of novel inherited DNA repair disorders increases our 
understanding of the cellular networks working to maintain genome integrity, 
preserve normal cellular function, and protect against tumorigenesis. These are 
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networks that work in all human cells to assure normal function, so the implications 




Chapter 2: Deficiency of UBE2T causes a new 
subtype of Fanconi anemia and is the primary 
E2 ubiquitin-conjugating enzyme necessary for 
FANCD2 and FANCI ubiquitination 
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2.1 Introduction 
A key step in the repair of ICLs is the monoubiquitination of FANCD2 and 
FANCI at residues K561 and K523 respectively. Site specific mutagenesis of either 
of these lysine residues results in failure of FANCD2 and FANCI to be ubiquitinated 
and recruited to ICLs (Garcia-Higuera et al., 2001; Smogorzewska et al., 2007b). 
FANCD2 and FANCI monoubiquitination requires an intact FA core complex that 
acts as an E3 ubiquitin ligase with FANCL as the catalytic subunit (Hodson et al., 
2014; Meetei et al., 2003a). The E2 ubiquitin-conjugating enzyme UBE2T was 
identified as an interactor of FANCL by a yeast two-hybrid screen (Machida et al., 
2006). Depletion of UBE2T results in defective ubiquitination of FANCD2, loss of 
FANCD2 recruitment to foci after DNA damage, and cellular sensitivity to ICLs (Alpi 
et al., 2008; Machida et al., 2006). Here we describe a new FA complementation 
group identified in a patient enrolled in the International Fanconi Anemia Registry 
(IFAR) presenting with typical FA features and deficiency of the ubiquitin-
conjugating enzyme (E2), UBE2T. 
2.2 Results 
2.2.1 Presentation of Fanconi anemia patient of unknown complementation 
group  
The subject of study was identified as a participant enrolled in the 
International Fanconi Anemia Registry (IFAR) diagnosed with FA of unknown 
complementation group. The patient was born premature at 36 weeks gestation 
weighing 3lbs 7oz and measuring 16.5 inches long in the 3rd percentile. At birth the 
subject presented with bilateral radial aplasia and absent thumbs, microcephaly, 
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micrognathia, café au lait spots, ventricular septal defect (VSD), patent ductus 
arteriosus (PDA), and absent left kidney. At birth the patient had thrombocytopenia 
that resolved in subsequent days. There was family history of Thalassemia, but no 
history of early onset cancer or bone marrow failure.  
 
The patient was clinically diagnosed with Fanconi anemia at birth. 
Cytogenetic studies were performed at the Laboratory of Human Genetics and 
Hematology at The Rockefeller University Hospital and showed elevated 
chromosomal breakage in peripheral blood (PB) samples treated with the DNA 
crosslinking agent diexpoxybutane (DEB). Initially, breakage levels of PB collected 
at 2 days old displayed significantly elevated chromosomal breakage levels at 5.8 
breaks per cell in 85% of the cell population. Decreasing breakage levels over time 
demonstrated the development of somatic mosaicism in the hematopoietic 
compartment, a phenomenon seen in a small subset of FA patients (Table 2.1) 
(Gregory et al., 2001; Lo Ten Foe et al., 1997; Soulier et al., 2005; Waisfisz et al., 
1999).  
 
The patient is seen at Cincinnati Chidlren’s hospital for bone marrow testing 
annually. Our most recent blood counts for age 16 years old report a hemoglobin 
of 13.9, platelet count of 202,000, and white blood cell count of 6.6 (absolute 
neutrophil count mildly decreased at 0.79 and an elevated absolute lymphocyte 
count of 5.6). Peripheral blood smear shows moderate neutropenia and microcytic  
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Age, Report Date # DEB treated cells analyzed 
Mean chromosome breaks per 
cell/ percent of cells with breaks 
2 days, 11/30/98 20 5.8, 85% 
10 days, 11/30/98 10 7.1, 80% 
1 years, 11/06/98 10 7.5, 80% 
6 years, 05/22/05 15 4.1, 47% 
6 years, 10/05/05 50 0.08, 8% 
6 years, 10/10/05 40 0.28, 17.5% 
16 years, 4/18/15 50 0.32,18% 
Table 2.1 Chromosome breakage analysis of subject's peripheral 
blood samples treated with DEB 
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red blood cells consistent with thalassemia trait. Bone marrow biopsy 
demonstrates mild hypocellularity for age in the 35-45% range with trilineage 
hematopoiesis. Chromosome studies show a normal 46, XY karyotype. To date 
there is no evidence of abnormal clonal cells, MDS, or leukemia in this patient. 
The patient has a history of normal Adrenocorticotropic hormone (ACTH) 
and Growth Hormone (GH) stimulation. The patient takes thyroid replacement 
therapy for hypothyroidism. Cardiac evaluation by ECG was normal and 
echocardiogram reveals a normal heart with normal valve anatomy and function. 
The patient has a solitary kidney and normal renal function with a creatinine value 
of 0.57. The patient at 16 years of age, performed well in school with no known 
learning disabilities, and is generally active. The patient has bilateral conductive 
hearing loss and uses hearing aids. The patient’s height remains below the 5th 
percentile and most recent bone age was slightly greater than chronological age. 
2.2.2 Cellular phenotype of Fanconi anemia cell line of unknown 
complementation group 
To support the elevated chromosomal breakage levels identified in early PB 
tests and diagnosis of FA, we analyzed patient derived fibroblasts (RA2627). 
RA2627 fibroblast are hypersensitive to crosslinking agents MMC and DEB in 
survival assays (Figure 2.1A-B). Chromosomal breakage levels are elevated in 
RA2627 fibroblasts treated with DEB as compared to BJ wild type fibroblast, 
although slightly lower than FA-A patient cells (RA3087) (Figure 2.1C-D). RA2627 
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cells are deficient for FANCD2 monoubiquitination (Figure 2.1E) while the 
lymphoblastoid cell line (LCLs) (RA2946), derived from blood that showed 
mosaicism, displayed normal FANCD2 monoubiquitination, consistent with genetic 
reversion (Figure 2.1F). By immunofluorescence, FANCD2 foci were not observed 
in RA2627 cells following 24-hour treatment with MMC (Figure 2.1G). These data 
demonstrate that the subject’s fibroblasts display deficiency of FA pathway 
activation, consistent with either the deficiency of the FA core complex, one of the 
associated proteins, or the ID2 complex, whereas the subject’s LCLs are 
phenotypically reverted consistent with mosaicism observed in the subject’s blood.  
 
2.2.3 Whole exome sequencing and high-resolution array comparative 
genomic hybridization 
High-resolution array comparative genomic hybridization (aCGH) of 
genomic DNA from the subject’s fibroblasts and peripheral blood samples did not 
detect deletions or duplications in the known FA genes. Whole exome sequencing 
(WES) of DNA derived from proband LCLs and parental peripheral blood samples 
was performed. Analysis of WES data revealed a single FANCA mutation, 
c.2574C>G/p.Ser858Arg, previously described in FA (Tamary et al., 2000; Wijker 
et al., 1999). A second mutation in FANCA was not identified, but detection may 
not be possible in DNA derived from a revertant cell line. Normal levels of FANCA 
were detected by western blot in RA2627 cells (Figure 2.2A) and overexpression 
of wild type FANCA in RA2627 failed to rescue the monoubiquitination defect of  
  
Figure 2.1 Characterization of cell lines from an individual with FA under 
study. 
(A-B) MMC and DEB cell survival assays of the subject’s RA2627 fibroblasts in 
comparison to FANCA-mutant (RA3087) and BJ wildtype fibroblasts. Cells were 
treated in triplicate with increasing concentration of MMC or DEB. Cell numbers 
were determined after 7 days and normalized to untreated control to give percent 
survival. Error bars indicate s.d. (C) Example of metaphase spread of RA2627 
following 0.1 ug/ml DEB treatment. Inset images highlight radial chromosomes. 
(D) Quantification of chromosome breaks of DEB treated BJ, FANCA-mutant, and 
RA2627 fibroblasts. Mean breaks per cell were 0.19, 7.5, and 3.3 respectively (E-
F) Western blot with FANCD2 antibody of BJ, RA2627 proband fibroblasts, and 
FANCA-mutant fibroblasts or non-FA control RA2987 lymphoblasts, RA2946 
proband lymphoblasts, and FANCA-mutant lymphoblasts. Cells were cultured with 
or without 1 µM MMC for 24h.  (G) FANCD2 foci formation following treatment 




FANCD2 and FANCI excluding FANCA as a causative gene in this cell line (Figure 
2.2C).  WES analysis identified no other mutations in reported FA genes. 
2.2.4 Identification of biallelic UBE2T mutations in the subject 
RNA sequencing (RNA-seq) was performed on RA2627 fibroblasts to 
assess altered transcript levels that might indicate functionally significant gene 
mutations not captured by WES.  Compared to a non-FA patient cell line (RA3380), 
a marked reduction in UBE2T was detected, but not in any of the known FA genes 
(Figure 2.3A). Decreased UBE2T transcript levels were confirmed by RT-qPCR 
(Figure 2.3B) and UBE2T protein was undetectable in RA2627 fibroblast lysates 
by western blot analysis (Figure 2.3C). Interestingly, UBE2T transcript and protein 
were present at near normal levels in proband LCLs (RA2946) (Figure 2.3D) 
supporting the presence of a genetic reversion in the hematopoietic compartment. 
Sanger sequencing of genomic DNA and cDNA from proband primary 
fibroblasts (RA2627), parental peripheral blood, and LCLs revealed compound 
heterozygous mutations in UBE2T, a large paternally derived deletion and 
maternally derived duplication (Figure 2.4). 
The paternally derived deletion, g.202332626_202341295del, appears to 
have resulted from recombination of two AluYa5 repeats within the UBE2T gene 
(Figure 2.5). The paternally derived deletion was uncovered by genomic 
sequencing of the proband and parental DNA. Genomic deletion was suspected 
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Figure 2.2 FANCA cDNA fails to complement RA2627 FANCD2 and FANCI 
monoubiquitination defect. 
A) Western blot with FANCA antibody of RA2627, BJ, and FANCA-mutant
fibroblasts. (B) Expression of wild type HA-FLAG tagged FANCA cDNA or empty 
vector control (EV) in RA2627 and FANCA-mutant fibroblasts. (C) Western blot 
with FANCD2 and FANCI antibody of FANCA complemented cells.   
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based on the inheritance of an informative polymorphic marker rs14451 (exon2) 
detected in WES of the proband and parental DNA. Somatic mosaicism of the 
proband LCLs complicated interpretation of WES data; however, the homozygous 
presence of rs14451 in the paternal data and absence in proband data suggested 
hemizygosisty for the proband in this region even in the revertant LCLs. PCR and 
Sanger sequencing of the UBE2T locus confirmed this finding and revealed 
additional informative markers rs10753914 (IVS1) and rs788801 (IVS6). The 
proband is hemizygous for the rs10753914 (IVS1) SNP, but heterozygous for the 
downstream rs788801 (IVS6) SNP suggesting break boundaries for the indel. A 
long range genomic PCR using primers flanking these markers failed to amplify 
the predicted 10,120bp product, but a smaller amplicon of ~1500 bp was present 
in the proband and the father but not the mother or non-FA control (Figure 2.5A). 
Sanger sequencing of this smaller PCR product confirmed a large genomic 
deletion, g.202332626_202341295del, in the proband and father likely resulting 
from Alu-Alu mediated non-allelic homologous recombination (NAHR) between 
two AluYa5 repeats within the UBE2T gene. The sequence intervening IVS1 
AluYa5 and IVS6 AluYa5 and one Alu is lost in the paternally derived allele 
resulting in an 8670bp deletion (Figure 2.5B). The resulting single AluYa5 
sequence is bordered by IVS1 on the 5’ side and IVS6 on the 3’ (Figure 2.5C). This 
deletion is expected to be a null allele, as it results in the loss of a majority of the 
gene including the start codon. 
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Figure 2.3 UBE2T is deficient in RA2627 cells. 
(A) Comparison of normalized RNA-seq expression, Fragments Per Kilobase of 
transcripts per Million reads (FPKM), of known FA genes and UBE2T for RA2627 
and non-FA control RA3380 primary cells. (B) RT-quantitative PCR of UBE2T 
expression levels in RA2627 fibroblasts (left) and RA2946 lymphoblasts (right) in 
comparison to wild type control and FANCA-mutant cells. Error bars indicate 
standard error of three replicates.  (C-D) Western blot with UBE2T antibody. 
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The maternal duplication, g.202332626_202341295dup, also appears to be 
mediated by Alu recombination. The maternally derived mutation consists of a 
large duplication of the genomic region between the two AluYa5 repeats (Figure 
2.4 and Figure 2.6). Analysis of UBE2T cDNA revealed a unique Exon6-Exon2 
junction suggesting a genomic duplication of a region of UBE2T (Figure 2.6A). This 
unique junction, was also identified in the genomic DNA from proband fibroblasts 
and mother’s LCLs using PCR and Sanger sequencing (Figure 2.6B). The region 
following exon 6 was found to contain IVS6 sequence flanking the 5’ of the AluYa5 
repeat and IVS1 sequence flanking the 3’ of the repeat, and was confirmed by 
cloning. This is likely a duplication event mediated by Alu recombination (Figure 
2.6C). 
 
Cloning of cDNA from proband fibroblasts revealed a transcript containing 
the hypothesized duplication c.-64_468dup (dupEx2_6) (Figure 2.6A and C).  In 
this transcript, exon 6 is spliced to the duplicated exon 2. Inclusion of the noncoding 
region from exon 2 results in a frameshift and a premature stop codon. The c.-
64_468dup transcript can be detected at very low frequency in RA2627 cells and 
is likely degraded by nonsense-mediated decay due to the premature stop codon. 
If any transcript is translated, it may produce a residual amount of the predicted 
protein p.A157Cfs*7. PCR analysis of gDNA demonstrates that the maternally 
derived mutation is absent in the RA2946 LCLs (Figure 2.6D). This indicates that 
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Figure 2.4 UBE2T deficiency is the result of AluYa5 mediated non-allelic 
homologous recombination. 
Schematic of the paternally derived deletion and maternally derived duplication 
resulting from Alu-Alu mediated non-allelic homologous recombination (NAHR) of 
AluYa5 repeats present in IVS1 and IVS6 of the UBE2T gene. For the paternal 
allele, recombination resulted in the loss of the intervening sequence and one 
AluYa5 repeat (8,670bp).  For the maternal allele, recombination resulted in the 
insertion of another AluYa5 repeat and duplication of the sequence between the 
Alu repeats. 
Figure 2.5 Identification of paternally-derived deletion resulting from AluYa5 
mediated non-allelic homologous recombination. 
A) PCR to identify mutations in UBE2T in the indicated cell lines and parental
peripheral blood (PB) samples. RA2627 are proband-derived fibroblasts and 
RA2946 are proband LCLs. The expected PCR product amplifying with primers 
474Fwd and 479Rev is 10,120bp. The large amplicon PCR failed, but a smaller 
amplicon of ~1,500bp was identified in the proband and father but not the mother 
and non-FA control. Asterisk denotes non-specific bands. (B) Schematic of 
UBE2T indicating the location of PCR primers 474Fwd and 479Rev and the span 
of PCR amplicons. Recombination between the AluYa5 sites results in an 8,670bp 
deletion that yields the smaller 1,450bp PCR products. (C) Chromatograms 
displaying sequencing results of the 1,450bp PCR product. UBE2T IVS1 borders 
the 5’ AluYa5 sequence and the 3’ AluYa5 sequence is bordered by IVS6.  The 
sequence intervening the Alu repeats and one AluYa5 repeat has been deleted.
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Figure 2.6 Identification of maternally-derived duplication mutation resulting 
from AluYa5 mediated non-allelic homologous recombination. 
(A) Examination of RT-PCR products amplified with primers 474Fwd and 479Rev 
yielded the maternal duplication transcript that is 1,250bp in length. 
Chromatograms depict the Exon6-Exon2 and Exon6-Exon7 junctions present in 
this mRNA transcript. (B) Analysis of genomic DNA for Alu mediated duplication. 
PCR using 509Fwd and 538Rev primers results in a 1,128bp PCR product in 
proband fibroblasts and maternal LCLs. Chromatograms display PCR sequencing 
demonstrating that UBE2T IVS6 borders the 5’ AluYa5 sequence and the 3’ 
AluYa5 sequence is bordered by IVS1. The sequence between the Alu repeats 
and one AluYa5 repeat has been duplicated. (C) Schematic of UBE2T indicating 
location of PCR primers and span of amplicons for genomic and cDNA assays. 
(D) 1,128bp PCR product that is specific to the maternal duplication (509Fwd and 
538Rev primers). Analysis of gDNA from fibroblasts, LCLs, and PB from the 




the expression of wild type UBE2T in the proband blood may be due to 
recombination of the maternally derived allele to restore the WT sequence. 
2.2.5 Complementation of RA2627 cellular defects by wild type UBE2T 
expression 
To prove that UBE2T deficiency is the cause of the subject’s FA, we 
introduced wild type UBE2T into RA2627 fibroblasts and assayed for rescue of FA 
phenotypes. Overexpression of UBE2T rescued cellular hypersensitivity to 
crosslinking agents MMC, DEB and cisplatin (Figure 2.7A-C). UBE2T expression 
restored monoubiquitination of FANCD2 and FANCI (Figure 2.7D) and FANCD2 
foci following treatment with MMC (Figure 2.7G). Analysis of cell cycle distribution 
following treatment with MMC revealed an accumulation of RA2627 cells in G2 that 
was rescued by UBE2T overexpression to the levels observed in wild type BJ cells 
(Figure 2.7E). These results confirm that deficiency of UBE2T results in Fanconi 
anemia-T complementation group. 
2.2.6 The primary role of UBE2T is in ICL repair 
To determine if UBE2T is important for resistance to other types of damage, 
RA2627 cells were tested for sensitivity to other genotoxic agents. RA2627 cells 
were not found to be sensitive to UV, IR, CPT, HU, or the PARP inhibitor olaparib 
(PARPi) (Figure 2.8A-F). These results are in contrast to previously reported UV 
and HU sensitivity of UBE2T deficient DT40 cells (Kelsall et al., 2012). These data 
suggest that UBE2T does not have a major role in responding to DNA lesions or 
Figure 2.7 UBE2T cDNA complements RA2627 hypersensitivity to 
crosslinking agents and monoubiquitination of FANCD2 and FANCI. 
(A-C) Complementation of MMC, DEB, and cisplatin sensitivity of proband 
fibroblasts (RA2627). Error bars indicate s.d. (D) Western blot analysis with 
FANCD2 and FANCI antibody of UBE2T complemented cells with 1 µM MMC 
treatment for 24h. (E) Complementation of cell cycle defect after 45 nM MMC 
treatment. Cells were treated with drug and cultured for 48 h before analysis. (F) 
Expression of wild type HA-FLAG tagged UBE2T cDNA or empty vector control 
(EV) in RA2627 fibroblasts. (G) FANCD2 foci formation of complemented cells 




replication stress produced by these agents and its primary function is in ICL 
repair. 
2.2.7 A potential a mechanism of FA pathway regulation through UBE2T 
While our manuscript was in press, Hira et al., published the identification 
of two individuals with compound heterozygous UBE2T mutations. Both individuals 
harbored different LOF mutations in trans to a N-terminal aa substitution p.Q2E 
(Hira et al., 2015). The Q2E substitution replaces a polar aa with an acidic residue 
and results in decreased FANCL binding and reduction in ID2 ubiquitination (Hira 
et al., 2015). 
Analysis of the S. pombe E1-E2 structure of Uba1-Ubc15 shows that acidic 
residues of the N-terminus may reduce E1-E2 binding and that introduction of 
negative charge at the N-terminus also reduces E1-E2 interaction. Similarly, 
phosphorylation of the N-terminal of Ub E2s may also serve to regulate the E1-E2 
interaction and a number of Ub E2s have serine/threonine phosphorylation sites in 
the N-terminal region (Lv et al., 2017). The UBE2T N-terminus contains a protein 
kinase C (PKC) consensus sequence and can be targeted by basophilic kinases 
on Ser5 in vitro (Lv et al., 2017). The structure of UBE2T and the FANCL RING 
domain demonstrates that the RING domain is also in proximity to UBE2T Ser5 
suggesting that phosphorylation would disrupt the E1 as well as the E3 interaction 
(Hodson et al., 2014; Lv et al., 2017). 
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Compared to unmodified wild type UBE2T protein, phosphorylated Ser5 
(pSer5) and the phosphomimetic mutant S5D have severely diminished 
monoubiquitination activity in vitro. Similarly, the Q2E substitution disrupts E1-E2 
thioester transfer and monoubiquitination of FANCD2 (Lv et al., 2017). To 
determine the consequences phosphorylation may have in vivo, we overexpressed 
the UBE2T S5D phosphomimetic mutant in UBE2T deficient RA2627 fibroblasts 
(Figure 2.9A).  The Q2E substitution was also overexpressed for comparison. Both 
S5D and Q2E showed significant defects in monoubiquitination of FANCI and 
FANCD2 by western blot and foci formation following treatment with mitomycin C 
(MMC) (Figure 2.9B-D). The S5D and Q2E mutants did not fully rescue sensitivity 
to MMC by cell survival assay (Figure 2.9E). In contrast, the S5A phosphomutant 
rescues monoubiquitination of FANCD2/I, FANCD2 foci formation, and 
hypersensitivity to MMC (Figure 2.9G-H). The pSer5 was undetectable in cell 
lysates using a phospho specific antibody and by mass spectrometry.  However, 
the S5A phosphomutant is able to fully rescue the defects of the UBE2T deficient 
cells suggesting the S5D phosphomimetic is not a non-specific disruption of the 
E1-E2 or E2-E3 interaction. These data demonstrate that phosphorylation of the 
N-terminus in UBE2T may serve to regulate E1-E2 and E2-E3 interactions, but 
more investigation and identification of a responsible kinase would be required to 
determine if this is an important mechanism of regulation of the FA pathway. 
Additionally, in light of these findings, we predict that the patient Q2E mutation 
Figure 2.8 UBE2T does not have a major role in repair of other types of DNA 
damage. 
(A) UV treated cell survival assay of the UBE2T complemented pair of RA2627 
fibroblasts compared to BJ wild type fibroblasts depleted of XPF. (B) Western blot 
of XPF levels for cells used in A. (C) IR cell survival assay of RA2627 fibroblasts 
in comparison to RAD50 patient fibroblasts (RAD50mut). (D-E) Camptothecin 
(CPT) and PARP inhibitor olaparib (PARPi) cell sensitivity assays comparing 
RA2627 fibrobalsts to a patient SLX4 fibroblast cell line (SLX4mut). Patient SLX4 
complemented pair are transduced with wild type SLX4 cDNA or empty vector 
(EV). (F) Cell survival assay to hydroxyurea (HU) of RA2627 cells compared to 
BRCA2 patient fibroblast cell line (BRCA2mut). Error bars indicate s.d. 
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Figure 2.9 UBE2T/FANCT deficient RA2627 cells expressing UBE2T S5D 
phosphomimetic are defective for FANCD2 and FANCI monoubiquitination. 
(A) Western blot of HA-FLAG-tagged UBE2T expression. RA2627 UBE2T/FANCT 
deficient fibroblasts expressing wild type (WT) UBE2T, empty vector control (EV), 
and UBE2T mutants Q2E and S5D. (B) Western blot analysis of FANCD2 and 
FANCI monoubiquitination in UBE2T complemented cells following 24h treatment 
with 1 µM MMC. (C) FANCD2 foci formation in RA2627 cells expressing wild type 
and mutant UBE2T after 24h treatment with 1 µM MMC. (D) Quantification of 
FANCD2 foci formation visualized in C. (E) MMC cell survival assay of RA2627 
hTERT cells expressing WT and mutant UBE2T. (F) Western blot of HA-FLAG-
tagged S5A UBE2T expression in RA2627 cells used in G-H. (G) Quantification 
of FANCD2 foci formation of UBE2T S5A mutant compared to EV and WT 
expressing RA2627 fibroblasts. (H) MMC cell survival assay of UBE2T S5A 




 described by Hira et al. likely disrupts both E1 and E2 interaction by substitution 
of an acidic residue leading to suboptimal activation of the FA pathway. 
2.3 Summary and Conclusion 
In this study, we have identified a Fanconi anemia subtype resulting from 
deficiency of UBE2T. Analysis of RNA-seq data was critical in identifying UBE2T 
deficiency stressing that multipronged diagnostic approaches are often necessary 
in a genetically heterogeneous disease like FA. 
We have identified compound heterozygous mutations in UBE2T, a large 
genomic deletion in the paternally derived allele and a large duplication in the 
maternally derived allele.  Both of the mutations appear to be driven by Alu-
mediated non-allelic homologous recombination (NAHR).  NAHR is a prevalent 
mechanism in genetic disorders arising from copy number defects due to recurrent 
intrachromosomal recombination events (Deininger, 2011). Recently, sequencing 
of FANCA deletion variants identified that breakpoints preferentially lie within Alu 
elements and has revealed NAHR as a major mechanism of deletion in FANCA 
(Flynn et al., 2014).  
The subject presented at birth with classic FA features including 
developmental defects and increased chromosomal breakage. The subject has not 
yet developed bone marrow failure at the age of 16. Blood counts are likely 
preserved due to the somatic mosaicism of the hematopoietic compartment. 
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Restoration of UBE2T expression is detected in the individual’s lymphoblast cells 
and we have observed increasing rescue of chromosomal breakage in peripheral 
blood since birth. The subject’s bone marrow remains stable but hypocellular for 
age (30-40%) and it is unclear whether mosaicism will continue to improve the 
bone marrow cellularity. 
The paternally derived deletion mutation is expected to not produce protein 
due to deletion of the majority of the coding region and start codon, while the 
maternally derived duplication results in very low levels of the c.-64_468dup 
UBE2T transcript.  This transcript may theoretically produce a UBE2T p.A157Cfs*7 
protein, but it is clearly  insufficient to fully support FA pathway function as evident 
by the phenotype of the subject and the cellular defects. The subject’s fibroblasts 
are as sensitive as FA-A patient cells by cell survival assay and no 
monoubiquitination of FANCD2 or FANCI is detected. However, breakage levels 
are not as elevated as the FA-A fibroblasts leaving the possibility that residual 
truncated UBE2T may be present and active at a very low level, affecting the 
breakage phenotype.  An alternative explanation could be that another E2 with low 
levels of activity may partially substitute in the pathway. 
UBE2T has been demonstrated to be the major E2 ubiquitin-conjugating 
enzyme required for the monoubiquitination of FANCD2 and FANCI (Alpi et al., 
2008; Hodson et al., 2014; Longerich et al., 2014; Longerich et al., 2009; Machida 
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et al., 2006; Sato et al., 2012). Efficient and specific FANCD2 monoubiquitination 
in vitro by UBE2T/FANCL requires the presence of FANCI and DNA (Longerich et 
al., 2014; Sato et al., 2012). In vitro studies have demonstrated that a second E2, 
UBE2W, can also ubiquitinate FANCD2 (Alpi et al., 2008; Zhang et al., 2011). In 
recent work, the in vitro monoubiquitination of FAND2 by UBE2W is demonstrated 
to be nonspecific, does not require interaction of ID2 complex, and is not stimulated 
by DNA (Longerich et al., 2014). Additionally, ΔUBE2W chicken DT40 cells do not 
display sensitivity to MMC and display normal levels of MMC induced 
monoubiquitination of FANCD2 (Longerich et al., 2014). 
The RA2627 patient cells do not have any detectable UBE2T by western 
blot and transcript levels are extremely low making them ideal for studying cellular 
defects of UBE2T deficiency. Previously, it was reported that UBE2T deficient 
DT40 cells are sensitivity to UV and HU (Kelsall et al., 2012). In RA2627 cells, 
UBE2T deficiency does not result in cellular sensitivity to UV and the patient does 
not report sensitivity to sun exposure. We also demonstrate that UBE2T is not 
required for cellular resistance to other types of DNA damage produced by IR, 
CPT, PARP inhibitor, or HU. These results demonstrate the primary role of UBE2T 
is in ICL repair and not in response to other types of DNA damage by these agents. 
The Olsen laboratory determined the S. pombe Uba1-Ubc15 E1-E2 
complex structure and observed that negative charge or phosphorylation of N-
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terminus residues of Ub E2s inhibits their function in vitro by interrupting the E1-
E2 interaction (Lv et al., 2017). The UBE2T and FANCL RING domain structure 
also indicates that disruption in this region of UBE2T may also impact the E2-E3 
interaction (Hodson et al., 2014; Lv et al., 2017). Expression of phosphomimetic 
S5D and Q2E UBE2T in RA2627 cells mildly ameliorates UBE2T deficiency but 
still results in reduced FA pathway activation and ICL sensitivity. UBE2T Ser5 may 
be a regulatory site that disrupts both E1-E2 and E2-E3 interaction; however, 
pSer5 was not detected in vivo. Nonetheless, the deleteriousness of the patient 
Q2E substitution, that is the outcome of a point mutation, likely results from the 
disruption of both the E1-E2 and E2-E3 interactions resulting in inadequate FA 
pathway activation. 
Our identification of biallelic UBE2T mutations and UBE2T deficiency in an 
individual with FA corroborates that UBE2T is the primary E2 of the FA pathway 
required for the activation of ID2 complex by monoubiquitination of FANCD2 and 
FANCI and repair of DNA interstrand crosslinks. Deficiency of UBE2T causes 
complementation group Fanconi anemia-T disease and future evaluation of FA 
patients with unknown gene mutations should include complementation studies of 
UBE2T. 
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Chapter 3: Differential roles of the BRCA2 DNA 
binding domain in replication fork protection in 
response to hydroxyurea and DNA interstrand 
crosslink damage  
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3.1 Introduction 
FANCD1/BRCA2 is an essential gene required for organismal development 
and cellular survival. Single allele mutations in BRCA2 predispose to breast and 
ovarian cancer and biallelic mutations results in a subtype of Fanconi anemia, FA-
D1 (Howlett et al., 2002). FA is a heterogeneous disease, but even within the 
disease spectrum, FANCD1 patients are phenotypically distinct. A higher 
proportion of FA-D1 patients have developmental abnormalities and the probability 
of presenting with malignancy is 97% by the age of 5 (Alter et al., 2007). FA-D1 
patients are rare, making up only 2% of Fanconi anemia cases (Wang and 
Smogorzewska, 2015). Here we identify individuals with atypical FA-D1 
presentation with mutations that lie within the BRCA2 DNA biding domain (DBD). 
The identification of these FA-D1 individuals suggests that certain mutations of 
BRCA2/FANCD1 may present differently than those previously described (Alter et 
al., 2007; Myers et al., 2012; Wagner et al., 2004). It provides a unique opportunity 
to uncover the BRCA2 function that is specific to this domain. 
Functional analysis of BRCA2 has historically focused on canonical 
homologous recombination (HR) and the requirement for BRCA2 in ICL repair has 
been attributed to the importance of HR repair of DSBs generated during ICL 
processing. As described in the main introduction of this thesis, the role of BRCA2 
has been expanded to the protection of stalled replication forks (Quinet et al., 
2017). Analysis of replication fork intermediates by EM corroborates that reversed 
replication forks are a structure that requires BRCA2-RAD51 protection to prevent 
Figure 3.1 BRCA2 mutations identified in a sibling pair with atypical Fanconi 
anemia 
Family pedigree showing a sibling pair with Fanconi anemia (red circles) who are 
compound heterozygous for BRCA2 c.2330dupA (maternal inheritance) and 
c.8524C>T (paternal inheritance) mutations. Family history of breast cancer
(purple), skin cancer (grey), and colon cancer (green). (B) Chromatograms of 
Sanger sequencing confirming BRCA2 c.2330dupA and c.8524C>T mutations 




nucleolytic degradation (Lemacon et al., 2017; Mijic et al., 2017). Mitomycin C 
(MMC) treatment is reported to increase reversed replication fork intermediates 
but the physiological relevance of fork reversal in ICL repair has not been 
investigated (Zellweger et al., 2015). RAD51 is recruited to replication forks stalled 
at ICLs prior to DSB production and has been shown to have a role in protecting 
ICLs against extensive resection by DNA2 and WRN (Long et al., 2011; Wang et 
al., 2015). Here, the requirement for BRCA2 to protect against hyper-resection of 
ICLs, separate from its role in HR, is investigated. These studies reveal that 
replication fork protection at hydroxyurea-stalled forks and ICLs both require 
BRCA2 but that they are distinct processes. 
3.2 Results 
3.2.1 Atypical presentation of Fanconi anemia in individuals with biallelic 
FANCD1/BRCA2 mutations 
Two female siblings with unknown causative gene mutations displaying a 
multitude of congenital abnormalities and mildly elevated levels of chromosomal 
breakage were entered into the International Fanconi Anemia Registry (IFAR). The 
first sibling, at three years of age, was diagnosed with probable FA based on 
congenital abnormalities. A DEB test showing elevated levels of chromosomal 
breakage above normal but lower than typically seen in FA suggested the 
possibility of somatic mosaicism. The second sibling was diagnosed at birth with 
similar findings. There is no reported family history of FA, but there are some cases 
Figure 3.2 Schematic of BRCA2 structure showing location of patient DNA 
binding domain mutations. 
(A) Schematic of BRCA2 domain structure and key interacting proteins. (B) 
BRCA2 structure of the DBD illustrating the location of the patient p.del2830-33 
and p.R2842C mutations at the base of the Tower domain and OB2. Structure 
adapted from Yang et al., 2005. (C) Alignment of the DBD peptide sequence in 
the region of the patient BRCA2 mutations. The alignment shows that this 
sequence is evolutionary conserved across many species. In green are the aa 
residues modified by the patient mutations, p.del2830-33 and p.R2842C are 





of breast cancer that were all diagnosed later in life (above 60 years of age) (Figure 
3.1A). 
Analysis of whole exome sequencing (WES) of patient LCLs was performed 
and the data was filtered for variants that were shared between the siblings with 
an allele frequency less than 1% in the 1000 genomes database (Genomes Project 
et al., 2010). Biallelic FANCD1/BRCA2 mutations, in the now young adult sibling 
pair, were identified and no other FA gene mutations were observed. These results 
were surprising since neither sibling displayed the typical clinical findings of the 
FANCD1/BRCA2 complementation group with no history of malignancy or bone 
marrow failure at the ages of 20 and 23. An updated family history was notable for 
early onset colorectal cancer of the father at the age of 40 and some skin cancer 
diagnosis in the family (Figure 3.1A). The role of BRCA2 in colorectal cancer 
(CRC) susceptibility is controversial, but there is some evidence that mutations in 
BRCA2 may account for some familial CRCs (Degrolard-Courcet et al., 2014a; 
Garre et al., 2015; Phelan et al., 2014). 
Sanger sequencing confirmed compound heterozygous BRCA2 mutations. 
A frameshift c.2330dupA mutation of exon 11 (maternal origin) results in premature 
truncation of BRCA2 (p.Asp777Glu Fs*11) and has previously been described in 
HBOC (Figure 3.1B). A second mutation, c.8524C>T, a missense variant of exon 
20 (paternal origin) results in an p.Arg2842Cys residue change in the highly 
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conserved DNA binding domain (DBD) of BRCA2 and has previously been 
identified as a variant of unknown significance (VUS) in HBOC (Figure 3.1B and 
Figure 3.2). At the protein level, the missense mutation results in the p.Arg2842Cys 
change at a highly conserved residue at the base of the BRCA2 Tower domain of 
the DBD (Figure 3.2.B-C). Sequencing of peripheral blood and lymphocytes 
demonstrates the presence of both mutations and no evidence of somatic 
mosaicism. With the recent release of the Genome Aggregation Database 
(gnomAD) allele frequencies for c.2330dupA and c.8524C>T are available at 
4.068e-6 and 1.084e-5 respectively. A combined annotation dependent depletion 
(CADD) score of 35 is reported for this variant (Kircher et al., 2014). Given the 
conservation of the affected amino acid (aa) residue, rare allele frequency, and 
predicted deleteriousness by prediction tools, we hypothesized that the BRCA2 
VUS c.8524C>T is pathogenic and contributing to diseases in this family. 
One other adult individual with biallelic BRCA2 mutations is cited in the 
literature (Howlett et al., 2002). This individual is homozygous for c.IVS19-1G>A 
mutation that impacts the splice acceptor site for exon 20. cDNA analysis 
demonstrated the use of an alternate spice acceptor that results in the loss of 12 
bp of exon 20 and translates into p.del2830-2833 (Howlett et al., 2002). Amino 
acid residues 2830-2833 are located at the transition of OB2 and the base of the 
Tower domain (Figure 3.2.B-C). This individual at the age of 30 had history of 
thumb malformation, but no history of bone marrow failure or malignancy. The 
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patient is deceased due to cause unrelated to disease. Similar to the sibling pair 
identified in the IFAR, the reported chromosomal breakage was modest (Howlett 
et al., 2002). 
We pursued characterization of patient-derived cells to determine how 
these DBD mutations affect the function of BRCA2. We hypothesized that the 
defects conferred by these BRCA2 DBD mutations leads to characteristic FA 
developmental defects, but not early childhood bone marrow failure and 
malignancies typically seen in other FANCD1 cases. The region of the BRCA2 
DBD mutated here has been proposed to bind at ssDNA-dsDNA junctions, but its 
role and the consequences of mutations here are unknown. In light of the HR 
independent role of the BRCA2 binding partner RAD51/FANCR in replication fork 
protection at ICLs, we hypothesized that these mutations may also disrupt 
replication fork protection where recognition of ssDNA-dsDNA junctions may be 
important. 
3.2.2 Phenotype of FANCD1/BRCA2 DNA binding domain patient cell lines 
Lymphoblastoid cell lines (LCLs) (RA3105 and RA3106) were derived from 
the sibling pair with compound heterozygous BRCA2 mutations, c.2330dupA and 
c.8524C>T. FA pathway activation, monitored by FANCI ubiquitination, was 
normal in patient-derived LCLs (Figure 3.3A). Analysis of BRCA2 expression by 
western blot demonstrated a full length (~390 kDa) band, the presumed product of 
the c.8524C>T allele, for both patient cell lines (Figure3.3B). DEB breakage 
Figure 3.3 Characterization of BRCA2 patient lymphoblast cell lines from a 
sibling pair with atypical Fanconi anemia. 
(A) Immunoblot analysis for FANCI ubiqutination following treatment with 1µM 
MMC for 24h of RA2985 (WT), RA2939 (FANCA), and patient RA3105 and 
RA3106 LCLs. (B) Immunoblot showing BRCA2 levels in RA2985 (WT) control, 
RA2525 (FANCD1) and patient RA3105 and RA3106 LCLs. (C) Quantification of 
chromosome breaks following DEB treatment of RA2985 (WT), RA2939 (FANCA), 
and patient RA3105 and RA3106 LCLs. (D) Metaphase for RA2985 and RA3105 
following DEB treatment. (E-F) Cell survival assays of patient derived lymphoblast 
cell line (LCLs) RA3105, RA2939 (FANCA), RA2985 (WT), and RA2525 
(FANCD1) after mitomycin C (MMC), diepoxybutane (DEB), PARP inhibitor 
olaparib (PARPi), and camptothecin (CPT) treatment. Survival assays were 
performed in triplicate. Cells were treated with increasing concentrations of 
genotoxic agents and counted after 7-10 days in culture. Relative cell survival was 




analysis confirmed previous clinical data that breakage is elevated, but not to 
levels of typical FANCA LCLs (RA2939) (Figure 3.3C-D). RA3105 LCLs displayed 
hypersensitivity to crosslinking agents MMC and DEB, but to a lesser degree than 
RA2939 FANCA LCLs (Figure 3.3E-F). RA3105 cells were also hypersensitive to 
the replication stress inducing agents including olaparib, a PARP inhibitor (PARPi), 
and topoisomerase I inhibitor camptothecin (CPT) (Figure 3.3G-H). 
Patient derived fibroblasts (HSC62) from the individual with homozygous 
c.IVS19-1G>A mutations were available (Howlett et al., 2002). Analysis of HSC62 
cells revealed more moderate chromosomal breakage to DEB and MMC and 
cellular hypersensitivity to crosslinking agents, DEB, MMC, and cisplatin (Figure 
3.4A-E). Interestingly, the cells were not hypersensitive to ionizing radiation (IR), 
but were sensitive to replication stress induced by CPT and PARPi (Figure 3.4F-
H). In contrast, the cells were not sensitive to replication stress produced by the 
agents aphidicolin and hydroxyurea (HU). 
To determine the impact of DBD disruption on the ability of c.IVS19-1G>A 
BRCA2 to load RAD51 onto ssDNA following DNA damage, we analyzed RAD51 
foci formation after IR and MMC in HSC62 cells. Levels of RAD51 foci were 
reduced after IR and MMC treatment (Figure 3.5B-C). The RAD51 foci were 
quantitatively fewer and qualitatively smaller (Figure 3.5A). Given the normal 
Figure 3.4 Cellular sensitivity of HSC62 BRCA2 c.IVS19-1G>A patient 
fibroblast cell line. 
(A-B) Quantification of chromosome breaks following DEB and MMC treatment of 
BJ wild type fibroblasts, FANCA patient fibroblasts (FA-Amut), and HSC62 
fibroblasts. (C-J) Cell survival of HSC62 fibroblasts compared to BJ WT fibroblast, 
FANCA patient fibroblast (FA-Amut), FANCA complemented patient cells 
expressing wild type FANCA (FA-A+A) or empty vector (FA-A+EV), or FA BRCA2 
patient fibroblast (BRCA2mut). Cell survival assays were performed in triplicate. 
Cells were treated with increasing concentrations of indicated agent. Cell survival 
was determined by counting cells after 7-9 days in culture. Relative cell survival 




Figure 3.5 Characterization of HSC62 BRCA2 c.IVS19-1G>A fibroblast cell 
line from an adult patient with atypical Fanconi anemia. 
(A) Immunofluorescence images of RAD51 foci, 8h following 12 Gy ionizing 
radiation (IR) of BJ WT fibroblast and patient derived HSC62 fibroblast, detected 
with anti-RAD51 antibody. Third row images are individual cells enlarged to better 
reveal differences in RAD51 foci size. (B) Quantification of RAD51 foci 1h, 8h, and 
24h following 12 Gy ionizing radiation (IR) of BJ WT fibroblast and HSC62 
fibroblast. Error bars indicate s.d. of two independent experiments (³200 cells per 
experiment). (C) Quantification of RAD51 foci 8h, 24h, and 48h following 1h 
treatment with 3 μM MMC of BJ WT fibroblast and HSC62 fibroblast. (D) Sister 
chromatid exchange (SCE) assay in BJ WT fibroblast and HSC62 fibroblast 
following treatment with MMC (0.1 μg/ml or 0.2 μg/ml). (E) SCE assay in BJ WT 
fibroblast and HSC62 fibroblast following depletion of BLM. (F) Representative 
images of SCEs in BJ WT fibroblast and HSC62 fibroblast metaphases. (G) qRT-




resistance to IR, sister chromatid exchange (SCEs) levels were analyzed as a 
readout of HR (Sonoda et al., 1999). SCEs were induced by increasing 
concentrations of MMC or depletion of the Bloom helicase (BLM) and no significant 
difference in SCE levels was observed between BJ wild type fibroblast and HSC62 
cells (Figure 3.5D-F). These observations suggest that the DNA binding domain 
defect in HSC62 cells, while moderately decreasing RAD51 foci formation, does 
not result in defective HR as observed by normal resistance to IR and SCE levels 
in these cells. Interestingly, there is a greater impact on replication fork stress 
induced by ICL generating agents as determined by cellular sensitivity. 
3.2.3 CRISPR/Cas9 mediated correction of the BRCA2 c.IVS19-1G>A 
mutation rescues cellular defects of patient HSC62 fibroblasts 
We complemented the patient cell line to demonstrate that the c.IVS19-
1G>A mutations cause the defects we observe in the HSC62 cell line, and so that 
future analysis could be performed in isogenic cell lines. The size of BRCA2 cDNA 
hinders efficient complementation by overexpression, so the homozygous 
c.IVS19-1G>A mutations were corrected to wild type at the endogenous locus 
using CRISPR/Cas9 gene targeting. Both heterozygous and homozygous clones 
were recovered (HSC62WT/MUT or HSC62WT/WT) (Figure 3.6A). cDNA analysis 
demonstrated that restoration of the splice acceptor base (A>G) in HSC62WT/MUT 
or HSC62WT/WT clones restored the cDNA exon 19 and exon 20 junction (Figure 
3.6C).  Both HSC62WT/MUT and HSC62WT/WT clones rescued RAD51 foci formation 
Figure 3.6 Complementation of HSC62 BRCA2 c.IVS19-1G>A DNA binding 
domain patient fibroblast cell line at the endogenous locus by CRISPR/Cas9 
mediated gene targeting. 
(A) Chromatograms of PCR amplified gDNA of CRISPR/Cas9 targeted HSC62 
fibroblasts. Gene editing reverted the c.IVS19-1G>A mutation either to 
homozygous WT (HSC62WT) or heterozygous WT (HSC62mut/WT) at the 
endogenous locus in HSC62 patient cells. The silent mutation that was 
incorporated to destroy the CRISPR PAM sequence is indicated. (B) Immunoblot 
showing BRCA2 levels in CRISPR/CAS9 corrected patient cell line HSC62WT, 
uncorrected HSC62 cells (HSC62mut), and RA2630 (FANCR) patient fibroblasts. 
(C) cDNA analysis of HSC62 clones with either homozygous or heterozygous 
correction of the c.IVS19-1G>A mutation demonstrating rescue of the 12bp 




 defects after IR and MMC, and also rescued hypersensitivity to replication stress 
inducing agents MMC, CPT, and PARPi (Figure 3.7A-D and Figure 3.8A-D). 
3.2.4 Defective ICL repair in HSC62 cells results in increased RPA activation 
that is dependent on DNA2 and WRN 
Our lab has previously described a FANCR/RAD51 p.T131P patient-
derived cell line that is proficient for HR but defective in ICL repair. One 
characteristic of this cell lines is hyperactivation of RPA upon MMC treatment 
(Wang et al., 2015). Given that BRCA2 and RAD51 interaction is required for their 
canonical function in HR and for the non-canonical function in replication fork 
protection at HU-stalled forks, we hypothesized that BRCA2 also functions with 
RAD51 in preventing increased ssDNA generation at ICLs (Schlacher et al., 2011; 
Wang et al., 2015). We observed an increase in RPA foci formation and 
phosphorylation in HSC62MUT cells compared to wild type fibroblast upon MMC 
treatment (Figure 3.9A-B). Similar to FANCR/RAD51 p.T131P expressing patient 
cells, the increased RPA foci formation in HSC62 cells was also dependent on 
DNA2 and WRN activity, but not MRE11, EXO1, CtIP, or BLM (Figure 3.9C). These 
results support an ICL repair model that requires both BRCA2 and RAD51 activity 
to protect against aberrant processing by DNA2 and WRN, but not the other 
effectors of DSB end resection such as MRE11, EXO1, or CtIP (Wang et al., 2015). 
Figure 3.7 Defects in RAD51 foci formation in HSC62 BRCA2 patient 
fibroblasts are rescued by gene correction. 
(A) Quantification of RAD51 foci 8h after 12 Gy ionizing radiation (IR) of BJ WT 
fibroblast, wild type HSC62 (HSC62WT) clones 1-3, and HSC62 uncorrected patient 
cell line (HSC62mut). (B) Quantification of RAD51 foci 24h following 1h treatment 
with 3 uM MMC. Error bars indicate s.d. of three independent experiments (³200 
cells per experiment). Representative images of RAD51 foci, 8h post IR (C) and 




Figure 3.8 Rescue of cellular sensitivity of HSC62 BRCA2 patient fibroblasts 
to genotoxic agents by gene correction. 
(A-D) Cell survival of HSC62 uncorrected patient cell line (HSC62mut) compared to 
BJ WT fibroblast and wild type HSC62 (HSC62WT) clones 1-3. Cell survival assays 
were performed in triplicate. Cells were treated with increasing concentrations of 
indicated agent. Cell survival was determined by counting cells after 7-9 days in 
culture. Relative cell survival was normalized to untreated controls to give percent 
survival. Error bars indicate s.d. 
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3.2.5 Generation of isogenic BRCA2 DNA binding domain mutations in 
human fibroblasts  
The lack of patient derived fibroblasts from the sibling pair with compound 
heterozygous BRCA2 mutations, c.2330dupA and c.8524C>T, precluded the 
direct comparison of the DNA binding domain mutations in similar cell types. In 
order to directly compare the defects conferred by the BRCA2 DBD mutations 
c.8524C>T (p.R2842C) and c.IVS19-1G>A (p.del2830-2833), we generated
isogenic cell lines by introducing the mutations into wild type BJ fibroblasts with 
CRISPR/Cas9 gene editing (Figure 3.10). To examine the specific impact of the 
DBD mutations, cells homozygous for the mutations were selected to be used in 
further analysis. Knock in of the BRCA2 c.IVS19-1G>A mutation in BJ fibroblasts 
confers the same splicing defect, loss of the first 12bp of exon 20 , observed in 
HSC62 cells (Figure 3.10B). Western blot analysis of BRCA2 levels demonstrates 
~390 kDa bands for all mutants except for BRCA2 clones harboring frameshift 
mutations in exon 20 (Figure 3.10E). The BRCA2 frameshift mutant is homozygous 
c.8531dupA with a predicted p.R2845K FS*22 truncation (BRCA2Trun.).
Functional analysis of isogenic DBD mutants demonstrated defects in 
RAD51 foci formation following IR and MMC (Figure 3.11 and Figure 3.12). The 
c.IVS19-1G>A mutation has a more deleterious impact on RAD51 foci formation,
resulting in reduction of cells with RAD51 foci and reduced foci size. The 
c.8524C>T mutants do not show a significant reduction in the number of cells with
Figure 3.9 Depletion of DNA2 and WRN in HSC62 patient cells suppresses 
increased RPA activation and foci formation induced by MMC. 
(A) Images of RPA foci, 24h post 1h treatment with 3 μM MMC, detected by 
immunofluorescence with anti-RPA32 antibody. (B) Quantification of RPA foci 24h 
following 1h treatment with 3 μM MMC of BJ WT fibroblast, wild type HSC62 clones 
(HSC62WT), and HSC62 uncorrected patient cell line (HSC62mut). (C) Quantification 
of RPA foci 24h following 1h treatment with 3 μM MMC in HSC62mut cells depleted 
of DNA2, MRE11, EXO1, CtIP, WRN, or BLM by siRNA compared to luciferase 
control (Luc). Error bars indicate s.d. of four independent experiments. (D) qRT-
PCR of DNA2, EXO1, WRN, and BLM expression levels of cells in C. Error bars 
are s.d. (E) Immunoblot analysis of MRE11 and CtIP siRNA depletion for cells 




RAD51 foci; however, the foci are much smaller in size (Figure 3.11B and Figure 
3.12B). By comparison the BRCA2Trun. mutant has complete loss of observable 
RAD51 foci formation. Analysis of cellular sensitivity of the DBD mutants revealed 
trends that correlated with the RAD51 foci data, demonstrating the c.IVS19-1G>A 
mutation to be more deleterious to BRCA2 function than the c.8524C>T mutation. 
Both mutations sensitize cells to MMC with some clonal variation for the c.IVS19-
1G>A  mutation, but overall the same trends are observed (Figure 3.13A-B). Both 
the c.8524C>T and c.IVS19-1G>A mutants are sensitive to replication stress 
inducing drugs PARPi and CPT compared to WT cells, but not aphidicolin as seen 
in the patient HSC62 fibroblast (Figure 3.4 and Figure 3.13C-E). Increased RPA 
foci following MMC was also observed for c.8524C>T and c.IVS19-1G>A mutants, 
with a greater increase in RPA foci seen in the c.IVS19-1G>A mutants (Figure 
3.14). 
The c.IVS19-1G>A mutation confers a splicing defect in which the 
consequence is the loss of the first four aa of exon 20 in a very conserved region 
of the DBD, at the OB2 and base of the Tower domain (Figure 3.2). How the loss 
of these four aa impact protein folding of this region is unknown; however, the 
greater defects in RAD51 recruitment, cellular viability to genotoxic agents, and 
increased generation of ssDNA at ICL lesions as measured by RPA foci suggest 
that this mutation is much more disruptive to BRCA2 activity than the c.8524C>T 
mutation. In this region, proximal to both the c.8524C>T and c.IVS19-1G>A 
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mutants, are three aa residues that have been identified for their direct interaction 
with DNA, K2833, Y2839, and F2841 (Yang et al., 2005). Using CRISPR/Cas9 in 
BJ wild type fibroblasts, we generated a DBD mutant (BRCA2DBDx3A) by mutating 
these three codons to alanine (Figure 3.15A). We hypothesized that the DBDx3A 
mutations would be less disruptive to BRCA2 structure and function than the 
c.IVS19-1G>A mutation, but would still interfere with proper DNA binding in this
region. BRCA2DBDx3A cells were hypersensitive to MMC but not to the extent of 
BRCA2IVS19-1G>A. RAD51 foci formation levels were nearly equivalent to WT cells 
following IR, but foci, similar to BRCA28524C>T clones, were greatly reduced in size 
(Figure 3.15C-D). A marked increase in RPA foci following MMC was seen in the 
BRCA2DBDx3A cells, but less than BRCA2IVS19-1G>A (Figure 3.15E). These data are 
consistent with the defects in BRCA2 c.8524C>T and c.IVS19-1G>A cells being 
due to diminution of BRCA2 DNA binding ability; however, the greater defects 
conferred by the c.IVS19-1G>A mutation may be an outcome of a more distorting 
effect on BRCA2 structure that effects other domains. 
Figure 3.10 Generation of isogenic BRCA2 DNA binding domain mutants by 
CRISPR/Cas9 mediated gene targeting in human fibroblasts. 
(A) Chromatograms of BRCA2 BJ fibroblast clones generated by CRISPR/Cas9 
targeting. BRCA2 exon 20 DNA binding domain mutations c.8524C>T and 
c.IVS19-1G>A were generated by targeting CRISPR/Cas9 in the vicinity of the
desired mutation and supplying a 100bp ssDNA donor containing the mutation. 
Sanger sequencing of PCR amplified genomic DNA demonstrated homozygous 
knock-in for both mutations. (B) cDNA analysis of homozygous c.IVS19-1,G>A BJ 
fibroblast clones demonstrated that the splice site mutation, as seen in the patient 
HSC62 fibroblasts, results in the usage of an alternative splice site donor resulting 
in a 12bp deletion at the start of BRCA2 exon 20. (C) A frameshift exon 20 BRCA2 
mutant was generated by a homozygous single base pair insertion (c.8531dupA) 
during CRISPR/Cas9 targeting. This presumed truncation mutant is annotated as 
BRCA2Trun. (D) cDNA sequencing of c.8524C>T BJ fibroblasts demonstrating the 
missense mutation and silent mutation introduced by CRISPR/Cas9 targeting. (E) 
Immunoblot showing BRCA2 levels in bulk BJ WT fibroblasts, BRCA2WT fibroblast 





Figure 3.11 RAD51 foci formation in BRCA2 DNA binding domain mutants 
following ionizing radiation. 
(A) Quantification of RAD51 foci 1h, 8h and 24h following 6 Gy ionizing radiation 
(IR) of BJ WT fibroblasts, BJ WT fibroblast clone (BRCA2WT), c.IVS19-1G>A BJ 
clones 2-3, c.8524C>T BJ clones 1-2, and a BRCA2 homozygous truncation 
mutant, c.8531dupA (BRCA2Trun). Error bars indicate s.d. of three independent 
experiments (³200 cells per experiment). (B) Representative images of RAD51 
foci, 8h post 6 Gy IR, detected by immunofluorescence with anti-RAD51 antibody. 
Third row images are individual cells enlarged to better reveal differences in 
RAD51 foci size. 
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Figure 3.12 RAD51 foci formation in BRCA2 DNA binding domain mutants 
following mitomycin C. 
(A) Quantification of RAD51 foci 8h, 24h and 48h following 1h treatment with 3 μM 
MMC of BJ WT fibroblasts, BJ WT fibroblast clone (BRCA2WT), c.IVS19-1G>A BJ 
clones 2-3, c.8524C>T BJ clones 1-2, and a BRCA2 truncation mutant, 
c.8531dupA (BRCA2Trun). Error bars indicate s.d. of three independent 
experiments (³200 cells per experiment). (B) Representative images of RAD51 
foci, 24h post 1h treatment with 3 μM MMC, detected by immunofluorescence with 
anti-RAD51antibody. Third row images are individual cells enlarged to better reveal 
differences in RAD51 foci size. 
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Figure 3.13 Cellular sensitivity of isogenic BRCA2 DNA binding domain 
mutants. 
(A-E) Cell survival of BJ WT fibroblasts, BJ WT fibroblast clone (BRCA2WT), 
c.IVS19-1G>A BJ clones, c.8524C>T BJ clones, and exon 20 BRCA2 frameshift 
mutant (BRCA2Trun.). Cell survival assays were performed in triplicate. Cells were 
treated with increasing concentrations of indicated agent. Cell survival was 
determined by counting cells after 7-9 days in culture. Relative cell survival was 
normalized to untreated controls to give the percent survival. Error bars indicate 
s.d. 
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Figure 3.14 BRCA2 DNA binding domain mutants have increased RPA foci 
formation following mitomycin C. 
(A) Quantification of RPA foci 8h, 24h and 48h following 1h treatment with 3 μM 
MMC of BJ WT fibroblasts, BJ WT fibroblast (BRCA2WT), c.IVS19-1G>A BJ 
clones 2-3, c.8524C>T BJ clones 1-2, and a BJ BRCA2 truncation mutant 
(BRCA2Trun.). Error bars indicate s.d. of three independent experiments (³200 
cells per experiment). (B) Representative images of RPA foci, 24h post 1h 
treatment with 3 uM MMC, detected by immunofluorescence with anti-RPA32 
antibody. Third row images are individual cells enlarged to better reveal RPA foci. 
Figure 3.15 CRISPR/Cas9 mediated gene targeting to mutagenize key DNA 
interacting residues of the BRCA2 DNA binding domain. 
(A) Chromatogram of BRCA2 CRISPR/Cas9 generated DNA binding domain triple 
mutant (DBDx3A). Three codons of exon 20, previously identified to interact with 
DNA (2833K, 2839Y, and 2841F), were mutagenized to produce alanine when 
translated. BRCA2DBDx3A was generated by targeting CRISPR/Cas9 in the vicinity 
of the desired mutations and supplying a 100bp ssDNA donor containing the three 
codon mutations. Sanger sequencing of PCR amplified genomic DNA 
demonstrates homozygous knock-in of the three alternate codons. (B) Cell 
survival of BRCA2WT, BRCA2IVS19-1G>A, and BRCA2DBDx3A BJ fibroblast cell lines. 
Survival assay was performed in triplicate and treated with increasing 
concentrations of MMC. Cell survival was determined by counting cells after 8 
days in culture. Relative cell survival was normalized to untreated controls for the 
percent survival. Error bars indicate s.d. (C) Quantification of RAD51 foci 8h after 
6 Gy ionizing radiation (IR) of BRCA2WT, BRCA2IVS19-1G>A, and BRCA2DBDx3A BJ 
fibroblast cell lines. Error bars indicate s.d of three independent experiments. (D) 
Representative images of RAD51 foci, 8h post 6 Gy IR, detected by 
immunofluorescence with anti-RAD51antibody. Third row images are individual 
cells enlarged to better reveal differences in RAD51 foci size. (E) Quantification of 
RPA foci, 24h post 1h treatment with 3 μM MMC, of BRCA2WT, BRCA2IVS19-1G>A, 
and BRCA2DBDx3A BJ fibroblast cell lines. Error bars indicate s.d of three 




3.2.6 Determination of homologous recombination efficiency in DNA binding 
domain mutants 
The patients harboring the c.8524C>T and c.IVS19-1G>A mutations have
an unusually mild clinical presentation for patients in the FANCD1/BRCA2 
complementation group. The embryonal tumors of this complementation group are 
not a prominent feature in the majority of other FA subtypes, suggesting these 
tumors may be the result of HR deficiency outside of the FA pathway during 
development. HR mediated double strand break repair is necessary for resolution 
of ICLs, but there is debate about the role of the BRCA2 DBD and its importance 
for HR (Saeki et al., 2006; Schlacher et al., 2011; Siaud et al., 2011). To analyze 
HR activity, DBD mutations as well as an exon 27 p.S3291A mutation, previously 
reported to have no effect on HR, were generated in HEK293T cells (Figure 3.16). 
Western blot analysis of BRCA2 indicated full length BRCA2 with the exception of 
a BRCA2Trun. (c.8531dupA) used as a control (Figure 3.16B). Cellular sensitivity to 
MMC was assessed in the BRCA2 HEK293T clones demonstrating increasing 
levels of sensitivity (p.S3291A < c.8524C>T < c.IVS19-1G>A) (Figure 3.16C). 
To determine the HR proficiency of BRCA2IVS19-1G>A and BRCA28524C>T
cells, we utilized an assay that takes advantage of the targeted DSBs generated
by CRISPR/Cas9. A CRISPR/Cas9 vector expressing a sgRNA targeting the 
LMNA locus was transfected along with a LMNA homology donor template 
containing a N-terminus mClover fluorescent protein tag (Figure 3.17A) (Arnoult et 
al., 2017; Pinder et al., 2015). Cells that undergo HR can utilize the HR donor 
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template which results in expression of fluorescently tagged LMNA that can be 
assessed by flow cytometry analysis. Compared to wild type, HR in all BRCA2 
clones was moderately decreased by their mutations (Figure 3.17D). The 
previously described separation of function mutation, p.S3291A, moderately 
impacts HR efficiency. This demonstrates that Ser3291 is important for BRCA2 C-
terminal domain activity during HR and not just exclusively at stalled replication 
forks (Kim et al., 2014; Schlacher et al., 2011). The DBD BRCA2IVS19-1G>A and
BRCA28524C>T cells showed similar decreases in HR levels to approximately half 
that of wild type cells, but they retained more HR activity than cells depleted of
RAD51 and BRCA2 or BRCA2Trun cells. Two of the c.IVS19-1G>A mutants appear 
to express lower BRCA2 levels (Figure 3.16B), suggesting these may be 
hemizygous clones, but this did not further impair HR levels as compared to similar 
levels in a third homozygous clone.
3.2.7 The BRCA2 DNA binding domain is required for replication fork 
protection at HU-stalled forks and ICLs to prevent resection by DNA2   
We previously demonstrated, in the patient HSC62 cell line (c.IVS19-
1G>A), that increased RPA foci formation observed following MMC treatment is
the result of DNA2 and WRN activity. In BJ fibroblast BRCA2 DBD mutants, we 
also observed increased RPA foci after MMC treatment (Figure 3.14 and Figure 
3.18). The increased RPA foci formation and phosphorylation of RPA in 
BRCA28524C>T, BRCA2IVS19-1G>A, and BRCA2DBD3xA cells were all reduced by DNA2 
and WRN depletion (Figure 3.18). The rescue of RPA activation was less striking 
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Figure 3.16 HEK293T BRCA2 DNA binding domain and Exon 27 p.S3291A 
clones generated by CRISPR/Cas9 gene editing. 
(A) Chromatograms of BRCA2 CRISPR/Cas9 generated HEK293T clones aligned 
to WT. A frameshift Exon 20 BRCA2 mutant (BRCA2Trun.) was generated by 
homozygous single base pair insertion as a result of CRISPR/Cas9 targeting. 
BRCA2 exon 20 mutations, c.8524C>T and c.IVS19-1G>A, and Exon 27 
p.S3291A clones were generated by targeting the respective BRCA2 exon with
CRISPR/Cas9 and a 100bp ssDNA template donor. Where applicable, silent 
mutations are indicated. (B) Immunoblot showing BRCA2 levels in WT HEK293T 
cells and BRCA2 mutant HEK293T clones: c.8531dupA (BRCA2Trun), c.8524C>T 
(clones 1-2), c.IVS19-1G>A (clones 1-3), and p.S3291A (clones 1-3). (C) Cell 
survival of WT cells and BRCA2 clones performed in triplicate and treated with 
increasing concentrations of MMC. Cell survival was determined by counting cells 
after 6 days in culture. Relative cell survival was normalized to untreated controls 
for the percent survival. Error bars indicate s.d. 
Figure 3.17 Homologous recombination efficiency of BRCA2 DNA binding 
domain mutants. 
(A) Schematic of mClover LMNA homologous recombination CRISPR/Cas9 
reporter assay. A plasmid expressing Cas9 and a sgRNA targeting the LMNA 5’ 
UTR was co-transfected with a donor template plasmid containing mClover 
flanked by LMNA homology. Repair at the LMNA locus by HR using the donor 
template results in mClover tagging of the N-terminus of LMNA. mClover green 
cells were quantified by flow cytometry analysis. (B) Immunoblot of RAD51 
knockdown for HEK293T cells used in D. (C) qRT-PCR of BRCA2 expression 
levels of cells utilized in D. Error bars are s.d. (D) Levels of mClover positive cells 
were normalized to WT HEK293T (siLuc). Error bars indicate s.d. of three 




in the BRCA2IVS19-1G>A cells, suggesting that for this more deleterious mutation 
there may be other sources of ssDNA besides DNA2 and WRN at ICLs. These 
data are consistent with the requirement for BRCA2 function at replication forks 
encountering ICLs to prevent over resection by DNA2 and WRN. 
To determine the requirement for the BRCA2 DBD in replication fork 
protection after HU, BRCA28524C>T and BRCA2IVS19-1G>A cells were examined using 
DNA fiber analysis. Replication fork protection by BRCA2 has largely been 
attributed to the C-terminal RAD51 interacting domain by analysis of the p.S3291A 
BRCA2 mutation. S3291 is a CDK phosphorylation site that when phosphorylated 
prohibits RAD51 binding. The C-terminal RAD51 interacting domain is thought to 
stabilize RAD51 nucleofilaments in a cell cycle controlled manner (Ayoub et al., 
2009; Schlacher et al., 2011). Our data, and another recently published study 
suggests that this mutant moderately impacts HR proficiency; nonetheless, it does 
abrogate replication fork protection at HU-stalled replication forks (Feng and Jasin, 
2017).
Analysis of BRCA2Trun., BRCA28524C>T, and BRCA2IVS19-1G>A cells
demonstrated defects in replication fork protection of HU-stalled forks as measured 
by the degradation of nascent DNA tracks labeled with nucleotide analogs, IdU 
and CldU (Figure 3.19). As previously reported, nascent strand degradation in the 
absence of BRCA2 was rescued by the MRE11 inhibitor mirin and MRE11 
depletion (Figure 3.19 and Figure 3.20A). These data demonstrate that the 
Figure 3.18 Depletion of DNA2 and WRN suppresses increased RPA 
activation and foci formation induced by MMC in BRCA2 DNA binding 
domain mutants. 
(A-B) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 
μM MMC. BRCA2WT, BRCA2c.8524C>T, BRCA2c.IVS19-1G>A, and BRCA2DBDx3A BJ 
fibroblast cells were transfected with siRNA control luciferase (Luc) or siRNAs 
targeting DNA2 or WRN. (C-D) Quantification of RPA foci 24h following 1h 
treatment with 3 μM MMC in cells depleted of DNA2 or WRN by siRNA. Error bars 
indicate s.d of two independent experiments. (E-G) qRT-PCR of DNA2 and WRN 




BRCA2Trun., BRCA28524C>T, and BRCA2IVS19-1G>A cells are all similarly defective for
replication fork protection and that the DBD is required for protection of replication 
forks from MRE11 processing in contrast to a previous report (Schlacher et al., 
2011). 
At ICLs, DNA2 is involved in aberrant processing in the absence of 
replication fork protection by RAD51 and BRCA2, as shown here (Wang et al., 
2015). To determine if processing of replication forks by DNA2 is distinct to ICLs, 
DNA2 was depleted in BRCA2 mutants, and cells were analyzed for nascent 
strand degradation following HU (Figure 3.20A). Depletion of DNA2 rescues 
resection in all of the BRCA2 mutants including BRCA2Trun., BRCA28524C>T,
BRCA2IVS19-1G>A, and BRCA2S3291A. These data demonstrate that both the DBD 
and C-terminal domain of BRCA2 are required for proper replication fork protection 
at HU-stalled forks, and that both domains are required to protect against 
degradation by MRE11 and DNA2. 
All of the BRCA2 mutants showed similar levels of nascent strand resection 
as measured by DNA fibers, but levels of chromosomal breakage differed (Figure 
3.20B). In parallel to our DNA fiber experiments, metaphases were analyzed after 
5 hours of 6 mM HU and release into colcemid. BRCA2Trun. cells showed a large 
increase in genomic instability upon stalling with HU in comparison to WT and the 
other BRCA2 mutants. BRCA28524C>T and BRCA2S3291A cells did not show an
elevation
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Figure 3.19 BRCA2 DNA binding domain mutants are defective in replication 
fork protection at hydroxyurea-stalled forks. 
Isogenic BJ fibroblast BRCA2 mutants, BRCA2Trun., BRCA28524C>T and 
BRCA2IVS19-1,G>A, were analyzed for replication fork resection. Cells were labeled 
with DNA analogs, IdU for 20 minutes and then CldU for 20 minutes. Cells were 
then incubated in 6 mM hydroxyurea (HU) with and without MRE11 inhibitor mirin 
(50 uM) for 4h before being harvested. DNA fibers were prepared and visualized 
by immunofluorescence detection of IdU and CldU and measured. Error bars 
indicate s.d. 
Figure 3.20 DNA2 promotes nascent strand degradation at hydroxyurea-
stalled replication forks. 
(A) Isogenic BJ fibroblast BRCA2 mutants, BRCA2Trun., BRCA28524C>T, 
BRCA2IVS19-1G>A, and BRCA2S3291A, were transfected with siRNA control luciferase 
(Luc) or siRNAs targeting DNA2 or MRE11. Cells were labeled with DNA analogs, 
IdU for 20 minutes and then CldU for 20 minutes. Cells were then incubated in 6 
mM hydroxyurea (HU) for 4h before being harvested. Error bars indicate s.d. (B) 
Quantification of chromosome breaks following 5h of 6 mM HU and released into 
colcemid. (C) Immunoblot analysis of MRE11 depletion for cells utilized in A. (D) 




elevation in breakage and BRCA2IVS19-1G>A cells had a mild increase. The elevated 
chromosomal breakage in BRCA2Trun. cells was reduced by MRE11 depletion, but 
was exacerbated by DNA2 depletion. DNA2 depletion results in a mild increase in 
breakage for all mutants but none to the extent of BRCA2Trun. Previous studies 
have reported elevated breakage resulting from replication fork degradation in 
p.S3291A expressing cells and BRCA2 deficient cells (Mijic et al., 2017; Schlacher 
et al., 2011). However, our data demonstrate that different levels of BRCA2 
function have different consequences at HU-stalled forks. These data demonstrate 
that replication fork resection at HU-stalled forks does not correlate with 
chromosomal breakage. Neither BRCA28524C>T or BRCA2S3291A cells have a 
significant increase in breakage after HU, despite having levels of fork degradation 
similar to BRCA2Trun. How this breakage results in BRCA2 depleted or LOF cells 
needs to be investigated further, but like nascent DNA degradation, it is in part 
dependent on MRE11. 
 
3.2.8 Depletion of SLX4 or MUS81 does not rescue MMC induced RPA foci in 
BRCA2 DBD mutants  
 SLX4 is a nuclease scaffold protein that complexes with XPF, MUS81, and 
SLX1, all nucleases that have been implicated in ICL repair (Dendouga et al., 
2005; McPherson et al., 2004; Niedernhofer et al., 2004). The unhooking of ICLs 
is dependent on the SLX4-XPF interaction and deficiency of either protein results 
in FANCP or FANCO FA complementation group, respectively (Bogliolo et al., 
2013; Kim et al., 2011). Furthermore, replication fork collapse has been reported 
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to be due to MUS81 nuclease activity and depletion of MUS81 has shown to rescue 
DSBs produced during replication stress. To determine if preventing ICL 
unhooking or nuclease mediated fork collapse would rescue RPA foci formation in 
BRCA2 DBD mutants following MMC, SLX4 and MUS81 were depleted. Depletion 
of either SLX4 or MUS81 did not rescue RPA hyperactivation in the BRCA28524C>T, 
BRCA2IVS19-1G>A, and BRCA2DBDx3A cells (Figure 3.21A-B). SLX4 depletion further 
increased RPA activation and foci formation. It was also observed that MMC 
treatment of SLX4 patient cells on their own have increased RPA foci formation, 
presumably due to inappropriate processing of MMC induced ICLs (Figure 3.28A). 
Depletion of SLX4 exacerbates the RPA phenotype in BRCA2 mutant cells, 
suggesting that further defects in ICL repair result in the absence of SLX4. This 
could be due to loss of activity of any of the SLX4-associated nucleases.  
  
3.2.9 Replication fork remodeling by SNF2 family translocases, SMARCAL1, 
ZRANB3, and HLTF, is not required for ICL repair 
 Replication fork reversal has been observed as a response to replication 
stress induced by a number of different classes of genotoxic agents including MMC 
(Zellweger et al., 2015). SMARCAL1, ZRANB3, and HLTF are ATPase dependent 
DNA translocases of the SNF2 family of chromatin remodelers that have recently 
been shown to promote replication fork reversal in vivo. Depletion of any of the 
three rescues nascent strand resection at HU stalled forks in BRCA2 deficient cells 
(Mijic et al., 2017; Taglialatela et al., 2017).  
Figure 3.21 Depletion of SLX4 or MUS81 does not rescue increased RPA 
activation and foci formation in BRCA2 DNA binding domain mutants. 
(A) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 μM 
MMC. BRCA2WT, BRCA2c.8524C>T, BRCA2DBDx3A, and BRCA2c.IVS19-1G>A. BJ 
fibroblast cells were transfected with control siRNA (Luc) or siRNAs targeting SLX4 
or MUS81. (B) Quantification of RPA foci 24h following 1h treatment with 3 uM 
MMC in cells depleted of SLX4 or MUS81 by siRNA. Error bars indicate s.d of two 
independent experiments. (C) Immunoblot analysis of MUS81 depletion for cells 
utilized in A-B. (D) qRT-PCR of SLX4 expression levels of cells utilized in A-B. Error 




To determine if replication fork reversal is important for the repair of ICLs, wild type 
cells were depleted of SMARCAL1 or ZRANB3 and tested for sensitization to 
MMC. Cells depleted of either translocase are not sensitive to MMC (Figure 
3.22A). In BRCA28524C>T and BRCA2IVS19-1G>A cells depleted of SMARCAL1 or 
ZRANB3 nascent strand degradation is rescued at HU stalled forks (Figure 3.23A). 
Depletion of either translocase did not rescue cellular hypersensitivity to MMC or 
CPT in BRCA2IVS19-1G>A cells (Figure 3.23B-C). Depletion of SMARCAL1, 
ZRANB3, or HLTF also did not rescue increased RPA activation and foci formation 
after MMC (Figure 3.24 and Figure 3.25). These data suggest that replication fork 
reversal is not an important intermediate step in ICL repair and that reversed forks 
observed in MMC treated cells may be part of a more general cellular response to 
replication stress to prevent genomic instability during replication but not 
specifically at the ICL. 
3.2.10 Depletion of RADX partially rescues defects of ICL repair in BRCA2 
DNA binding domain mutants 
RADX depletion has been shown to rescue nascent strand degradation at 
HU-stalled replication forks in BRCA2 deficient cells. RADX depletion restores fork 
protection without restoring HR, placing the RADX modulation of RAD51 
specifically at replication forks.  (Dungrawala et al., 2017). We hypothesized that if 
BRCA2 is involved in the early steps of fork protection at ICLs then RADX depletion 
would rescue increased ssDNA and RPA foci resulting from MMC treatment (Wang 
et al., 2015). Consistent with previously reported data, depletion of RADX did 
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Figure 3.22 SMARCAL1 and ZRANB3 translocases do not have a major role 
in cellular resistance to DNA interstrand crosslinks. 
(A) MMC cell survival of BJ BRCA2WT fibroblasts depleted of SMARCAL1 or 
ZRANB3 by shRNA or transduced with shRNA luciferase control (shLuc). Cell 
survival assays were performed in triplicate and treated with increasing 
concentrations of the indicated agent. Cell survival was determined by counting 
cells after 7-9 days in culture. Relative cell survival was normalized to untreated 
controls to give percent survival. Error bars indicate s.d. (B-C) Immunoblot 
analysis of shRNA depletion of SMARCAL1 and ZRANB3. 
Figure 3.23 Depletion of SMARCAL1 and ZRANB3 translocases rescues 
nascent strand degradation at HU-stalled replication forks but does not 
promote cellular resistance to MMC or CPT in BRCA2 DBD mutants. 
(A) BJ fibroblast BRCA2 mutants BRCA28524C>T and BRCA2IVS19-1G>A, were 
analyzed for replication fork resection when depleted of either SMARCAL1 or 
ZRANB3 by shRNA or transduced with control shRNA (shLuc). Cells were labeled 
with DNA analogs, IdU for 20 minutes and then CldU for 20 minutes. Cells were 
then incubated in 6 mM hydroxyurea (HU) for 4h before being harvested. DNA 
fibers were prepared and visualized by immunofluorescence detection of IdU and 
CldU and measured. Error bars indicate s.d. (B-C) MMC and CPT cell survival 
assay of BJ BRCA2c.IVS19-1G>A depleted of either SMARCAL1 or ZRANB3 by 
shRNA or transduced with shRNA luciferase control (shLuc). Cell survival assays 
were performed in triplicate. Cells were treated with increasing concentrations of 
indicated agent. Cell survival was determined by counting cells after 7-9 days in 
culture. Relative cell survival was normalized to untreated controls to give percent 




Figure 3.24 Depletion of SMARCAL1 or ZRANB2 translocases does not 
rescue increased RPA activation and foci formation induced by MMC in 
BRCA2 DNA binding domain mutants. 
(A) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 uM 
MMC. BRCA2c.8524C>T and BRCA2c.IVS19-1G>A BJ fibroblast cells were depleted of 
either SMARCAL1 or ZRANB3 by shRNA or transduced with shRNA control (Luc) 
(B) Quantification of RPA foci 24h following 1h treatment with 3 uM MMC in cells 
depleted of SMARCAL1 or ZRANB3. Error bars indicate s.d of two independent 
experiments. 
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Figure 3.25 Depletion of HLTF translocase does not rescue increased RPA 
activation and foci formation in BRCA2 DNA binding domain mutants. 
A) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 uM 
MMC. BRCA2WT, BRCA2c.8524C>T, BRCA2DBDx3A, and BRCA2c.IVS19-1G>A BJ 
fibroblast cells were transfected with siRNA control (Luc) or siRNAs targeting 
HLTF. (B) Quantification of RPA foci 24h following 1h treatment with 3 uM MMC 
in cells depleted of HLTF. Error bars indicate s.d of two independent experiments. 
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not rescue HR levels in BRCA2 mutant cell lines (Figure 3.26C-D) (Dungrawala et 
al., 2017). However, as expected, RADX depletion rescued nascent strand 
degradation of HU-stalled replication forks in BRCA28524C>T and BRCA2IVS19-1G>A 
cells (Figure 3.27A). 
RADX depletion in BRCA28524C>T and BRCA2IVS19-1G>A cells partially 
ameliorated the increased RPA foci formation following MMC (Figure 3.27B). 
RADX depletion also makes BRCA2 mutant cells more resistant to MMC (Figure 
3.27C-D). These data taken together support a role for both BRCA2 and RAD51 
at the early steps of ICL repair independent of HR (Figure 3.27F). It is possible that 
in the absence of RADX antagonism that BRCA2 defective cells have improved 
BRCA2-RAD51 protection at ICLs from DNA2-WRN. However, we also observe 
that RADX depletion sensitizes WT cells to MMC (Figure 3.27C). RADX activity 
may also be required for the response to MMC induced ICLs. Further investigation 
is needed to determine how RADX promotes proper ICL repair and if this is 
mediated through RAD51 modulation. However, the partial rescue effect of RADX 
depletion on MMC sensitivity in BRCA2 mutants also indicates that RADX activity 
is deleterious for ICL repair in the setting of defective BRCA2 function. 
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Figure 3.26 Deficiency of RADX does not impact homologous recombination 
efficiency in BRCA2 DNA binding domain mutants. 
(A) Immunoblot analysis of RADX depletion by siRNA for cells utilized in C. (B) 
Immunoblot analysis of RADX depletion by two shRNAs for cells utilized in D. (C) 
Comparison of levels of mClover positive cells of HEK293T BRCA2 mutants 
transfected with siRNAs targeting RADX or control (Luc). (D) Comparison of levels 
of mClover positive cells of HEK293T BRCA2 mutants (c.8524C>T, c.IVS19-
1G>A, p.S3291A, BRCA2Trun.) transduced with shRNAs targeting RADX (1 or 2) 
or shRNA control (C). Error bars indicate s.d. of experiments performed in 
triplicate. 
Figure 3.27 Depletion of RADX partially rescues ICL repair defects in BRCA2 
DNA binding domain mutants. 
(A) BJ fibroblast with BRCA2 mutations, BRCA28524C>T and BRCA2IVS19-1G>A, were 
analyzed for replication fork resection when depleted of RADX by shRNA or 
transduced with shRNA control (shCONT.). Cells were labeled with DNA analogs, 
IdU for 20 minutes and then CldU for 20 minutes. Cells were then incubated in 6 
mM hydroxyurea (HU) for 4h before being harvested. DNA fibers were prepared 
and visualized by immunofluorescence detection of IdU and CldU and measured. 
Error bars indicate s.d. (B) Quantification of RPA foci 24h following 1h treatment 
with 3 μM MMC in cells depleted of RADX by shRNA. Error bars indicate s.d. of 
two independent experiments. (C-D) Cell survival of BJ BRCA2WT, BRCA2c.IVS19-
1G>A, and BRCA2c.8524C>T fibroblasts depleted of RADX by shRNA or transduced 
with control shRNA (shCONT.). Cell survival assays were performed in triplicate 
and cells were treated with increasing concentrations of MMC. Cell survival was 
determined by counting cells after 8 days in culture. Relative cell survival was 
normalized to untreated controls to give percent survival. Error bars indicate s.d. 
(E) qRT-PCR of RADX expression levels of cells utilized in A-C. Error bars indicate 
s.d. (F) Schematic of proposed model of how RADX depletion partially ameliorates 




3.2.11 ICLs are a substrate of nucleolytic processing in the absence of a 
functioning FA pathway  
Having demonstrated that BRCA2 and RAD51 share a role in protecting 
ICLs from over resection by DNA2 and WRN, we investigated whether other FA 
proteins are required for protection against DNA hyper-resection at ICLs. Analysis 
of a panel of FA patient derived cells FANCA, FANCL, FANCD2, FANCI, FANCJ, 
and FANCP/SLX4 demonstrated increased RPA foci formation following MMC 
treatment for all complementation groups (Figure 3.28A). To determine if the 
source of RPA was the same as in BRCA2 and RAD51 mutant cells, DNA2 and 
WRN were depleted in a complemented pair of FANCA patient-derived cells 
(Figure 3.28B). Interestingly, the dependence on DNA2 was the same, but the 
helicase dependency is different, as WRN did not rescue RPA levels but BLM 
depletion did (Figure 3.28B-C). These data demonstrate a dependence on the FA 
core complex to prevent resection of ICLs by DNA2 and BLM. However, whether 
the source of RPA is the same in each of these FA patient cell lines needs further 
investigation because these factors have different roles in the repair of ICLs. 
Figure 3.28 Deficiency of Fanconi anemia proteins results in hyper-
phosphorylation and foci formation of RPA after MMC. 
(A) Quantification of RPA foci 8h, 24h and 48h following 1h treatment with 3 μM 
MMC of FA patient derived fibroblasts compared to BJ wild type fibroblasts. 
Patient cells lines from FA complementation group FANCR/RAD51 (FA-Rmut), 
FANCA (FA-Amut), FANCL (FA-Lmut), FANCD2 (FA-D2mut), FANCI (FA-Imut), 
FANCJ/BRIP (FA-Jmut), and FANCP/SLX4 (FA-Pmut). FANCA patient 
complemented cell lines were generated by transducing WT FANCA cDNA (FA-
A) or empty vector control (EV). Error bars indicate s.d. of two independent 
experiments. (B) FANCA patient cells expressing WT FANCA (FA-A+A) or empty 
vector (FA-A+EV) were transfected with siRNA control luciferase (Luc) or siRNAs 
targeting DNA2 and WRN. Quantification of RPA foci 24h following 1h treatment 
with 3 μM MMC. Error bars indicate s.d. of two independent experiments. (C) qRT-
PCR of DNA2 and WRN expression levels of FANCA cells utilized in B. Error bars 
indicate s.d. (D) FA-A+EV were transfected with siRNA Luc or siRNAs targeting 
DNA2 and BLM. Quantification of RPA foci 24h following 1h treatment with 3 μM 
MMC. Error bars indicate s.d. of two independent experiments. (E) qRT-PCR of 
DNA2 and BLM expression levels of FANCA cells utilized in D. Error bars indicate 
s.d. Experiment shown in (A) performed by Athena Huang and Experiment shown 




Figure 3.29 The role of BRCA2 in homologous recombination and replication 
fork protection requires the DNA binding domain. 
Schematic representing the different roles of BRCA2 in replication fork protection 
and homologous recombination. BRCA2 has a role in two distinct types of 
replication fork protection. At HU stalled forks, BRCA2 and RAD51 protect DNA 
from degradation by nucleases that include, MRE11, CtIP, EXO1, and DNA2. 
Replication fork reversal is dependent on RAD51 and the SNF2 translocases, 
SMARCAL1, ZRANB3, and HLTF. At ICLs, BRCA2 and RAD51protect against 
resection by DNA2-WRN. This process does not involve replication fork reversal. 
During homologous recombination repair of DSBs, BRCA2 assembles RAD51 
nucleofilaments onto ssDNA overhangs, which is important for the RAD51 
mediated homology search of the sister chromatid for use as a repair template. 
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3.3 Summary and Conclusions 
We have identified a family with an unusual clinical presentation of biallelic 
BRCA2 mutations. Unlike other FANCD1/BRCA2 patients, the sibling pair displays 
a relatively mild phenotype, even as adults, which is characterized by marked 
developmental abnormalities, but no bone marrow failure or cancer. The BRCA2 
mutations consist of a LOF frameshift mutation of exon 11 in trans to a missense 
mutation c.8524C>T/p.R2842C of the BRCA2 DBD. An additional 
FANCD1/BRCA2 adult presenting with mild disease was identified in the literature 
and is homozygous for the splice site mutation, c.IVS19-1G>A, that translates into 
the loss of the first four aa of exon 20 of the BRCA2 DBD (Howlett et al., 2002). 
Analysis of LCLs from the sibling pair (RA3105/RA3106) show cellular 
sensitivity to ICL generating agents and a mild elevation in chromosomal breakage 
to DEB. Comprehensive analysis of HSC62 fibroblasts (c.IVS19-1G>A) reveals 
sensitivity to ICL generating agents, but not IR. Lack of IR sensitivity and normal 
SCEs levels suggest that HR is largely intact in these fibroblasts. Using 
CRISPR/Cas9 gene editing, the c.IVS19-1G>A splice site mutation was corrected 
to WT in HSC62 fibroblasts, and the observed cellular defects were rescued 
demonstrating that the c.IVS19-1G>A base substitution is responsible for the 
cellular defects. 
To compare the phenotypes of both DBD mutations in isogenic cell lines, 
c.8524C>T and c.IVS19-1G>A, were generated in human fibroblasts using 
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CRISPR/Cas9 targeting of the endogenous BRCA2 locus. Side-by-side 
comparison of the mutations demonstrated that the BRCA2 c.IVS19-1G>A 
mutation has a more pronounced phenotype than c.8524C>T. BRCA2IVS19-1G>A and 
BRCA28524C>T cells both have defects in RAD51 foci formation, cellular sensitivity 
to MMC, and elicit increased RPA activation and foci formation after MMC. 
Furthermore, to evaluate these mutations for HR proficiency, BRCA2 DBD mutants 
were generated in HEK293T cells and analyzed using a mClover LMNA 
homologous recombination CRISPR/Cas9 reporter assay (Arnoult et al., 2017; 
Pinder et al., 2015). Interestingly, the DBD mutants showed a similar moderate 
reduction in HR despite the greater defect in MMC sensitivity in the c.IVS19-1G>A 
clones than the c.8524C>T clones. The previously described separation of function 
mutant, p.S3291A, showed a moderate reduction in HR, which demonstrated that 
p.S3291A, like our BRCA2 mutations, decreases HR  function in contrast to a 
previous report (Schlacher et al., 2011). These results demonstrate that the 
c.8524C>T mutation, identified previously as a VUS, is pathogenic and deleterious 
to BRCA2 function. 
HSC62 cells show markedly increased RPA foci formation that is dependent 
on DNA2 and WRN after MMC treatment. Previously, DNA2-WRN dependent 
resection at ICLs was reported in the RAD51/FANCR p.T131P patient cell line. In 
the RAD51/FANCR p.T131P patient cell line, the mutant protein makes up 20% of 
cellular RAD51 and has a dominant negative effect on RAD51 function. The minor 
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amount of mutant protein does not impact HR, but disrupts RAD51 function at ICLs 
revealing an HR-independent role for RAD51 in ICL repair (Wang et al., 2015). 
These results suggest that like the well described interdependence of BRCA2 and 
RAD51 in HR and the protection of HU-stalled forks, BRCA2 and RAD51 function 
together to prevent resection at ICLs.  
 
 Like HSC62 fibroblasts, isogenic BRCA2 DBD mutants have elevated RPA 
activation and foci formation after MMC that is DNA2-WRN dependent. The greater 
increase in RPA activation and foci formation resulting from the c.IVS19-1G>A 
mutation is not fully rescued. However, there is a marked reduction in pRPA and 
RPA foci in c.8524C>T cells and in another DBD mutant, DBDx3A. The DBDx3A 
mutant has 3 aa substitutions at residues that interact with DNA (K2833A, Y2839A, 
and F2841A) (Yang et al., 2005). We hypothesize that the alanine substitutions of 
these residues disrupt DNA binding, but are minimally disruptive to the BRCA2 
structure. The DBDx3A mutant cells have a slightly milder phenotype than 
c.IVS19-1G>A cells by MMC cellular sensitivity and RPA activation and RPA foci 
formation. The c.IVS19-1G>A splice site mutation results in the deletion of four aa, 
which may distort the BRCA2 structure and further impair BRCA2 function. This 
likely results in more ssDNA from sources other than DNA2-WRN activity. 
 
Our analysis of BRCA2 DBD mutants demonstrates that the function of the 
DBD is required for replication fork protection of HU-stalled forks from MRE11 and 
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DNA2. While the role of MRE11 in nascent strand degradation of BRCA2 deficient 
cells has been widely shown, there is conflicting data about resection mediated by 
DNA2 (Lemacon et al., 2017; Ray Chaudhuri et al., 2016). However, a role for 
DNA2 with WRN has been described in a mechanism of replication fork restart, 
and it has also been reported that DNA2 degrades nascent DNA at stalled forks in 
the setting of RECQ1, BOD1L, or Abro1 deficiency (Higgs et al., 2015; Thangavel 
et al., 2015; Xu et al., 2017).  
 
Previously, it was reported in Brca2 deficient hamster V-C8 cells, 
complemented with a BRCA2 bacterial artificial chromosome (BAC) construct 
missing the entire DBD (p.D2451-3210), that the DBD was dispensable for 
replication fork protection at HU-stalled forks (Schlacher et al., 2011). Our analysis 
of BRCA2 DBD mutants demonstrate that the replication fork protection role of 
BRCA2 at HU-stalled replication forks is not distinct to the C-terminal domain and 
that fork protection likely requires the DBD to bind DNA at the replication fork. 
Biochemical analysis of BRCA2 mutants will need to be carried out to determine 
how these mutations impact binding at replication fork structures. The location of 
the mutations at the transition of the OB2 and base of the Tower domain suggests 
that they may interfere with ssDNA-dsDNA binding. The Tower domain contains a 
3HB domain at the apex that binds dsDNA, so interruption of this region may 
preclude binding at replication fork ssDNA-dsDNA junctions where BRCA2 binding 
may be especially important for replication fork protection (Yang et al., 2002).  
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 Genomic instability resulting from the absence of proper replication fork 
protection has largely been studied by depletion of BRCA2 by RNAi (Lemacon et 
al., 2017; Mijic et al., 2017; Taglialatela et al., 2017). Here we show that a 
significant increase in chromosomal breakage after HU does not correlate with 
replication fork resection. For some of the BRCA2 mutants (c.8524C>T and 
p.S3291A) described in this study replication fork protection at HU-stalled forks is 
defective, but there is no significant increase in chromosomal breakage after HU. 
Our results showing increased breakage in cells expressing a BRCA2 LOF 
truncation, are consistent with many previous reports that BRCA2 knockdown 
results in increased chromosomal breakage that is rescued by MRE11 
depletion/inhibition (Lemacon et al., 2017; Mijic et al., 2017; Schlacher et al., 2011; 
Taglialatela et al., 2017). All of the BRCA2 mutants in our analysis that undergo 
MRE11 dependent fork resection at HU-stalled replication forks do not have 
elevated breakage. The consequences of nascent strand degradation requires 
further investigation in the background of hypomorphic fork protection mutants 
such as, c.8524C>T and p.S3291A, instead of BRCA2 knockdown by RNAi. These 
results demonstrate the importance of using BRCA2 mutants that permit 
distinguishing between different BRCA2 functions as opposed to RNAi depletion 
that removes all function. 
 
 We show that DNA2 depletion in BRCA2 mutant cells also rescues 
resection at HU-stalled replication forks. Interestingly, at the same time we observe 
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that DNA2 depletion exacerbates chromosomal breakage to HU. This observation 
suggests that in the setting of BRCA2 deficiency DNA2 depletion is deleterious, 
which may be due to its role in replication-coupled repair or modulation of reversed 
forks (Hu et al., 2012; Karanja et al., 2012; Thangavel et al., 2015). Recent reports 
have also implicated EXO1 and CtIP as degrading HU-stalled forks in the absence 
of BRCA2 (Lemacon et al., 2017). It would be interesting to know what the 
consequences of EXO1 and CtIP depletion are on chromosomal breakage to HU 
given the different effects of MRE11 and DNA2 depletion on the breakage levels. 
Taken together, resection of the regressed fork in the absence of BRCA2 is now 
reported to involve all of the DSB end-resection nucleases. MRE11 and DNA2 are 
already reported to be required for replication fork restart (Bryant et al., 2009; 
Thangavel et al., 2015). However, further investigation is required to determine if 
all of these factors have a normal function in processing stalled forks or restoring 
reversed forks under normal genetic conditions. These results are also interesting 
in that all of the nucleases may be acting at HU-stalled forks in BRCA2 deficient 
cells, but only DNA2 has activity at the ICL. 
Depletion of the replication fork remodelers SMARCAL1, ZRANB3, and 
HLTF rescues nascent strand degradation at HU-stalled forks in BRCA2 DBD 
mutants, but does not mitigate cellular sensitivity or increased RPA after MMC. 
Despite the observation that MMC increases replication fork reversal in cells 
(Zellweger et al., 2015), our study demonstrates that replication fork reversal is not 
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a major step in the repair of ICLs and that the processing at HU-stalled forks is 
different from ICLs. However, RADX depletion does ameliorate the increased RPA 
foci and cellular sensitivity to MMC independent of HR. RADX specifically 
modulates RAD51 at replication forks indicating that this rescue is related to 
BRCA2-RAD51 replication fork protection at the ICL and not downstream 
processing of DSBs. This is also consistent with the previous identification of 
RAD51 localization to ICLs prior to DSBs (Long et al., 2011). 
 
 FA proteins have previously been shown to be important for protection at 
HU-stalled replication forks (Schlacher et al., 2012). Analysis of FA patient cell 
lines of various complementation groups also demonstrates increased ssDNA and 
RPA foci formation after MMC. In FANCA cells, the increase in RPA foci is due to 
DNA2 and BLM, but not WRN. This suggest that the fork protection of BRCA2-
RAD51 is not redundant with the FA core complex, but further investigation would 
be needed to determine the source of increased ssDNA in the absence of the other 
FA proteins. DNA2 has previously been reported to interact with FANCD2 and be 
recruited to ICLs where it is required for repair but is deleterious in the absence of 
FANCD2 (Karanja et al., 2012; Karanja et al., 2014). BLM has been reported to 
interact with a number of FA proteins and co-localize with FANCD2 at ICLs (Meetei 
et al., 2003b; Pichierri et al., 2004; Suhasini and Brosh, 2012). Consistent with 
BLM depletion rescuing increased ssDNA at the fork in the absence of FANCA, 
BLM knockout was also recently reported to rescue ICL sensitivity and reduce DNA 
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damage in FA deficient cells (Moder et al., 2017). It is possible that DNA2, WRN, 
and BLM are recruited to ICLs to perform normal functions, but in the absence of 
key FA/BRCA pathway components are left unregulated.  
 
 The mutations reported in this study may have more differential impact on 
BRCA2 function depending on the nature of the DNA lesion. It is clear that the 
BRCA2 DBD is important for HR and replication fork protection (Figure 3.29). Both 
BRCA2 mutations, c.8524C>T and c.IVS19-1G>A, have a similar and moderate 
impact on HR efficiency. However, the impact on BRCA2 function in ICL repair 
demonstrates the c.IVS19-1G>A mutation to be more deleterious than either the 
c.8524C>T substitution or DBDx3A mutant. For HR, DSBs generated by targeted 
nuclease are likely different than DNA substrates encountered by the replication 
fork due to stalling by HU or ICLs. It is possible that DSB repair by HR may not be 
as sensitive to defects in BRCA2 ssDNA-dsDNA binding which could be of greater 
importance at a replication fork.  
 
 The identification of BRCA2 DBD mutations in conjunction with atypical 
disease presentation gives the opportunity to investigate how defects in the DBD 
impact BRCA2 function and gives insight into how these defects may give rise to 
the developmental defects characteristic of FA but not the early childhood 
malignancies seen in other patients with biallelic FANCD1/BRCA2 mutations. 
There is not a clear correlation of disease severity and deleteriousness of the 
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mutation for the sibling pair with the c.8524 C>T variant and the individual with 
homozygous c.IVS19-1G>A mutation. Analysis of the mutations in isogenic cell 
lines in the homozygous state demonstrates the c.IVS19-1G>A to be more 
deleterious to BRCA2 function than c.8524C>T. However, the sibling pair presents 
with much more severe congenital abnormalities. It is possible that there are other 
modifying factors, environmental and/or genetic, that impact the phenotypes of 
these patients. The dose of hypomorphic BRCA2 during development may also 
play a role. In the sibling pair the c.8524C>T mutation is in trans to a LOF allele 
instead of two hypomorphic alleles in the case of the individual with c.IVS19-1G>A. 
Regardless, the disease presentation of these individuals is very atypical for 
FANCD1/BRCA2 complementation group and resembles the phenotype of FA-like 
patients described for FANCR/RAD51 and FANCO/RAD51C complementation 
groups (Vaz et al., 2010; Wang et al., 2015). The patients have congenital 
abnormalities typical of FA but no bone marrow failure or malignancy even into 
adulthood. Due to the moderate impact that these DBD mutations have on HR, we 
hypothesize that the retention of ~50% of HR function that we observe is sufficient 
enough for cellular function and to safeguarded against early embryonal tumors in 
these individuals. However, the sibling pair will have to be monitored for 
hematopoietic abnormalities, FA related cancers, and HBOC cancers as adults. In 
the future, diagnosis and classification as FANCD1/BRCA2 complementation 
group should also be considered for patients appearing with FA-like syndrome.  
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Chapter 4: Novel bone marrow failure and DNA 




 Bone marrow failure (BMF) occurring during childhood is frequently genetic 
while BMF arising later in life is more often acquired. The most common inherited 
causes of aplastic anemia are Fanconi anemia (FA), Dyskeratosis congenita 
(DKC), Diamond Blackfan anemia (DBA), and Shwachman-Diamond syndrome 
(SDS) (Alter, 2017). DKC is the result of defects in telomere homeostasis and DBA 
and SDS are a result of defects in ribosome biogenesis. All three disorders are 
also associated with an increase in hematopoietic malignancies and solid tumors 
(Alter, 2002; Khincha and Savage, 2013). Diagnostically FA can be distinguished 
from other BMF syndromes by chromosomal breakage analysis. However, somatic 
mosaicism can skew breakage results and false positive results can occur in cases 
of other chromosomal instability syndromes (Oostra et al., 2012). FA is a very 
heterogeneous disorder and as a consequence of overlapping clinical features with 
BMF and chromosomal instability syndromes, patients may be misdiagnosed. Our 
studies have identified an individual enrolled in the IFAR misdiagnosed with FA. 
The characterization of patient derived cells indicated proficient ICL repair, but a 




4.2.1 A patient enrolled in the International Fanconi Anemia Registry 
identified as non-FA 
An individual enrolled in the IFAR without known disease-causing mutations 
presented at 5 years of age with recurrent pneumonia and was discovered to be  
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Figure 4.1 Bone marrow failure in a non-Fanconi anemia family enrolled in 
the IFAR. 
Family pedigree showing a child with bone marrow failure diagnosed at 5 years 
old. The patient had two failed bone marrow transplants and died after 
complications of the second transplant. Family history is significant for a first cousin 
that was diagnosed with acute lymphoblastic leukemia (ALL) at 4 years old who 
was treated, and is currently alive and well. Maternal grandmother had history of 
skin cancer and paternal grandfather had history of bladder cancer. There was no 
history of FA.   
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pancytopenic. On exam, the patient was described as having short stature, small 
midface, microopathalmia, and café-au-lait spots. Birth history reported a normal 
full-term pregnancy without complication and a birth weight of 6lbs 4oz (25th 
percentile). The patient had no history of myelodysplasia or leukemia and bone 
marrow studies only reported hypocellularity. 
 
Two subsequent DEB-induced chromosomal breakage tests on peripheral 
blood showed mildly elevated breakage, 0.54 and 0.61 breaks per cell. These 
values are higher than normal but much lower than expected for a typical FA 
patient. The patient was presumed to have FA with somatic mosaicism to account 
for the low chromosomal breakage levels. There was no family history of FA, but 
a first cousin was diagnosed with leukemia (ALL) at 4 years of age (Figure 4.1). 
The maternal grandmother had a history of skin cancer and paternal grandfather 
had history of bladder cancer. The family denied consanguinity. 
 
The patient underwent bone marrow transplant (BMT) at 8 years old with a 
FA conditioning regimen of fludarabine and cyclophosphamide which ultimately 
failed. A second transplant with the same donor was performed with the addition 
of total body irradiation (TBI) to the regimen. The second transplant failed and the 
patient developed graft versus host disease (GVHD). The patient developed 
encephalopathy, Parkinsonian features, congestive heart failure, respiratory 
failure, and died at 10 years of age.  
 160 
4.2.2 Characterization of patient derived cells reveals no defects in ICL repair 
 Bone marrow failure can have many etiologies so to better characterize the 
presumed defect in ICL repair in this family, patient derived fibroblasts were 
analyzed. Unlike typical FA cells, the patient derived fibroblasts (RA2177) were not 
sensitive to the crosslinking agents MMC or cisplatin and did not show increased 
chromosomal aberrations upon treatment with DEB (Figure 4.2A-C). Clinical 
breakage analysis showed a mild increase in breakage to DEB, but our analysis 
of chromosomal breakage in LCLs from the proband (RA2143) and family (father, 
mother, and healthy sibling) does not show an increase above normal cells (Figure 
4.2D-E). The patient cells do not show the hallmark LCL sensitivity and 
chromosomal breakage of FA. The lack of ICL repair deficits in the patient derived 
fibroblasts indicates that the patient does not have FA. 
 
 To investigate whether the patient’s disease may be due to defects in DNA 
repair of other pathways, the cells were tested for hypersensitivity to other DNA 
damaging agents. Patient cells did not show increased sensitivity to IR (Figure 
4.3A) suggesting no defect in the NHEJ pathway of DSB repair. Additionally, the 
patient cells did not show a significant increase or decrease in SCEs compared to 
BJ wild type fibroblasts suggesting no defect in HR or deficiency of BLM helicase 
(Figure 4.3B). The patient RA2177 fibroblasts were sensitive to a number of 
replication stress inducing agents including CPT, olaparib (PARPi), HU, and 
aphidicolin (Figure 4.4C-F). These data demonstrate that the patient’s disease 
may result from defects in the cellular response to replication stress. Defects in HR  
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Figure 4.2 RA2177 fibroblasts do not display features of ICL repair defects. 
(A-B) MMC and DEB treated cell survival assays of RA2177 patient fibroblasts, 
WT BJ fibroblasts, and SLX4 patient fibroblasts (SLX4mut). (C) Quantification of 
chromosomal breaks in metaphases of DEB treated RA2177, parental (RA3572, 
RA3573), and FANCA deficient (FA-A) fibroblasts. (D-E) Quantification of 
chromosomal breaks in metaphases of DEB treated LCLs from the proband 
(RA2143), parents (RA3534, RA3535), and FANCA deficient (FA-A) cells. Error 
bars indicate s.d. 
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Figure 4.3 RA2177 fibroblasts are hypersensitive to replication stress 
inducing agents 
(A) Cell survival of RA2177 cells after IR compared to RAD50 patient fibroblasts 
(RAD50mut). (B) SCE assay in BJ WT fibroblasts and RA2177 fibroblasts following 
treatment with MMC (0.1 μg/ml or 0.2 μg/ml). (C-F) Cell survival of RA2177 cells 
after CPT, olaparib (PARPi), HU, and aphidicolin treatment. SLX4mut and 
BRCA2mut are FA patient control cell lines. Error bars indicate s.d. 
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can also result in sensitivity to these agents, but HR is also required in the later 
steps of ICL repair and similar cellular sensitivity would then be expected for ICL 
generating agents which was not observed (Figure 4.2A-B). 
 
 Fibroblasts derived from the proband’s parents were obtained to evaluate 
for similar defects. The parental fibroblasts (RA3572 and RA3573) behaved as wild 
type and were not sensitive to replication stress inducing agents (Figure 4.4A-D). 
The fibroblasts were tested for chromosomal breakage following treatment with 
HU and aphidicolin. The patient RA2177 cells displayed a significant increase in 
chromosomal breakage compared to BJ wild type fibroblasts and parental 
fibroblasts (Figure 4.4E-F). Analysis of LCLs derived from the proband also 
demonstrated sensitivity to HU and CPT suggesting no somatic mosaicism of the 
blood (Figure 4.5A-B).  
 
4.2.3 Analysis of DNA replication in RA2177 cells reveals abnormalities only 
under conditions of replication stress 
 Given the hypersensitivity of RA2177 cells to replication stress inducing 
agents, we wanted to investigate the replication dynamics in these cell on the 
single molecule level. To visualize in situ replication dynamics, DNA combing of 
patient and parental cells grown in the presence of replication stress inducing 
agents (hydroxyurea or aphidicolin) was performed (Figure 4.6). For DNA combing 
analysis, DNA was labeled in replicating cells with the nucleotide analogs IdU and 
CldU and then immunostained for visualization. RA2177 cells have replication 
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 speeds that are similar to those of parental cell lines, RA3572 and RA3573, under 
unperturbed conditions (Figure 4.6B). RA2177 cells have slowed replication 
compared to parental cell lines under conditions of replication stress induced by 
low dose HU or aphidicolin (Figure 4.6C-D). To test the ability of RA2177 cells to 
resume replication following replication fork stalling, cells were treated with high 
dose HU (2 uM) to stall progressing forks. HU was then washed out and 
resumption of replication was monitored by incorporation of CldU. RA2177 cells 
did not have increased levels of fork stalling as measured by analysis of IdU and 
CldU labeled DNA fibers (Figure 4.7A-C). However, in RA2177 cells, CldU:IdU 
ratios were lower, indicating that CldU tracks after HU were shorter. It is possible 
that in RA2177 cells the replication forks are able to recover from replication 
stalling but the recovery or the ensuing replication may be slower (Figure 4.7D). 
These data demonstrate that unperturbed replication is normal in RA2177 cells but 
under conditions of replication stress it is defective 
 
4.2.4 Genetic analysis and evaluation of candidate disease-causing genes  
 The analysis of the patient-derived cell lines links a defect in cellular 
response to replication stress to the patient’s disease. Previously described 
diseases, including Fanconi anemia and Dyskeratosis congenita, link genome 
instability and bone marrow failure like in this patient. Both fibroblasts and LCLs 
were equally susceptible to replication stress demonstrating the genetic cause to 
likely be germline and not somatic. WES was analyzed for gene candidates from 
the family trio. WES data revealed no mutations in known FA genes or genes  
 165 
  
Figure 4.4 Parental fibroblasts behave as wild type. 
(A-D) Cell survival of RA2177 fibroblasts and parental fibroblasts, RA3572 and 
RA3573, after HU, aphidicolin, olaparib (PARPi), and CPT treatment. (E-F) 
Quantification of chromosomal breaks in metaphases of HU and aphidicolin 
treated BJ, RA2177 (proband), RA3572 (paternal), and RA3573 (maternal) 




Figure 4.5 RA2143 patient LCLs display hypersensitivity to replication 
stress. 
(A-B) Cell survival of RA2143 patient derived LCLs and parental LCLs (RA3535 
and RA3536) after HU and CPT treatment. Error bars indicate s.d. Assays 




Figure 4.6 Assessment of replication fork progression in RA2177 cells under 
conditions of replication stress. 
(A) Schematic of experimental conditions. Cells were labeled with nucleotide 
analogs Idu and CldU and DNA fibers were immunostained and visualized. (B) 
Average DNA fiber lengths in RA2177 patient cells and wild type parental cell lines 
RA3572 and RA3573. Total DNA track length was measured after 30min of IdU 
and 1h of CldU treatment. (C-D) Ratio of CldU:IdU DNA track lengths. Cells were 
labeled with IdU for 30 mins and subsequently with CldU for 2h with HU or 
aphidicolin. Error bars indicate s.d. 
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Figure 4.7 Assessment of replication fork dynamics in RA2177 patient cells. 
(A) Cells were labeled with IdU for 30 mins and subsequently treated with 2 mM 
HU to stall replication forks for 2 hours. Cells were washed and released into CldU 
for 2 hours. Quantification of ongoing replication forks, characterized as having 
both IdU and CldU label, as a percent of all DNA species. (B) Quantification of 
newly fired replication forks, characterized as CldU only. (C) Quantification of 
stalled or terminated replication forks, characterized as IdU only. (D) Ratio of 
CldU:IdU DNA track lengths. Error bars indicate s.d. 
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mutated in known DNA repair disorders. Variants were filtered for an allele 
frequency of 0.01 or less in the 1000 Genome database. Possible modes of 
inheritance that were prioritized were autosomal recessive and de novo. The family 
reported non-consanguinity. 
 No LOF de novo mutations were identified. One coding de novo missense 
mutation of sedoheptulokinase (SHPK) was identified; however, a second 
mutation was not identified and homozygous LOF has previously been described 
in isolated Sedoheptulokinase deficiency and infantile nephropathic cyctinosis that 
includes a 53kb deletion encompassing SHPK (Wamelink et al., 2015). No LOF or 
missense homozygous coding variants of rare allele frequency in genes that could 
be linked to the phenotype were identified. Compound heterozygous mutations, 
p.R206H and p.A466T, in PFAS were identified having an allele frequency less 
than or equal to 0.01 in 1000 Genome database (0.01 and 0.002, respectively) and 
CADD scores of 25.4 and 31. Each parent is a carrier of one allele and the healthy 
sibling only carries one variant (Figure 4.8A). We decided to pursue this as a 
candidate gene as PFAS is important for the 4th step of de novo purine synthesis. 
Purines are necessary for cellular processes such as DNA replication, 
transcription, and energy metabolism. Disorders of nucleotide metabolism have 
previously been described and have a heterogeneous clinical spectrum that 
includes immunodeficiency and anemia (Ng et al., 2015; Ng et al., 2010; Rainger 
et al., 2012; Roach et al., 2010; Stone et al., 1992).  
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 Depletion of PFAS in BJ WT fibroblasts results in cellular sensitivity to HU 
and CPT similar to RA2177 fibroblasts (Figure 4.8C-E). Complementation of 
patient RA2177 fibroblasts by expression of wild type PFAS was complicated by 
toxicity and increased hypersensitivity resulting from overexpression of the protein 
(Figure 4.8B). To test PFAS variants for pathogenicity, CRISPR/Cas9 gene editing 
was used to knock in the p.A466T mutation at the endogenous locus in the 
maternal cell line RA3573, so that the protein is expressed at levels regulated by 
the cell (Figure 4.8E). Homozygous p.A466T RA3573 cells were tested for 
hypersensitivity to HU and the homozygous mutation did not produce the cellular 
hypersensitivity seen in the proband’s RA2177 cell line (Figure 4.8F). These data 
demonstrate that the PFAS variants are not responsible for the defect in this 
patient’s cells and are unlikely to have caused her disease. 
 
Whole genome sequencing (WGS) on DNA derived from primary fibroblasts 
obtained from the mother, father, and proband was performed. Thus far, no 
additional gene candidates were identified using a 0.001 allele frequency cut off 
for coding variants in the Exome Aggregation Consortium (ExAC) with CADD 
scores greater than the mutational significance cutoff (MSC) (Itan et al., 2016). 
Further analysis of WGS will permit a more comprehensive investigation of copy 
number and non-coding variants that may be disease-causing. 
 
  
Figure 4.8 PFAS variants do not cause the cellular defects to replication 
stress in RA2177 patient cells 
(A) Chromatograms of Sanger sequencing of PFAS variants identified in this 
family, exon 6 p.R206H and exon 12 p.A466T. (B) CPT treated cell survival 
assays of patient RA2177 cells expressing empty vector (EV) control and HA 
tagged WT PFAS compared to WT BJ fibroblasts. (C-D) HU and CPT treated cell 
survival assays of WT BJ fibroblasts with PFAS targeting shRNAs (1 and 2) and 
shRNA control (shCONT.) compared to RA2177 cells. (E) Validation of shRNA 
knockdown of PFAS in BJ WT cells by RTqPCR. (F) Chromatograms of Sanger 
sequencing of CRISPR/Cas9 edited RA3573 fibroblasts (maternal cell line) 
containing the exon 12 p.A466T mutation. (G) Cell survival assay of RA3573 clone 





4.3 Summary and Conclusions 
Here we describe an individual with proficient ICL repair but defects in 
cellular response to replication stress. The patient’s clinical picture had many 
overlapping features of FA including developmental abnormalities and BMF in 
childhood. DEB chromosomal breakage testing is the gold standard for FA 
diagnosis, but in some instances a mild increase in breakage can be observed due 
to another chromosomal instability syndrome (Oostra et al., 2012). Another 
explanation for lower breakage levels in the blood in FA is somatic mosaicism, 
which was the conclusion for this individual at the time of diagnosis. Examination 
of patient derived cells, LCLs and fibroblasts, demonstrates no defects in ICL 
repair. Fibroblasts from FA patients with somatic mosaicism display the typical 
hallmarks of ICL deficiency, so this individual does not have FA. The failure of bone 
marrow transplant in this individual may have been in part due to modified 
conditioning protocol typically used for FA patients. 
Patient-derived fibroblasts, RA2177, are hypersensitive to PARP inhibitor, 
CPT, aphidicolin, and HU and display elevated chromosomal breaks following HU 
or aphidicolin, suggesting a defect in resolving replication stress. Replication 
stress, if not resolved, can cause replication fork collapse and DNA double strand 
breaks that are repaired by homologous recombination (HR) mediated double 
strand break repair (Lundin et al., 2002). RA2177 cells do not display 
hypersensitivity to double strand breaks induced by ionizing radiation (IR) and 
have normal levels of homologous recombination as measured by sister chromatid 
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exchange levels (SCE) suggesting proficient HR and double strand break repair 
(Sonoda et al., 1999). This is also consistent with proficient ICL repair that requires 
HR mediated DSB repair. Single molecule analysis of replication forks 
demonstrates that the RA2177 cells replicate at normal speeds when not 
perturbed, but are significantly slower during conditions of replication stress and 
recover from replication fork stalling more slowly than parental control cell lines.  
These studies help us to better understand what cellular processes may be 
defective in this individual and suggest that defects in the cellular response to 
replication stress may underlie disease in this individual. In cases where breakage 
analysis of peripheral blood is inconclusive and disease-causing mutations are not 
known, analysis of fibroblasts should be performed to support a FA diagnosis. In 
this case, a diagnosis of FA had implications for treatment and impacted the choice 
of the bone marrow transplant regimen. Fludarabine is a purine analog, that like 
HU, inhibits DNA synthesis by causing a shortage of nucleotides (Montillo et al., 
2006). Whether RA2177 cells are hypersensitive to fludarabine still needs to be 
investigated, but given the similar mechanism of action to HU it seems likely. The 
patient cells are sensitive to replication stress so the use of this drug as a 
conditioning regimen may have contributed to the patients decline and multi organ 
failure.  
The investigation into the genetic cause of disease in this individual is 
ongoing. Analysis of WES yielded candidate disease-causing variants, compound 
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heterozygous missense mutations in PFAS, but after thorough investigation we 
conclude that the variants identified are not disease causing. WGS was performed 
on the family trio using fibroblast DNA to compare to our WES results, done on 
LCLs, in the event of somatic mosaicism and for better mutation detection (Belkadi 
et al., 2015). The more recently published Exome Aggregation Consortium (ExAC) 
and Genome Aggregation Database (gnomAD) are much larger gene variant 
databases that permit filtering patient sequencing data at a lower allele frequency 
without possibly removing rare variants (Lek et al., 2016). The WGS was analyzed 
using a MAF cutoff of 0.001 in ExAC to be consistent with rare disease incidence 
of pediatric bone marrow failure and FA (Young et al., 2008). No new gene 
candidates with biallelic coding variants were identified. Analysis of WGS will have 
to be expanded to copy number variants and non-coding regions of the genome. 
Identification of disease-causing variants in a single patient can be challenging, 
but here we have an ideal system in which a cellular phenotype has been identified 
and complementation can be used to rescue defects conferred by the defective 
gene. In this individual, the characterization of patient cells gives insight into 
potential gene candidates that can be explored further. In similar cases, 
concomitant cellular characterization, even in the absence of knowing the genetic 
origin of the disease, may improve disease management. 
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Chapter 5: Discussion 
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5.1 Investigating the genetic cause of disease in individuals not assigned to 
a Fanconi anemia complementation group  
The International Fanconi Anemia Registry (IFAR) at the Rockefeller 
University has been enrolling patients since 1982 when it was established by Dr. 
Arleen Auerbach. The IFAR has numerous FA patient-derived cell lines and DNA 
samples archived, which presents the opportunity to investigate those patients 
enrolled in the registry without a designated FA complementation group. The 
studies described in this thesis evolved from the hypothesis that the patients 
without gene classifications may represent undiscovered FA complementation 
groups and thus, provide the opportunity to study new genes important for DNA 
interstrand crosslink (ICL) repair. 
A key advantage of our study was the ability to search for the genetic cause 
of disease in several unclassified patients while simultaneously characterizing their 
patient-derived cell lines. The characterization of patient-derived cells from the 
families of interest, allowed for the patients to be classified into different subgroups. 
We were able to exclude some patients from further study, because, although they 
appeared to have FA, no DNA repair deficits were identified in their cell lines. Our 
understanding of the FA pathway was applied to further delineate the patients. A 
key step in the FA pathway is the activation of FANCI and FANCD2 by 
monoubiquitination, which requires an intact FA core complex, composed of 8 FA 
proteins and associated factors. Some of the cell lines we studied were defective 
for monoubiquitination of FANCI and FANCD2, so our genetic analysis could be 
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focused to core complex proteins and associated factors. With regards to this 
group, we identified the subject of the new FANCT complementation group as well 
as an individual of the already established FANCE complementation group. 
Other individuals had normal activation of the FA pathway, but defective ICL 
repair. From this subgroup, the sibling pair with atypical presentation of biallelic 
FANCD1/BRCA2 mutations was identified. We also followed a bone marrow failure 
(BMF) patient, whose analysis revealed no defects in ICL repair, but rather 
demonstrated defects in another DNA damage pathway that could underlie their 
disease. Collectively, in these studies we discovered a surprisingly wide spectrum 
of cellular phenotypes that provided insight for our genetic analysis. These studies 
resulted in the identification of a new FA complementation group, surprising 
separation of function mutations in an already known FA gene, and exclusion of 
some patients from FA. 
Whole exome sequencing (WES) was performed on patient and parental 
DNA where available. We found that for some cases, the identification of candidate 
disease-causing mutations was more straightforward as rare coding mutations 
were identified in genes that could be linked to the phenotype and further validated. 
However, there are still significant challenges in identifying patient disease-
causing mutations by Next-generation sequencing (NGS) because of the 
limitations in detecting structural and copy number variants (Boycott and Ardigo, 
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2018). For instance, WES analysis was not sufficient alone to ascertain the UBE2T 
patient mutations because the large paternal indel was not detected and the LCLs 
were mosaic for the maternal indel. We identified low UBE2T transcript levels in 
patient fibroblasts by RNAseq, which was supported by the absence of UBE2T 
protein by immunoblot. We utilized Sanger sequencing of the UBE2T locus to 
identify the mutations, which was aided by SNPs detected in the UBE2T locus by 
WES. Therefore, even though NGS has increased the pace at which rare genetic 
diseases can be identified and enables single patient studies, our study highlights 
some of the limitations of its application (Boycott et al., 2017; Casanova et al., 
2014). We have demonstrated here that a multifaceted approach may be required 
to identify disease-causing mutations that are structural or copy number variants 
(CNV), or reside outside coding regions (Boycott et al., 2017; Casanova et al., 
2014). Although WGS offers broader coverage of the genome and better SNP 
detection in coding regions, CNV and structural variant identification still remains 
unreliable (Boycott and Ardigo, 2018; Casanova et al., 2014). Non-coding variants 
identified in WGS are more problematic to interpret given their vast numbers and 
the difficulty in predicting their functional consequences. Moreover, current variant 
databases have much lower genome coverage than exome for precisely 
determining non-coding variant allele frequency (Lek et al., 2016).  
 
 In the case of the individual described in Chapter 4, with BMF of unknown 
genetic origin and cellular defects in responding to DNA replication stress, we will 
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have to expand our analysis of the WGS and employ other strategies to determine 
the genetic basis of their disease. With the development of new informatics tools, 
more information and annotations of non-coding genetic variants may be available 
to streamline WGS analysis. In the meantime, the clinical knowledge and cellular 
observations in this case can be applied to analyze the non-coding variants of 
potential candidate genes. We can consider various possibilities including the 
likelihood that the disease presentation and cellular phenotypes described may be 
the result of a novel disorder or alternatively, an atypical clinical presentation of a 
known disease. Our investigation going forward should include screening intronic 
regions of genes implicated in disorders with overlapping features. 
Our knowledge of proteins at the replication fork during normal replication 
and conditions of stress are expanding. We can apply this data to identifying 
additional gene candidates. cDNA screening is another possible technique that we 
can employ to identify deficient genes. Patient cells can be transduced with a 
cDNA library and their pronounced cellular sensitivity to replication stress can be 
exploited in a competition screen to enrich for and identify the complementing 
cDNA (Buck et al., 2006). While the genetic cause of disease remains elusive in 
this individual, the cellular characterization provides information about potential 
pathways and genes that may be of interest for future investigation. 
 181 
 Identifying the genetic etiology of rare diseases is important for improving 
the understanding of the mechanism of DNA repair and how lack of repair results 
in abnormal function. It also aids in the classification of other affected individuals 
and leads to improved patient care. For example, our identification of the FANCT 
complementation group will permit the classification of FA patients to this 
complementation group in the future. Our analysis also demonstrates that complex 
copy number variants may occur at this locus and that besides sequencing, 
UBE2T/FANCT complementation may be necessary for classification. The clinical 
presentation of the FANCT patient identified in our study differed from two patients 
published in another parallel study (Hira et al., 2015; Rickman et al., 2015). Due to 
somatic mosaicism of the blood our patient was likely protected from bone marrow 
failure, but Hira et al. reported a case of bone marrow failure and AML in two 
FANCT individuals. Taken together, these cases give a clinical picture for the 
FANCT complementation group, and suggest that FANCT patients will likely 
present with typical FA and are susceptible to bone marrow failure.  
 
 The identification and analysis of the individuals with biallelic 
FANCD1/BRCA2 mutations and their atypical presentation expands the 
phenotypic spectrum for this complementation group. These FANCD1/BRCA2 
patients have phenotypes that are akin to the FA-like complementation groups 
FANCR/RAD51 and FANCO/RAD51C (Jacquinet et al., 2018; Vaz et al., 2010; 
Wang et al., 2015). Our findings highlight that in the future, patients with FA-like 
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disease features should also be screened for BRCA2 mutations. The FANCD1 
complementation group also has implications for HBOC in carriers, so earlier 
molecular designation for these individuals is advantageous for preventative 
screening in the family. 
5.2 BRCA2 DNA binding domain mutations and implications for cancer 
The analysis of individuals with atypical disease presentation of the 
FANCD1/BRCA2 complementation group determined that their disease is due to 
mutations in the highly conserved BRCA2 DBD. Interestingly, these patients 
presented with developmental defects seen in FA, but have no history of BMF or 
malignancy into adulthood (Alter, 2014; Howlett et al., 2002). We functionally 
analyzed their BRCA2 DBD mutations, c.8524C>T, and c.IVS19-1G>A, to 
determine if the atypical patient phenotypes were a consequence of disturbing a 
specific function of BRCA2. In our studies, we observed that both mutations 
reduced HR efficiency by about half and that replication fork protection was 
defective at HU-stalled forks and ICLs. 
Previously reported analysis of cDNA from HSC62 patient-derived cells, 
homozygous for the c.IVS19-1G>A mutation, revealed the mutation to cause 
aberrant splicing that results in a 4 aa deletion of exon 20 (Howlett et al., 2002). 
HSC62 cells were also reported to have moderately elevated chromosomal 
breakage, and taken together c.IVS19-1G>A was presumed pathogenic (Alter et 
al., 2007; Howlett et al., 2002). Our analysis, also confirmed these findings. By 
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complementing the homozygous c.IVS19-1G>A patient fibroblasts by 
CRISPR/Cas9 mediated genome editing, we have demonstrated that this mutation 
is indeed the cause of cellular defects and disease in this individual, proving this 
variant to be pathogenic. Recently c.IVS19-1G>A has also been reported to 
segregate with familial breast cancer (Santos et al., 2014).   
 
 The c.8524C>T mutation has previously been described as a variant of 
unknown significance (VUS) in HBOC. Many pathogenic LOF mutations of BRCA2 
have previously been described that result in early termination of the protein. 
However, in BRCA HBOC genetic testing, approximately 1,600 unique VUS have 
been discovered and they account for 2-10% of all variants identified during testing 
(Guidugli et al., 2014). The clinical significance of these rare missense mutations 
is unclear and often, familial information is limited, so variant segregation cannot 
be determined. Evaluation of many BRCA2 VUS relies on multifactorial probability 
models to estimate if a variant is pathogenic (Guidugli et al., 2014). In vitro analysis 
of BRCA2 VUS function is an alternative approach to determine potential 
pathogenicity. Functional assays have traditionally assessed HR through reporter 
assays by measuring HR mediated repair of DSBs in reporter constructs 
(Moynahan et al., 2001). Several studies have utilized the V-C8 Brca2 deficient 
hamster cell line or mouse embryonic stem cells to assess HR of BRCA2 VUS by 
the DR-GFP assay (Farrugia et al., 2008; Guidugli et al., 2014; Guidugli et al., 
2013; Wu et al., 2005). Additional studies have used other functional readouts of 
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BRCA2 VUS including ssDNA binding assays, nuclear localization, centrosome 
amplification, and MMC or PARP inhibitor cell survival (Guidugli et al., 2014). 
A large number of BRCA2 DBD mutants, including c.8524C>T, were 
analyzed for HR proficiency in V-C8 cells using the DR-GFP assay. The 
pathogenicity of the VUS were predicted by comparing their HR efficiency to that 
of known pathogenic and benign variants in this study (Guidugli et al., 2013). Some 
VUS can be easily classified if HR is dramatically reduced; however, a number of 
VUS including c.8524C>T showed intermediate phenotypes in this evaluation, 
making it difficult to interpret their role in HBOC (Guidugli et al., 2013; Shimelis et 
al., 2017). 
One caveat of these studies is that they only consider the HR function of 
BRCA2 for pathogenic classification. The contribution of other BRCA2 functions, 
including replication fork protection, to cellular function and tumorigenesis requires 
further investigation. In our system, the c.8524C>T mutant did have a moderate 
impact on HR, but we also demonstrate additional deficiency in replication fork 
protection. The consequences of loss of replication fork protection in c.8524C>T 
cells is still unclear given the observation that this mutant does not show a 
significant increase in chromosomal breakage after replication fork stalling by HU. 
Predicting VUS pathogenicity only in the context of HR efficiency does not give a 
complete picture for all of the functions of BRCA2. It is important to further 
185 
understand the full spectrum of BRCA2 functions and how each might contribute 
to genomic instability and tumorigenesis. This determination is essential to gain a 
better understanding of how HBOC cancers arise and to make more confident 
predictions about the outcome of patient mutations. 
The individual with homozygous c.IVS19-1G>A mutations is deceased due 
to causes unrelated to FA, but they were not reported to have acquired malignancy 
to the age of 30. We note that the FANCD1/BRCA2 sibling pair will have to be 
screened for FA related cancers and HBOC. These patients seem to have been 
protected from early embryonal cancers, which we hypothesize to be due to 
sufficient HR activity of the hypomorphic BRCA2 alleles expressed in their cells. 
However, it is unclear whether these patients will be predisposed to squamous cell 
carcinoma (SCC) because the majority of FANCD1 patients develop early 
childhood malignancy long before SCCs are diagnosed in FA. SCCs in FA are 
generally diagnosed in adulthood with a median age of 30, therefore the patients 
should be screened regularly for these malignancies because of their cellular 
defects in ICL repair (Kutler et al., 2016). HBOC cancer risk may be especially high 
for these individuals in adulthood because they have biallelic BRCA2 mutations, 
one of which (c.2330dupA) is already reported to predispose to HBOC. There is 
insufficient evidence for whether the c.8524C>T variant predisposes to HBOC in 
this family, but it is deleterious in terms of BRCA2 function, and causes FA in the 
context of biallelic mutations. The father is a carrier of the c.8524C>T mutation and 
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developed early onset colorectal cancer, which may have been related to his 
carrier status (Degrolard-Courcet et al., 2014b; Garre et al., 2015; Phelan et al., 
2014). However, the father’s tumor was not assessed to determine BRCA2 status. 
5.3 Defective replication fork protection at ICLs and HU-stalled forks 
We have examined the requirement of the BRCA2 DBD for replication fork 
protection in the context of HU- and ICL-stalled replication forks. By studying the 
BRCA2 DBD mutant cell lines, we determined some differences in how cells 
respond to replication forks stalled by HU versus at ICLs. In this analysis, it was 
determined that replication fork protection of HU stalled forks is as much 
dependent on the BRCA2 DBD as the C-terminal RAD51 interacting domain. 
Similar to previously published studies, the nascent strand degradation at HU 
stalled replication forks in our BRCA2 DBD mutant cells is rescued by inhibition of 
nucleases or by inhibiting replication fork reversal by the depletion of fork 
remodelers, SMARCAL1, ZRANB3, or HLTF (Lemacon et al., 2017; Mijic et al., 
2017; Schlacher et al., 2011; Taglialatela et al., 2017). We found that by 
comparison, depletion of these fork remodelers does not rescue the increased 
ssDNA generated at ICLs and their deficiency does not sensitize wild type cells to 
MMC. These observations, suggest that fork reversal is not an important 
intermediate in the repair at ICLs. 
We note that when interpreting results, we have to keep in mind that cells 
respond differently to treatment with HU and MMC making some direct 
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comparisons of DNA fiber analysis after HU and MMC difficult. Here we looked at 
single molecule DNA fiber analysis of HU stalled replication forks to measure 
nuclease resection. At the dose of HU used for these investigations, all of the 
replication forks are prohibited from replicating due to nucleotide depletion in both 
WT and BRCA2 mutant cells. Using DNA fibers to study replication fork resection 
in MMC treated cells has been confounding because MMC does not globally stall 
all forks even at high concentrations (Kehrli and Sidorova, 2014)and data not 
shown). This would be consistent with replication forks stalling as a result of 
collision with an ICL; while other replication forks that do not encounter a DNA 
lesion, continue replicating. It is also possible, that in a FANCM dependent 
manner, some replication forks bypass the ICL, and are also able to keep 
replicating (Huang et al., 2013). 
The next steps to investigate processing of ICLs specifically, would be to 
utilize the ICL generating agent trimethylpsoralen, tagged with digoxigenin (Dig-
TMP), that can be detected by immunolabeling of DNA fibers (Huang et al., 2013). 
We hypothesize that by using this method our analysis could be limited to those 
replication forks that have encountered ICLs. A similar strategy could also be 
applied to EM studies if TMP was detected with an appropriate probe. By EM 
analysis ssDNA can be detected and measured at replication forks based on the 
differences in the width of the DNA molecules (Vindigni and Lopes, 2017). We 
predict that with these experimental approaches, the replication fork structures and 
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genetic requirements of nucleases and helicases for resection at ICLs can be 
examined in FA/BRCA pathway defective cells.   
 
5.4 Implications of defective replication fork protection 
 As discussed in detail in the introduction, rescue of replication fork 
protection in BRCA2 deficient cells has been observed by depleting factors that 
either promote MRE11 association with the fork or prevent replication fork reversal. 
As an essential gene, the HR function of BRCA2 has traditionally been viewed as 
its critical activity for cell viability. Deficiency of PARP1 is reported to prevent 
degradation of stalled replication forks and genomic instability by preventing 
MRE11 recruitment (Bryant et al., 2009; Ding et al., 2016; Ray Chaudhuri et al., 
2016; Ray Chaudhuri et al., 2012). A recent study reported that PARP1 or PTIP 
deficiency rescues lethality of BRCA2 knockout mouse embryonic stem cells 
(mESC), which was attributed to restoration of fork protection (Ding et al., 2016; 
Ray Chaudhuri et al., 2016). However, in another system, MCF10 epithelial cells, 
PARP1 knockout does protect against nascent strand degradation, but it does not 
rescue viability of BRCA2 null cells (Feng and Jasin, 2017). Moreover, cells 
expressing the BRCA2 S3291E/A fork protection mutant show defects in fork 
protection similar to losses incurred by BRCA2 LOF or depletion, but do not have 
the marked hypersensitivity or breakage phenotype to DNA damaging agents 
(Schlacher et al, 2011; Feng and Jasin, 2017). These reported findings, along with 
our data, converge on the central question of what are the specific consequences 
of the loss of replication fork protection on viability, cellular function, and genomic 
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instability. There needs to be further investigation to determine how this function 
specifically contributes to the process of tumorigenesis and later chemoresistance. 
In our analysis, we observed that increased chromosomal breakage after 
HU-mediated replication fork stalling, does not underlie replication fork resection. 
Stalled replication forks in BRCA2 c.8524C>T and p.S3291A cells undergo 
resection by MRE11, but do not have elevated levels of chromosomal breakage 
as a result. BRCA2 c.IVS19-1G>A mutant cells however, have a mild increase in 
breakage and cells expressing truncated BRCA2 show a large increase in 
breakage that is MRE11 dependent. We speculate that it is possible that 
c.8524C>T and p.S3291A BRCA2 are functionally able to prevent breaks at the
stalled replication forks or alternatively, these mutants retain enough HR function 
to repair breaks that do arise. The majority of BRCA2 replication fork protection 
studies have been done in the context of BRCA2 knockdown using siRNAs, so the 
reported chromosomal breakage cannot be attributed to only deficiency of 
replication fork protection, because the cells would also be deficient for HR. It is 
already known that DSBs can arise from replication fork collapse as a result of HU 
treatment. In the context of BRCA2 deficiency or LOF, the absence of replication 
fork protection may further precipitate fork collapse that cannot be properly 
repaired due to the concomitant loss of HR function. 
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Further investigation is needed to fully determine the consequences of the 
loss of BRCA2 replication fork protection function. It is possible that there is 
another mutagenic process occurring at replication forks in the context of defective 
replication fork protection other than chromosomal breakage. The recent study of 
replication through the Escherichia coli Tus/Ter replication fork barrier complex in 
mouse cells demonstrates that BRCA2 suppresses long tract gene conversions at 
stalled forks (Willis et al., 2014). How exactly the different functions of BRCA2 
converge to prevent gene conversion at replication forks needs further 
investigation. The BRCA2 mutants that we have identified may be helpful in 
parsing out whether this function relies on replication fork protection, HR, or both. 
It will be interesting to investigate whether fork protection mutants have an 
increase in mutations or gene conversion events at the sites of stalled forks. This 
would give insight into the outcome of these resection events and would help clarify 
how different defects in BRCA2 may contribute to genomic instability. 
In the context of cancer cells, replication fork protection might play a more 
significant role for chemoresistance. Alterations in a number of proteins already 
discussed, restore fork protection (without restoring HR activity) by precluding 
nuclease recruitment or access to DNA. Analysis of BRCA2 ovarian cancers, with 
low PTIP or CHD4 expression had poorer prognosis, which hints at a potential 
mechanism of restoration of fork protection in these tumors (Guillemette et al., 
2015; Ray Chaudhuri et al., 2016). Similarly, low levels of SMARCAL1 also 
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correlated with poor prognosis in BRCA1 breast cancer (Taglialatela et al., 2017). 
In BRCA2 ovarian cancers, low EZH2 levels were associated with worse prognosis 
(Rondinelli et al., 2017). Taken together these studies link restorations of 
replication fork protection with the development of chemoresistance in BRCA1/2 
deficient cancers; however, validation of the mechanism conferring 
chemoresistance in these cancers warrants further investigation. It would be 
interesting to know if specific loss of replication fork protection results in increased 
breakage in cancer cell lines or if this occurs only with BRCA2 LOF. It is possible 
that BRCA2 replication fork protection might play a more important role in the 
context of cancers where replication fork reversal may be deregulated and 
oncogenic stress or chemotherapy agents might be driving increased fork reversal 
activity (Neelsen et al., 2013) 
 
5.5 Concluding Remarks 
 This work was pursued under the hypothesis that by studying a subset of 
patients with unclassified FA we would likely discover novel genes not previously 
identified in FA. We found that some of the subjects had deficiencies in the FA 
pathway which resulted in the identification of a new complementation group and 
interesting separation of function mutations. While other patients had defects in 
different DNA repair pathways that are imperative to genome maintenance. In 
studying these individuals’ mutations, we have increased our understanding of how 
these factors operate to maintain genome integrity. Even in the case of an already 
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discovered FA complementation groups, the study of specific patient mutations 
provides a unique tool to learn about a protein’s functions. 
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Chapter 6: Materials and Methods 
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6.1 Experimental Procedures 
6.1.1 Study subjects 
 DNA samples and cell lines were derived from subjects enrolled in the 
International Fanconi Anemia Registry (IFAR) after obtaining informed written 
consent. The Institutional Review Board of The Rockefeller University, New York, 
NY, USA, approved these studies.   
 
6.1.2 Cell lines 
 Patient-derived fibroblast cell lines (Table 6.1) and BJ foreskin normal 
control fibroblasts (ATCC) were transformed by expression of HPV16 E6E7 and 
immortalized with the catalytic subunit of human telomerase (hTERT). Fibroblasts 
were cultured in Dulbecco Modified Eagle medium (DMEM) supplemented with 
15% FBS, 100 units of penicillin per mL, 0.1 mg of streptomycin per mL, non-
essential amino acids, and glutamax (Invitrogen). Fibroblasts cell lines were 
incubated at 37°C, 5% CO2, and 3% O2. Lymphoblast cell lines (Table 6.1) were 
established from patient peripheral blood mononuclear cells by Epstein-Barr Virus 
(EBV) transformation and grown in Roswell Park Memorial Institute medium 
(RPMI) with 20% FBS and further supplemented as above. HEK293T (ATCC) cells 
were cultured in DMEM supplemented with 10% FBS and penicillin/streptomycin 
and glutamax as indicated above. Lymphoblast and HEK293T cell lines were 
incubated at 37°C, 5% CO2, and ambient O2.  
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6.1.3 Plasmids and mutagenesis 
UBE2T cDNA (Human ORFeome V8.1 Library, GE Healthcare) was 
recombined into pDONR223 using Gateway system BP reaction (Invitrogen). A 
Gateway system LR reaction (Invitrogen) was used to recombine the pDONR223 
with a pMSCV retroviral vector resulting in a C-terminally HA-FLAG tagged 
UBE2T. A PFAS expressing pMSCV vector was made by cloning PFAS from WT 
cDNA with attB primers for recombination by BP reaction into the pDONR223. 
pDONR223-PFAS was recombined with pMSCV by LR reaction. Mutagenesis was 
performed using QuickChange Multi Site-Directed Mutagenesis Kit (Agilent) see 
Table 6.2 for primers. 
6.1.4 Viral transfection/transduction 
cDNAs were delivered by retroviral or lentiviral transduction after packaging 
in HEK293T cells (TransIT-293 transfection reagent, Mirus). HEK293T cells were 
plated at 4.5*106 the evening before transfection of DNA and viral packaging 
vectors. Transfection was performed according to the manufacturer’s instructions. 
The next day after transfection cell media was replaced and two days after 
transfection viral supernatants were harvested and used to infect target cells in the 
presence of 4 mg/ml polybrene. Stably expressing cells were selected with the 
appropriate agent ((puromycin (2  µg/ml), hygromycin (100-200 µg/ml), blasticidin 
(500 µg/ml), neomycin (600 µg/ml).  
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6.1.5 RNAi 
 Cells were transfected with pools of 3 siRNAs against MRE11, DNA2, 
EXO1, CtIP, WRN, BLM, BRCA2, RAD51, MUS81, XPF, and SLX4. For RADX 
and HLTF depletion a single previously published siRNA was used (Table 6.3) 
(Dungrawala et al., 2017; Taglialatela et al., 2017). Cells were transfected using 
Lipofectamine RNAiMAX (Invitorgen) according to the manufacturer’s instructions. 
For shRNA depletion, virus was packaged in HEK293T cells and used to infect 
target cells and cells with stable integration were selected. shRNA constructs for 
SMARCAL1 and ZRANB3 were a gift from Alberto Ciccia (Table 6.4). shRNAs to 
RADX and PFAS were purchased from Transomics and used in the 
pZIP_hCMV_Puro vector or pMSCV-PM-mir30. shRNAs were PCR amplified and 
cloned into pMSCV-PM-mir30 by digestion with XhoI and MluI and vector ligation. 
See Table 6.2 for PCR primers for amplification of shRNA from UltramiRs of 
pZIP_hCMV vector. RNAi knockdown was measured by RT qPCR or western blot.  
 
6.1.6 PCR, reverse transcription, and RT qPCR  
 PCR reactions were performed using Taq DNA Polymerase (Qiagen), 
Phusion High-Fidelity PCR Master Mix with GC buffer (Thermo Scientific), and 
PCR SuperMix High Fidelity (Invitrogen) according to manufacturer’s protocols 
and primers are listed in Table 6.5. Total messenger RNA was extracted using 
RNeasy plus kit (Qiagen). RNA was reverse transcribed to cDNA using the 
SuperScript III Reverse Transcriptase (Invitrogen). Platinum SYBR Green 
SuperMix-UDG (Invitrogen) was used according to manufacturer’s protocol to 
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determine relative transcript levels which were normalized against GAPDH levels. 
See Table 6.6 for RT qPCR primers. 
6.1.7 Gene targeting 
To correct the BRCA2 c.IVS19-1G>A mutation in HSC62 fibroblasts, cells 
were transduced with the pCW-Cas9-Puro (addgene #50661) vector which 
contains a doxycycline inducible Cas9. Subsequently, HSC62 cells were 
transduced with plentiGuide-Hygro (derived from addgene #52963) that expresses 
a single guide RNA (sgRNA) (see Table 6.7 for sgRNA sequence) that targets 
DNA in proximity to the c.IVS19-1G>A mutation. sgRNAs were designed using the 
online CRISPR design tool from the Zhang laboratory (crispr.mit.edu). 1*106 cells 
were electroporated with a 100bp template oligonucleotide (see Table 6.8 for 
sequence) using Lonza 2b-Nucleofector. Cells were cultured in 500 ng/mL 
doxycycline for 48 hours to induce Cas9 expression and then incubated in fresh 
doxycycline free media for another 48 hours before being single cell cloned into 
96-well plates. Clones were expanded and screened by sequencing of genomic 
DNA. For clones HSC62mut/WT-1and HSC62WT/WT-2, cells were selected in low dose 
MMC (50 ng/mL) once a week for three weeks before seeding in 96-wells. Clone 
3 (HSC62WT/WT) was not selected for.  
The rest of the gene targeting was performed by electroporation of 
Cas9/gRNA ribonucleoprotein (RNP) complexes with 100bp oligonucleotide donor 
templates, with phosphorothioate protected ends. sgRNA was prepared by 
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combining crRNA (designed using crispr.mit.edu) and universal tracrRNA as per 
manufactures guidelines (IDT). To form RNP complexes gRNA duplex and Cas9-
3NLS (IDT) were combined, incubated at room temperature for 10-15 minutes, and 
then placed on ice until used. RNP complexes and 10 ug of 100bp donor template 
oligonucleotide were electroporated into 2*105 fibroblasts or 3.5*105 HEK293T 
cells using Lonza 4D-Nucleofector. Cells were plated in a 12-well for 48-72 hours 
to recover before single-cell plating in 96-wells. Clones were expanded and 
screened by sequencing of genomic DNA. No selection was used. 
6.1.8 Chromosomal breakage 
Cells were treated with 0.1 µg DEB per mL of media for 48-72 hours or 45-
100 nM of MMC for 24 hours. HU and aphidicolin treatments were as indicated. 
LCLs were arrested with colcemid (0.17 µg/mL) for 20 minutes and fibroblasts for 
90 minutes. Cells were harvested and incubated in 0.075 M KCL for 10 minutes 
before being fixed in methanol and acetic acid (3:1). Cells were dropped onto wet 
slides and dried at 40°C for at least one hour before staining with Karyomax 
Giemsa (Invitrogen) for three minutes. Dry slides were then imaged on the 
Metasystems Metafer slide scanning platform. 
6.1.9 Cell survival studies 
Fibroblasts were seeded overnight in triplicate and treated the next day with 
DNA damaging agents at indicated concentrations. Cells were grown for 4-6 days 
and passaged once at appropriate ratios. Once cells reached near confluence (7-
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9 days), cells were counted using Z2 Coulter counter (Beckman Coulter). In the 
case of cisplatin treatment, drug was removed after 1 hour and cells were washed 
with PBS and given fresh drug-free media. For aphidicolin treatment, after 48 hours 
cells were washed with PBS and given fresh drug-free media. For PARPi 
treatment, cells were given fresh media with olaparib daily.  For ionizing radiation 
cells were treated with the indicated IR dose in Falcon tubes prior to being plated. 
LCLs were treated at the time of seeding, agitated daily, and counted on the 7th 
day. HEK293T cells were seeded overnight, treated with MMC, passaged after 3 
days, and counted on the 5th day.  
6.1.10 Cell cycle 
For cell cycle analysis cells were treated with 45 nM MMC for 48 hours. 
Cells were collected and washed in cold PBS. Cells were resuspended in 300 ul 
PBS and slowly vortexed while 700 ul of cold 100% ethanol was added dropwise. 
Cells were stored at -20°C overnight or longer. Fixed cells were washed two times 
in cold PBS and resuspended in propidium iodine solution with RNase in PBS. 
Cells were incubated at 37°C for 30 minutes and cell cycle analysis was performed 
on BD Accuri C6 and analyzed with FlowJo software. 
6.1.11 Western blot 
Whole cell extracts were prepared by lysing cell pellets in Laemmli sample 
buffer (Bio-Rad or 4% SDS, 20% glycerol, 125 mM Tris-HCl pH 6.8). Samples were 
either sonicated or vortexed at highest speed for 30 seconds. Samples were boiled 
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for 5 minutes. For pRPA and BRCA2 western blots, samples were instead heated 
at 50°C for 10 minutes. Proteins were separated on 4-12% or 3-8% gradient gels 
(Invitrogen) by SDS-PAGE. Immunoblotting was performed using the antibodies 
indicated in Table 6.9.  
6.1.12 Immunofluorescence 
Cells were seeded on coverslips the day before. For FAND2 foci, cells were 
treated with 1 µM MMC for 24 hours. For RAD51 foci, cells were irradiated for 
indicated dose or treated with 3 µM MMC for 1 hour and harvested at indicated 
times. For RPA foci cells were treated with 3 µM MMC for 1 hour and harvested at 
indicated times. Cells were washed with PBS twice, fixed in 3.7% formaldehyde 
for 10 minutes, washed twice with PBS, and permeablized with 0.5% Triton in PBS 
for 10 mins. Cells were blocked in 5% [v/v] FBS in PBS, and incubated with primary 
antibodies in blocking buffer for two hours at room temperature or overnight at 4°C 
(for antibodies see Table 6.9). Cells were washed three times for five minutes with 
blocking buffer and then incubated with secondary antibody (1:1000) (Alexa Fluor). 
Cells were washed again three times with blocking buffer, rinsed quickly with 
water, air dried, and then embedded on glass slides with DAPI Fluoromount-G 
(SouthernBiotech). 
6.1.13 Sister chromatid exchange 
For MMC induced SCEs, fibroblasts were cultured for 24 hours in 10 ug/mL 
BrdU and then treated with 0.1 or 0.2 ug/mL MMC for one hour. Cells were washed 
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and put into fresh media with 10 ug/mL BrdU for another 24 hours. For cells 
depleted of BLM, siRNA transfection was performed twice as described. For the 
second siRNA transfection 10 ug/mL BrdU was added to media and cells were 
cultured in BrdU for a total of 48 hours before harvest. Cells were collected, fixed, 
and dropped on glass slides for metaphases as previously described. Slides were 
dried overnight at 42°C and then stained in 20 ug/mL Hoechst 33342 for 30 
minutes. Slides were treated with 254 nM UV light for 3 hours. Slides were 
incubated at 65°C in 2x SCC for 2 hours, then rinsed in 1x GURR buffer, and 
stained in 8% Giemsa Karyomax for 3 minutes. Metaphases were scanned and 
imaged on Metasystems Metafer Slide Scanning Platform. 
6.1.14 mClover homologous recombination assay 
Cells were plated in a 24-well plate the day before and transfected with 0.25 
ug pCMV-Cas9-sgLMNA-BFP and 0.4 ug pDONR-LMNA using TransIT-293 
Transfection Reagent (Mirus) according to manufactures instructions (plasmids 
were a gift from Jan Karlseder)(Arnoult et al., 2017). 24 hours after transfection 
cell media was replaced. Cells were incubated for another 48 hours and were then 
harvested and analyzed on BD LSRII to determine the proportion of mClover 
positive cells and data was analyzed with FlowJo. 
6.1.15 DNA molecular combing and DNA fibers 
For DNA molecular combing, cells were plated the evening before and 
labeled with nucleotide analogs and treated with genotoxic agents as indicated. 
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Cells were harvested and pellets were processed using Genomic Vision Extraction 
Kit. Briefly, cells were embedded in low melting point agarose. Within the agarose 
gel matrix, proteins were digested and cell membranes were solubilized. The 
agarose plugs were melted and digested with beta-agarase. Using the Genomic 
Vision Molecular Combing System DNA molecules were stretched on coverslips. 
Coverslips were dried at 65°C for 2-4 hours. Coverslips were denatured in 0.5M 
NaOH and 1M NaCl solution for 8 minutes at room temperature. Coverslips were 
then dehydrated 5 minutes each in 70, 90, and 100 percent ethanol and then air 
dried at room temperature. For immunostaining coverslips were blocked in 5% 
FBS in PBS [v/v] for 30 minutes at 37°C and then incubated with primary antibodies 
for one hour at 37°C. Rat anti-BrdU antibody (1:25) was used to detect CldU and 
mouse anti-BrdU antibody (1:10) was used to detect IdU. Coverslips were washed 
and then incubated with secondary (Alexa Fluor) anti-rat (594) and anti-mouse 
(488) at a dilution of 1:100 each for 30 minutes at 37°C. Coverslips were washed 
and air dried. Dry coverslips were mounted on glass slides using Fluoromount-G 
(SouthernBiotech). 
For DNA fibers, cells were plated and treated/labeled as above. Cells were 
harvested and cell pellets were washed one time in cold PBS. Cells were 
resuspended at a concentration of 1*106 cells/mL in cold PBS. On a clean glass 
coverslip 10 ul droplets of spreading buffer (0.5% SDS, 200mM Tris-HCl pH 7.4, 
and 50 mM EDTA pH 8) was placed. 2.5 ul of cell suspension was pipetted into 
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the spreading buffer, stirred, and pipetted up and down three times. Coverslips 
were incubated horizontally for nine minutes at room temperature before gently 
being tilted vertically to allow the buffer to run down the slide. Coverslips were dried 
at room temperature at an angle and then heated at 65°C for 30 minutes. 
Coverslips were fixed in methanol/acetic acid 3:1 overnight at 4°C. The next day 
coverslips were washed in PBS three times at room temperature and then 
incubated in 2.5M HCl for 1 hour. Coverslips were then washed five times for five 
minutes with PBS and after the final wash they were blocked in 5% FBS in PBS 
for 30 minutes. For immunostaining, coverslips were incubated with primary 
antibodies for 2.5 hours at room temperature. Rat anti-BrdU antibody (1:40) was 
used to detect CldU and mouse anti-BrdU antibody (1:20) was used to detect ldU. 
Coverslips were washed 5 times with PBS with 0.2% Tween and then blocked for 
30 minutes in 5% FBS in PBS. Coverslips were incubated with secondary (Alexa 
Fluor) anti-rat (594) and anti-mouse (488) at a dilution of 1:300 for 1 hour at room 
temperature. Coverslips were washed 5 times with with PBS with 0.2% Tween and 
rinsed with water and air dried. Dry coverslips were mounted on glass slides using 
Fluoromount-G. DNA tracks were all imaged on the DeltaVision Image Restoration 
microscope and measured using ImageJ.  
 
6.1.16 aCGH 
 A custom CGH array was designed as previously described 
(Chandrasekharappa et al., 2013). NimbleGen Service for CGH was used for 
manufacturing, hybridization, scanning, and preliminary analysis. DNA from the 
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proband was compared to reference human male DNA (Promega). Data analysis 
was performed using NimbleScan and intensity variations were visualized using 
SignalMap (NimbleGen software). 
6.1.17 Whole Exome Sequencing 
The libraries for whole exome sequencing (WES) were constructed and 
sequenced on Illumina HiSeq 2000 or Illumina GA-IIX using 76 bp paired-end 
reads at the Broad Institute or by using Agilent SureSelect Human All Exon V4 
capture kit and 100 bp paired-end sequencing on Illumina HiSeq 2500. Sequence 
was aligned to human genome build GRCh37 using BWA (Burrows-Wheeler 
Aligner) (Li and Durbin, 2009). Duplicate reads were marked using Picard 
[http://picard.sourceforge.net]. Genome Analysis Toolkit (GATK) was used for 
base quality score recalibration (BQSR), and local realignment around indels 
(DePristo et al., 2011). Variant discovery was performed in part by variant calling 
with GATK HaplotypeCaller and then joint genotyping with GATK 
GenotypeGVCFs. The variant call sets were then refined with Variant Quality 
Score Recalibration (VQSR) and VQSR scores helped discriminate low quality 
variants.  Variant annotation was performed using SnpEff, VCFtools, and in-house 
software (NYGC) (Cingolani et al., 2012; Danecek et al., 2011). All WES was 
analyzed with the NYGC sequence analysis pipeline. 
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6.1.18 RNA sequencing 
Indexed RNA sequencing (RNA-seq) libraries were constructed using 
TruSeq RNA Sample Prep Kit version 2 (Illumina). Each library was sequenced in 
pair-end mode using 1 lane of Illumina HiSeq2000 flowcell to generate 2 x 100 bp 
reads.  Raw-reads were aligned to the human genome (hg19) using TopHat with 
default parameters. Cufflinks with GC and upper quartile normalization was then 
used to calculate normalized expression levels, Fragments Per Kilobase of 
transcripts per Million reads (FPKM) (Trapnell et al., 2012). 
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Table 6.1 List of cell lines 
Cell Line Cell type Source 
BJ WT Fibroblast ATCC 
HA239F RAD50 Fibroblast (Waltes et al., 2009) 
HEK293T WT Epithelial kidney ATCC 
HSC62 BRCA2/FANCD2 Fibroblast Howlett et al., 2002 
RA3226 FANCD1/BRCA2 Fibroblast IFAR, (Kim et al., 2013) 
RA2143 BMF patient, unknown Lymphoblast IFAR 
RA2177 BMF patient, unknown Fibroblast IFAR 
RA2374 BRIP1/FANCJ Fibroblast IFAR 
RA2480 FANCI Fibroblast IFAR, (Kim et al., 2013) 
RA2525 BRCA2/FANCD1 Lymphoblast IFAR 
RA2627 UBE2T/FANCT Fibroblast IFAR, (Rickman et al., 2015) 
RA2630 RAD51/FANCR Fibroblast IFAR, (Wang et al., 2015) 
RA2645 FAND2 Fibroblast IFAR, (Kalb et al., 2007) 
RA2939 FANCA Lymphoblast IFAR, (Zhou et al., 2012) 
RA2985 WT Lymphoblast IFAR 
RA2987 WT Lymphoblast IFAR 
RA3045 FANCL Fibroblast IFAR 
RA3087 FANCA Fibroblast IFAR, (Kim et al., 2013) 
RA3105 BRCA2/FANCD1 Lymphoblast IFAR 
RA3106 BRCA2/FANCD1 Lymphoblast IFAR 
RA3331 SLX4/FANCP Fibroblast IFAR, (Kim et al., 2011) 
RA3534 Unaffected sibling control Lymphoblast IFAR 
RA3535 Unaffected parental control Lymphoblast IFAR 
RA3536 Unaffected parental control Lymphoblast IFAR 
RA3572 Unaffected parental control Fibroblast IFAR 
RA3573 Unaffected parental control Fibroblast IFAR 
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Table 6.3 List of siRNAs 
siRNAs 
Name Sequence Supplier 
siLuciferase CGUACGCGGAAUACUUCGA Sigma 
siRAD51 GGUAGAAUCUAGGUAUGCAtt Ambion 
siRAD51 CAGUGGUAAUCACUAAUCAtt Ambion 
siRAD51 CCAGCUCCUUUAUCAAGCAtt Ambion 
siMRE11 GAUAGACAUUAGUCCGGUUtt Ambion 
siMRE11 CCCGAAAUGUCACUACUAAtt Ambion 
siMRE11 CGACUGCGAGUGGACUAUAtt Ambion 
siCTIP GUACAAGGUUUACAAGUAAtt Ambion 
siCTIP GGAUCUGUCUGAUCGAUUUtt Ambion 
siCTIP GGGUCUGAAGUGAACAAGAtt Ambion 
siEXO1 GCCUGAGAAUAAUAUGUCUtt Ambion 
siEXO1 CUUUUGAACAGAUCGAUGAtt Ambion 
siEXO1 GGCUAGGAAUGUGCAGACAtt Ambion 
siDNA2 CAUCCAAUAUUUUCCCGUAt Ambion 
siDNA2 CCGUACAGGCAGCAAUUAAtt Ambion 
siDNA2 GUAACUUGUUUAUUAGACAtt Ambion 
siBLM CCCACUACUUUGCAAGUAA Ambion 
siBLM GGAUGUUCUUAGCACAUCA Ambion 
siBLM GAUAUCUUCCAAAACGAAA Ambion 
siWRN GGAGGGUUUCUAUCUUACUtt Ambion 
siWRN CUGUAGCAAUUGGAGUAAAtt Ambion 
siWRN CGAUGCUAGUGAUUGCUCUtt Ambion 
siMUS81 UUCUGAAAUACGAAGCGCG Ambion 
siMUS81 AGAGGGUUUGGAGAGGUCAU Ambion 
siMUS81 UUAGGAUUCAGGUGCUCCC Ambion 
siBRCA2 UAAUGGAUCAGUAUCAUUUGGUUC Invitrogen 
siBRCA2 GGAGGACUCCUUAUGUCCAAAUUU Invitrogen 
siBRCA2 GAGCGCAAAUAUAUCUGAAACUUC Invitrogen 
siSLX4 UUUGGAUGAAGAUUUCUGAGAUCUG Invitrogen 
siSLX4 UUCCGUGGCUCCUUCUUGCUGGUGG Invitrogen 
siSLX4 AAGAGUUCCUGGAAAUUCUCGGCCC Invitrogen 
siXPF UCGAAAUUCACGCAUAUCC Invitrogen 
siXPF UGUAUAGCAAGCAUGGUAG Invitrogen 





























BRCA2 Exon20_FWD GTTCAAGTGATTCTCCTGCCT 
BRCA2 Exon20_REV CAATAGGTCCTAGTTCCAGGC 
BRCA2 Exon27_FWD GGAGACTGTGTGTAATATTTGCG 
BRCA2 Exon27_REV GTCGCCTTTGCAAATGCTTAGA 
BRCA2 cDNA_313 GCTGTTAAGGCCCAGTTAGATCC 
















shRADX #46 ACAGCTTGAACTCTCTCGTATA 
shRADX #49 CCACGCTAATCCAGTTGCTGTA 
shPFAS #87 CCAGCCGACACTGGTTCTTCAA 
shPFAS #88 CCGGGAGTGTCCTGTCAGAAGA 
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Table 6.8 List of oligonucleotide donor templates for 
CRISPR/Cas9 






































Table 6.9 List of antibodies 
Antibody IF Western 
a-tubulin Sigma T9026 NA 1:1000 
BRCA2 Millipore Sigma OP95 NA 1:250 
CtIP Bethyl A300-488 NA 1:500 
FANCA Bethyl A301-980A NA 1:1000 
FANCD2 Novus NB100-182 1:1000 1:1000 
FANCI antibody raised in-house, #589 NA 1:1000 
HA Covance MMS-101R 1:5000 1:1000 
HLTF Abcam ab17984 NA 1:1000 
MRE11 Gift from John Petrini NA 1:10000 
MUS81 Abcam MTA30 2G10/3 NA 1:1000 
pRPA S4/S8 Bethyl A300-245A NA  
RAD51 Clone SWE47, gift from Steve West 1:1000 1:1000 
RPA32 Bethyl A300-244A 1:5000 1:1000 
SMARCAL1 Santa Cruz sc-376377 NA 1:1000 
UBE2T Abcam EPR9446 NA 1:1000 
Vinculin Sigma hVIN-1 NA 1:1000 
XPF NeoMarkers MS1381P NA 1:1000 
ZRANB3 Bethyl A303-033A NA 1:1000 
DNA combing and fibers Fibers Combing 
BRDU  BD Biosciences B44 1:20 1:10 
BRDU EuroBioSciences (BU1/75) NA 1:20 
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